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I INTRODUCTION
Until today more than 160 million organic and inorganic substances have been registered at the
chemical abstracts service (CAS),1 including 147 million small molecules.2 Despite cell and gene
therapy revolutionizing the drug market, small molecules still make up half the amount of the
worlds 200 most selling drugs.3 Therefore, the development of new molecules and especially
efficient methods for their synthesis is of great interest. The construction of carbon bonds is
crucial for the synthesis of new molecules. Palladium-catalyzed cross-coupling reactions proved
to be powerful tools for the synthesis of carbon-carbon or carbon-heteroatom bonds, since they
often proceed under mild reaction conditions and with high chemoselectivity.4 The highlight in this
field of research was reached in 2010, when Richard Heck, Ei-ichi Negishi and Akira Suzuki5 got
awarded with the Nobel prize for palladium-catalyzed cross-coupling reactions. Yet, they often
require costly and sophisticated ligands and palladium itself is comparably expensive.6 Therefore,
the search for alternative transition-metals for their use in cross-coupling reactions is of great
interest.
1https://www.cas.org/about/cas-content; retrieved March 2020.
2 a) Below 900 u , b) https://www.cas.org/support/documentation/cas-databases; retrieved March 2020.
3 https://njardarson.lab.arizona.edu/sites/njardarson.lab.arizona.edu/files/2018Top200 PharmaceuticalRetailSales
PosterLowResFinalV2.pdf.
4 a) A. O. King, N. Yasuda in Organometallics in Process Chemistry, Springer Berlin Heidelberg, 2004, S. 205–245; b)
A. Dumrath, C. Lübbe, M. Beller in Palladium-Catalyzed Coupling Reactions, John Wiley & Sons, Ltd, Chichester,
U.K., 2013, Kap. 12, S. 445–489; c) P. Ruiz-Castillo, S. L. Buchwald, Chem. Rev. 2016, 116, 12564–12649; d)
P. Devendar, R.-Y. Qu, W.-M. Kang, B. He, G.-F. Yang, J. Agr. Food Chem. 2018, 66, 8914–8934.
5 https://www.nobelprize.org/uploads/2018/06/advanced-chemistryprize2010-1.pdf.
6 a) R. Martin, S. L. Buchwald, Acc. Chem. Res. 2008, 41, 1461–1473; b) C. C. C. Johansson Seechurn, M. O. Kitching,
T. J. Colacot, V. Snieckus, Angew. Chem. Int. Ed. 2012, 51, 5062–5085; c) C. A. Fleckenstein, H. Plenio, Chem. Soc.
Rev. 2010, 39, 694–711; d) R. J. Lundgren, M. Stradiotto, Chem. – Eur. J. 2012, 18, 9758–9769; e) World market
price: 1,449.69 e/ozt, 46.61 e/g, 4960 e/mol, from http://www.infomine.com/investment/metal-prices/palladium/
retrieved March 2020; f) P. G. Gildner, T. J. Colacot, Organometallics 2015, 34, 5497–5508.
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I INTRODUCTION
1 Beginnings of Cobalt-Catalyzed Carbon-Carbon Bond Forming
Reactions
One transition-metal, which has recently attracted a lot of attention in cross-coupling reactions is
cobalt. Cobalt has only one stable isotope (59Co) and is able to form the oxidation states -I, 0, +I,
+II, +III, +IV, +V of which oxidation states +II, +III are the most frequent ones.7 The occurrence of
cobalt is about 40 ppm in the earth crust and only in chemically combined form.7 The main cobalt
mining country is the DR Congo and the total worldwide mine production is about 120 0000 tons.7
Cobalt salts often have characteristic color, thus finding broad application as dyes until now.
In fact, more than 3000 years old shards were found covered with cobalt blue (CoAl2O4) also
known as Thénard blue after Louis Jacques Thénard, who rediscovered it in 1802.8 Today
cobalt is applied in lithium-ion batteries, alloys and it is still used for its blue color in ceramics,
inks and paints.7 Furthermore, it became a popular catalyst in organic chemistry, especially for
cross-coupling reactions.9
The first cobalt-catalyzed carbon-carbon bond formation were homocoupling reactions.10 In
1941 Kharasch et al. showed that only a catalytic amount of CoCl2 is needed, to enable the
homo-coupling of aryl magnesium reagents in the presence of an organic halide such as phenyl
or ethyl bromide (see Scheme 1).
2 ArMgBr Ar-Ar
86% 95%
Me Me
75%
Me
Me
76%
MeO OMe
PhBr or EtBr
CoCl2 (2.5–10 mol%)
Et2O, reflux
Scheme 1 Cobalt-catalyzed homocoupling reaction of aromatic Grignard reagents.10
Just two years later the first cobalt-catalyzed cross-coupling was discovered.11 The same
conditions allowed the cross-coupling of Grignard reagents with vinyl halides (see Scheme 2).
However, this reaction gave moderate yields and proceeded only by using a large excess of vinyl
7 H. Sicius in Handbuch der chemischen Elemente, Springer Berlin Heidelberg, Berlin, Heidelberg, 2019, S. 1–37.
8G. Schwedt in Chemische Experimente in Schlössern, Klöstern und Museen, Wiley-VCH, Weinheim, Berlin,
Heidelberg, 2009.
9 a) C. Gosmini, J.-M. Bégouin, A. Moncomble, Chem. Commun. 2008, 3221–3233; b) G. Cahiez, A. Moyeux, Chem.
Rev. 2010, 110, 1435–1462; c) J. M. Hammann, M. S. Hofmayer, F. H. Lutter, L. Thomas, P. Knochel, Synthesis
2017, 49, 3887–3894; d) G. Dorval, C. Gosmini in Cobalt Catalysis in Organic Synthesis, (ed.: G. Hilt), Wiley-VCH,
Weinheim, 2020, pp. 163–205
10 M. S. Kharasch, E. K. Fields, J. Am. Chem. Soc. 1941, 63, 2316–2320.
11 M. S. Kharasch, C. F. Fuchs, J. Am. Chem. Soc. 1943, 65, 504–507.
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halide, due to high homocoupling products formation. Also, sterically hindered vinyl halides only
were coupled in poor yields.
PhBr or EtBr
CoCl2 (5 mol%)
Et2O, 0 °C–rt , 12 h
R2
R1 R3
X
R4MgBr
X = Br, Cl
(2.0 equiv) (1.0 equiv)
R2
R1 R3
R4
Ph
56%
Cy
7%
Ph
51%
Me
Ph
23%
Me
Bn
75%
Ph
7%
Me
Me
Me
+
Scheme 2 Cobalt-catalyzed cross-coupling of vinyl halides and Grignard reagents.11
It took more than 50 years until this drawback could be overcome. The key to a higher selectivity
was the use of a NMP-THF 1:1 solvent mixture, which doubled the yield, compared to THF. Thus,
various alkenyl halides could be coupled with several Grignard reagents in good yields.12
Co(acac)2 (3 mol%)
solvent, -5 to 0 °C, 15 min
Me
Br
OctMgCl
(1.0 equiv) (1.1 equiv)
Me
Oct
THF:            44%
THF/NMP (9.0 equiv):   88%
Co(acac)2 (3–8 mol%)
THF/NMP  (4.0 equiv) 
-5 °C to rt, 15 min
R4MgCl
(1.0 equiv) (1.1–1.5 equiv)
R2
R1 R3
Br R2
R1 R3
R4
Me
Ph
82%
Bu
Bu
Bu
67%
Dec
Hex
73%
Me
80%
OMe
52%
Cl
Me
O
O
+
Scheme 3 Cobalt-catalyzed alkenylation of Grignard regents.12
From the beginnings to date, cobalt-catalyzed cross couplings have been refined. The addition
of ligands and additives, the use of different organometallics and also the application to
stereoselective reactions led to numerous publications. In the following part a short summary of
the highlights in cobalt catalyzed cross-coupling reactions of the last decade will be given.
12 G. Cahiez, H. Avedissian, Tetrahedron Lett. 1998, 39, 6159–6162.
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2 Recent Advances in Cobalt-Catalyzed Carbon-Carbon Bond
Forming Reactions
The construction of carbon-carbon bonds is one of the most versatile and popular
cross-coupling reaction. Especially the preparation of biaryl compounds is of great interest,
since they are scaffolds in natural products, pharmaceuticals or ligands.13 Whereas,
Kumada-type cobalt-catalyzed C(sp2)-C(sp2) cross-couplings were already discovered earlier,11
the development of Negishi and Suzuki-Miyaura type reaction seemed to be more challenging
to achieve. Gosmini and co-workers discovered the beneficial effect of cobalt bromide for the
generation of arylzinc reagents.14 Those could be generated by reduction of the aryl halide
by a zinc anode14a,b or by zinc dust14c in the presence of CoBr2 and ZnBr2 in acetonitrile
at rt. A few years later this method was applied to cobalt-catalyzed cross-couplings with
2-chloropyrimidine or 2-chloropyrazine.15 In 2016, Knochel and co-workers could broaden
the scope of the cobalt-catalyzed Negishi cross-coupling. A catalytic system consisting of the
THF-soluble CoCl2·LiCl and HCO2Na enabled the cross-coupling of N-heterocyclic chlorides, as
well as, bromides and aromatic halogenated ketones. The cross-coupling proceeded smoothly
with various electron-rich and -poor arylzinc reagents (see Scheme 4).16
CoCl22LiCl (5 mol%)
HCO2Na (50 mol%)
THF, rt, 8 h
ZnCl
R
X = Cl, Br (Het)Ar
R
(1.2 equiv)
(Het)Ar-X
N
OMe
65% without HCO2Na
88% with HCO2Na
Cl
Ph
O
CF3
89%
N
CO2Et
OBn
71%
N
N
N
Ph
Ph
61%
OBoc
Scheme 4 Cobalt-catalyzed Negishi cross-coupling of (hetero)arylzinc reagents with (hetero)
aryl halides.16
13a) G. Bringmann, C. Günther, M. Ochse, O. Schupp, S. Tasler in Fortschritte der Chemie organischer Naturstoffe /
Progress in the Chemistry of Organic Natural Products, (eds.: W. Herz, H. Falk, G. W. Kirby, R. E. Moore), Springer
Vienna, Vienna, 2001, pp. 1–249; b) J. Hassan, M. Sévignon, C. Gozzi, E. Schulz, M. Lemaire, Chem. Rev. 2002,
102, 1359–1470; c) D. A. Horton, G. T. Bourne, M. L. Smythe, Chem. Rev. 2003, 103, 893–930.
14a) C. Gosmini, Y. Rollin, J. Y. Nédélec, J. Périchon, J. Org. Chem. 2000, 65, 6024–6026; b) H. Fillon, E. L. Gall,
C. Gosmini, J. Périchon, Tetrahedron Lett. 2002, 43, 5941–5944; c) H. Fillon, C. Gosmini, J. Périchon, J. Am. Chem.
Soc. 2003, 125, 3867–3870.
15J.-M. Bégouin, C. Gosmini, J. Org. Chem. 2009, 74, 3221–3224.
16D. Haas, J. M. Hammann, F. H. Lutter, P. Knochel, Angew. Chem. Int. Ed. 2016, 55, 3809–3812.
4
I INTRODUCTION
The same year a cobalt-catalyzed Suzuki-Miyaura cross-coupling was discovered by the group
of Chirik.17 The key to this transformation was the preparation of a new class of tetrahedral,
high-spin bis(phosphino)pyridine cobalt(I) alkoxide and aryloxide complexes, which enabled
the coupling of (benzo)furanylboronic esters with various aryl triflate electrophiles. Duong et al.
could broaden the scope of the cobalt-catalyzed Suzuki-Miyaura coupling by a catalytic system
comprising cobalt(II)/terpyridine and potassium methoxide.18 Under these conditions a broad
range of (hetero)aryl halides with (hetero)arylboronic esters could be coupled, leading to various
(hetero)biaryl products (see Scheme 5).
CoCl2 (5 mol%)
TPy (50 mol%)
KOMe (1.5 equiv)
DMF, 80 °C, 16 h
(Het)Ar-B(neo)
(Het)Ar
R
(1.5 equiv)
(Het)ArX
N Ph
67%
MeO2C
OMe
73%
N S
75%
N
N
Ph
Me
77%
X = Br, Cl
MeO2C
N
NN
TPy
Scheme 5 Cobalt-catalyzed cross-coupling of arylboronic esters and aryl halides.18
The formation of C(sp2)-C(sp3) centers can be hampered due to β-hydride elimination, therefore
their preparation is often more challenging.19 Hammann et al. reported a cobalt catalyzed
cross-coupling of bisarylzinc reagents, generated by directed metalation using TMP2Zn with
primary and secondary alkyl halides, avoiding rearrangement of the secondary halides (see
Scheme 6).20
TMP2Zn (0.6 equiv)
THF, -40 to 0 °C
8–24 h
(Het)Ar-H (Het)Ar2-Zn (Het)Ar-Alk
Alkyl-X (0.7 equiv)
CoCl22LiCl (20 mol%)
TMEDA (30 mol%)
THF, 0 °C to rt, 6h
F
CN
EtO2C
F
ortho: 68% (dr = 99:1)
para:  79% (dr = 50:50)
S
81%
O
Me
Me
51%
O O
CN
76 %
OTBS
Scheme 6 Cobalt-catalyzed cross-coupling reaction of bis(heteo)arylzinc reagents with primary
and secondary alkyl bromides and iodides.20
17J. M. Neely, M. J. Bezdek, P. J. Chirik, ACS Cent. Sci. 2016, 2, 935–942.
18H. A. Duong, W. Wu, Y.-Y. Teo, Organometallics 2017, 36, 4363–4366.
19 a) M. Netherton, G. Fu, Adv. Synth. Catal. 2004, 346, 1525–1532; b) A. C. Frisch, M. Beller, Angew. Chem. Int.
Ed. 2005, 44, 674–688; c) A. Rudolph, M. Lautens, Angew. Chem. Int. Ed. 2009, 48, 2656–2670; d) R. Jana,
T. P. Pathak, M. S. Sigman, Chem. Rev. 2011, 111, 1417–1492.
20J. M. Hammann, D. Haas, P. Knochel, Angew. Chem. Int. Ed. 2015, 54, 4478–4481.
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The coupling of disubstituted cyclohexyl iodides in a diastereoselective manner was only
possible for 1,2-substitution, 1,3-OTBS-substituted cyclohexyliodide led to a 1:1 mixture of the
corresponding product.
A C(sp3)-C(sp2) cobalt-catalyzed coupling using alkylzinc reagents was developed by Zhang
et al. in 2019 (see Scheme 7).21 A catalytic system consisting of Co(acac)3 and a
cyclohexyloxy-substituted bipyridine ligand facilitated the coupling of N-heterocyclic phosphonium
salts, which could be selectively installed in one step from C-H precursors, with alkylzinc reagents.
Thus, alkylated N-heterocylces could be obtained in a two step procedure.
N
XR1
Tf2O (1.0 equiv)
PPh3 (1.1 equiv)
NEt3 or DBU (1.1 equiv)
DCM or EtOAc
-78 °C to rt,
(2.0 equiv)
NMI
THF, rt, 12 h
H
N
XR1
PPh3TfO
ZnX
Co(acac)3 (5–10 mol%)
Ligand (5–10 mol%)
N
XR1
R2
N
N
CyO
CyO
Ligand
NMe
CO2Me
80%
N O
BocN
n-Bu
60%
NCF3 n-Bu
S
78%
N
N
n-Bu
F
OCF3
37%
R2
Scheme 7 Cobalt-catalyzed alkylation of N-heterocyclic phosphonium salts.21
Phenylacetylenes are important motifs in organic synthesis, especially for materials and in polymer
science.22 Therefore, the installation of the alkyne unit is of great interest. The group of Gosmini
developed a cobalt-catalyzed C(sp2)-C(sp) cross-coupling of in situ generated arylzinc reagents
with alkynyl bromides (see Scheme 8).23 The freshly prepared arylzinc reagent in combination
with PPh3, enabled the coupling with electron rich phenylalkynyl bromides. For the coupling of
bromoalkynes bearing an alkyl group, CoBr2(phen) was used as catalyst. Under these conditions
bromo alkynes bearing aryl and alkyl moieties could be used.
21X. Zhang, A. McNally, ACS Catal. 2019, 9, 4862–4866.
22a) The Chemistry of Triple-Bonded Functional Groups, (eds.: S. Patai), John Wiley & Sons, Ltd, New York, 1994; b)
H. Hirakawa, Angew. Chem. Int. Ed. 2001, 40, 2574–2580; c) J. Liu, J. W. Y. Lam, B. Z. Tang, Chem. Rev. 2009,
109, 5799–5867.
23M. Corpet, X.-Z. Bai, C. Gosmini, Adv. Synth. Catal. 2014, 356, 2937–2942.
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(1.00 euqiv)
R1
Br
Conditions A)
1) CoBr2(13 mol%)
    Zn (2.0 equiv), 
    MeCN, rt
2) filtration
R2 Br3)
    (0.58 equiv)
    PPh3, MeCN, 
    0 °C–rt
R1
R2
Conditions B)
1) CoBr2(phen) (10 mol%)
    Zn (2.0 equiv), 
    MeCN, rt
2) filtration
R2 Br3)
    (0.95 equiv)
    MeCN, 0 °C–rt
R1
R2
R2 = alkyl R2 = aryl, alkyl
PhEtO2C
77%
NC
80%66%
OMe
Br
Conditions A)
CF3
78%
Me
93%88%
Conditions B)
OAcN
CN
Scheme 8 Cobalt-catalyzed cross-coupling of organozinc halides with bromoalkynes.23
3 Stereoselective Cobalt-Catalyzed Cross-Couplings
The access to diastereomerically or enantiomericmerically pure products is crucial for the
synthesis of many natural products and pharmaceuticals.3,24 Stereoselective reactions are still
challenging and the use of cobalt-salts in those transformations is rare. Cossy and co-workers
could apply cobalt-catalysis to the formation of anomeric C-C bonds in carbohydrate derivatives
(see Scheme 9).25 Co(acac)3 and TMEDA enabled the diastereoselective cross-coupling
THF, 0 °C–rt, 1h
Co(acac)3 (5 mol%)
TMEDA (5 mol%)
(1.5 equiv)
MgX
O
OR1
O
AcO
AcO
OAc
OAc
p-F-C6H4
83%, a:ß > 9:1
O
AcO
AcO
OAc
OAc
p-OMe-C6H4
83%, a:ß = 71:29
R3
OTBDPSO Ph
O O
Me Me
77%, a:ß > 1:9
OBzO Ph
O O
Me Me
88%, a:ß > 9:1
O
OR1
Br
R2 R2
R3
Scheme 9 Diastereoselective cobalt-catalyzed synthesis of C-aryl glycosides and furanosides.25
24 a) V. Yeh, W. A. Szabo in Applications of Transition Metal Catalysis in Drug Discovery and Development, John Wiley
& Sons, Ltd, Chichester, U.K., 2012, pp. 165–213; b) Stereoselective Synthesis of Drugs and Natural Products,
(eds.: V. Andrushko, N. Andrushko), John Wiley & Sons, Inc., Hoboken, 2013.
25 a) L. Nicolas, P. Angibaud, I. Stansfield, P. Bonnet, L. Meerpoel, S. Reymond, J. Cossy, Angew. Chem. Int. Ed.
2012, 51, 11101–11104; b) L. Nicolas, E. Izquierdo, P. Angibaud, I. Stansfield, L. Meerpoel, S. Reymond, J. Cossy,
J. Org. Chem. 2013, 78, 11807–11814.
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of 1-bromo glycosides and furanosides with several unsaturated magnesium reagents.25
The transformation of bromo-mannose and galactose derivatives, proceeded in highly
diastereoselective manner. Whereas, the coupling of bromo-galactose turned out to be more
challenging, since only α/β ratios of only 75:25 could be reached. The high α-selectivity of this
coupling is presumably induced by a radical pathway, including an anomeric radical intermediate,
which was confirmed by a cyclization reaction with a radical clock precursor.25a Furthermore,
under the same conditions diastereoselective cross-couplings of aryl and vinyl Gringard reagents
with 1-halo furanosides were possible.25b In contrast to the coupling with 1-bromo glycosides the
diastereoselectivity is only controlled by the substituent present at the C2 position, leading to the
thermodynamically more stable 1,2-trans product.
Another diastereoselective protocol utilizing 1,2-substituted systems was reported by Hammann
et al.26 A catalytic system comprising CoCl2·LiCl and neocuproine enabled the coupling of various
substituted cycloalkyl iodides with aryl and alkynyl Grignard reagents with high diastereoselectivity
(see Scheme 10).
THF, -40–0 °C, 8h
CoCl22LiCl (50 mol%)
neocuproine (20 mol%)
(1.5 equiv)
n = 0,1 (1.0 euqiv)
I
R1
R2
R3
n
R3
R1
R2
n
R3 = Aryl, Alkyl
Me
TMS
68%, dr = 99:1
OTBS p-CN-C6H4
69%, dr = 97:3
N
Ts
88%, 99:1
OTBS
OO
Me Me
CF3
77%, dr = 99:1
MgCl
NN
Me Me
neocuproine
Scheme 10 Diastereoselective cobalt-mediated cross-couplings of cycloalkyl iodides with
alknynyl or aryl Grignard reagents.26
Remarkably, there also have been reported enantioselective protocols using cobalt-catalysis.
The group of Walsh discovered a catalytic system, consisting of CoI2 and a bisoxazoline-ligand,
which enabled the asymmetric Kumada cross-coupling of racemic α-bromo esters with aryl
magnesium reagents (see Scheme 11).27 For this coupling not only the ligand had an effect on
the enantioselectivity, but also the choice of the cobalt salt was crucial for the reaction outcome.
For example using CoCl2, led to a significantly decreased ee of 23%. Under these conditions
26J. M. Hammann, D. Haas, C.-P. Tüllmann, K. Karaghiosoff, P. Knochel, Org. Lett. 2016, 18, 4778–4781.
27 J. Mao, F. Liu, M. Wang, L. Wu, B. Zheng, S. Liu, J. Zhong, Q. Bian, P. J. Walsh, J. Am. Chem. Soc. 2014, 136,
17662–17668.
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THF, -80 °C, 5–24 h
CoI2 (10 mol%)
Ligand (12 mol%)
ArMgBr 
(1.4–2.0 equiv)
R1O
Alkyl
Br
O
R1O
Alkyl
Ar
O
N N
O O
Me Me
Bn Bn
Ligand
BnO
Me
Ph
O
95%, 94% ee
i-PrO
Et
Ph
O
94%, 93% ee
BnO
Ph
O
82%, 90% ee
OBn
O
BnO
Me
m-Cl-C6H4
O
82%, 96% ee
BnO
Me
p-OMe-C6H4
O
81%, 91% ee
Scheme 11 Cobalt-bisoxazoline-catalyzed asymmetric Kumada cross-coupling of racemic
α-bromo esters with aryl magnesium reagents.27
a variety of chiral α-aryl alkanoic esters in high enantioselectivity up to 97% ee was obtained,
which were also transformed into α-arylcarboxylic acids and primary alcohols without significant
loss of ee. Due to the reactivity of magnesium reagents toward carbonyl groups, the reaction
temperature had to be held at -80 ◦C. To overcome this drawback and also to ensure a higher
functional group tolerance, Liu et al. switched to arylzinc reagents (see Scheme 12).28
THF, -25 °C, 24 h
Co(I)2 (10 mol%)
Ligand (12 mol%)
ArZnBr
(2.0–5.0 equiv)
R1O
Alkyl
Br
O
R1O
Alkyl
Ar
O
N N
O O
Bn Bn
Ligand
BnO
Me
Ph
O
94%, 92% ee
FF
MeO
Ph
O
91%, 91% ee
O
O
O
Me
O
85%, 93% ee
MeO
CO2Et
O
Me
Ph
O
90%, 90% ee
Cl
Scheme 12 Cobalt-catalyzed eantioselective Negishi cross-coupling of racemic α-bromo esters
with arylzinc reagents.28
Thus, the reaction temperature could be increased to -25 ◦C . In addition ester functions in
corresponding organometallic reagent could be tolerated. To gain insight into the mechanism,
radical clock experiments were performed, which indicated the involvement of radical
intermediates.
28F. Liu, J. Zhong, Y. Zhou, Z. Gao, P. J. Walsh, X. Wang, S. Ma, S. Hou, S. Liu, M. Wang, M. Wang, Q. Bian, Chem. –
Eur. J. 2018, 24, 2059–2064.
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4 Cobalt-Catalyzed Acylation Reactions
The formation of carbon-carbon bonds in the presence of carbonyl moieties using reactive
organometallic reagents is often challenging due to a moderate chemoselectivity. Therefore,
the usage of less reactive zinc reagents is beneficial.29 For the synthesis of bisaryl ketones
acylation reactions proved to be valuable tools.29a,30 The group of Gosmini developed a range of
cobalt catalyzed acylation reactions using aryl zinc reagents with various nucleophiles such as
acid chlorides31 and anhydrides.32 Moreover, the formation of symmetrical diaryl ketones was
discovered by a cross-coupling of in situ generated arylzinc bromides with ethyl chloroformate
in the presence of CoBr2(bipy) and zinc in acetonitrile.
33 Additionally, the in situ generated
arylzinc reagents could be coupled with amides, without the need for a ligand, leading to several
bis(hetero)aryl ketones in very high yields (see Scheme 13).34
CoBr2 (10–20 mol%)
Zn (4.0 equiv)
allylCl (40–80 mol%)
H+  MeCN, rt, 1 h filtration
(0.5 equiv)
rt, overnight
N
O
O
Ar
O
Ar(Het) Ar
O
Ph
O
MeO
90%
Ph
O
S
59%
O
Me
OMe
96%
O
Me
46%
CN
(Het)ArBr (Het)Ar-ZnBr
Scheme 13 Cobalt-catalyzed diaryl ketone formation of amides with (hetero)arylzinc reagents.34
5 Cobalt-Catalyzed C-H Activation
Besides the classical cross-coupling between two polarized carbon bonds, cobalt-catalyzed
C-C-bond formations by activation of unpolar C-H bonds are also available. A large number of
cobalt-catalyzed C-H activations need high temperatures and proceed between activated C-H
bonds and terminal double or triple bonds in the presence of organometallic reagents.35 Li et al.
29a) R. Dieter, Tetrahedron 1999, 55, 4177–4236; b) D. Haas, J. M. Hammann, R. Greiner, P. Knochel, ACS Catal.
2016, 6, 1540–1552.
30D. S. Walter in Comprehensive Organic Functional Group Transformations, (eds.: A. R. Katritzky, O. Meth-Cohn, C.
W. Rees), Elsevier Science, Oxford, 1995, pp. 277–312.
31 H. Fillon, C. Gosmini, J. Périchon, Tetrahedron 2003, 59, 8199–8202.
32 I. Kazmierski, M. Bastienne, C. Gosmini, J.-M. Paris, J. Périchon, J. Org. Chem. 2004, 69, 936–942.
33A. Rérat, C. Michon, F. Agbossou-Niedercorn, C. Gosmini, Eur. J. Org. Chem. 2016, 2016, 4554–4560.
34C. Dorval, E. Dubois, Y. Bourne-Branchu, C. Gosmini, G. Danoun, Adv. Synth. Catal. 2019, 361, 1777–1780.
35a) K. Gao, P.-S. Lee, T. Fujita, N. Yoshikai, J. Am. Chem. Soc. 2010, 132, 12249–12251; b) Z. Ding, N. Yoshikai,
Angew. Chem. Int. Ed. 2012, 51, 4698–4701; c) T. Yamakawa, N. Yoshikai, Tetrahedron 2013, 69, 4459–4465; d)
K. Gao, N. Yoshikai, J. Am. Chem. Soc. 2011, 133, 400–402; e) W. Xu, N. Yoshikai, Angew. Chem. Int. Ed. 2014,
53, 14166–14170; f) M. Moselage, J. Li, L. Ackermann, ACS Catal. 2016, 6, 498–525.
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discovered a cobalt-catalyzed C-H activation protocol, by direct coupling of Grignard reagents
with no need for high temperatures (see Scheme 14).36 Co(acac)3, TMEDA and DCB facilitate
the highly regioselective coupling of aryl and primary alkyl magnesium reagents. However, the
coupling of secondary Grignard reagents like i-PrMgBr led to a mixture of the branched and
unbranched product with only 35% yield in total. The additional performance of radical trapping
experiments, indicated a mechanism without the involvement of radical intermediates. As the
addition of two equivalents of the free radical reagent TEMPO did not lead to an inhibition of the
cross-coupling.
Co(acac)3 (10 mol%)
TMEDA (100 mol%)
DCB (1.5–2.0 equiv)
THF, rt, 48–72 h
(4.0–8.0 equiv)
R2-MgBr
N
R2
R1
N
H
R1
N
R2
R2 = m-OMe-C6H4: 93%
R2 = Me:                 83%
R2 = Et:                   54%
R2 = Bn:                  42%
N
Ph
HO
Ph
82%
N
Ph
OMe
N
Ph
N
O
92% 64%
Scheme 14 Cobalt-catalyzed direct cross-coupling of C-H bonds with Grignard reagents.36
6 Cobalt-Catalyzed Carbon-Heteroatom Bond Forming Reactions
Apart from the construction of carbon-carbon bonds, cobalt catalysis was also applied to the
formation of carbon-heretoatom bonds, such as C-O, C-S and C-N bonds. The group of Gosmini
applied the under cobalt-catalysis generated arylzinc species in electrophilic aminations (see
Scheme 15). The arylhalides were either reduced by zinc dust or electrochemically via a zinc
anode and the corresponding arylzinc reagents could directly be coupled with N-chloroamines
and required no supplementary addition of cobalt. This protocol allowed the use of secondary
and tertiary N-chloramines, leading to various aminated aromatics, bearing sensitive functional
groups, like esters, nitriles or ketones 37
36B. Li, Z.-H. Wu, Y.-F. Gu, C.-L. Sun, B.-Q. Wang, Z.-J. Shi, Angew. Chem. Int. Ed. 2011, 50, 1109–1113.
37 X. Qian, Z. Yu, A. Auffrant, C. Gosmini, Chem. – Eur. J. 2013, 19, 6225–6229.
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X = Br, I
R1
X CoBr2 (13 mol%
Zn (2.67 equiv)
allylCl (40 mol%)
H+ MeCN
R1
ZnX
filtration
(0.67 euqiv)
Et3N (0.27 equiv*)
* vs. ArX
Cl
N
R2
R2
R1
N
R2
R2
N
O
Me
81%
N
CN
Ph
OMe
71%
N
CO2Et
CF3
52%
MeO
H
N Me
Me
78%
Scheme 15 Cobalt catalyzed electrophilic amination of arylzinc reagents with N-chloramines.37
Moreover, cobalt catalysis facilitates the formation of carbon-oxygen bonds.38 The cross-coupling
of phenols with vinyl or aryl halides was enabled by a catalytic system consisting of Co(acac)2
and CuI (see Scheme 16). This combination is crucial for the success of this coupling, in the
R2
R1 X
R3
Co(acac)2 (10 mol%)
CuI (10 mol%)
Cs2CO3 (2.0 equiv)
NMP, 100 °C, 8 - 10 h, R2
R1 OAr
R3
EtO2C O
OMe
88%
O
Br
80%
N
Me
O
86%
Ph
MeO
OMe
O
COMe
Br
80%
X = Br, I
(1.0 equiv)
ArOH
Scheme 16 Cobalt-catalyzed C(sp2)-O cross-coupling.38
absence of one of those components, no product formation was observed. The authors propose a
mechanism via an aryloxy-copper intermediate, which is then transmetalated to the Co(III) center
with the vinyl halide, followed by the reductive elimination, leading to the product.
The homologue higher chalcogen such as thiols undergoes cobalt catalyzed cross-couplings
as well. The group of Glorius reported in 2016 a dehydrogenative C-H thiolation of indoles (see
Scheme 17).39 Mechanistic studies indicated a pathway, starting with a C-H activation, thiolate
transfer, followed by the reductive elimination. Similarly, to the previous reaction with the phenols,
copper also plays an essential role in this formation, by forming an active copper-thiolate reagent.
38D. Kundu, M. Tripathy, P. Maity, B. C. Ranu, Chem. – Eur. J. 2015, 21, 8727–8732.
39T. Gensch, F. J. R. Klauck, F. Glorius, Angew. Chem. Int. Ed 2016, 55, 11287–11291.
12
I INTRODUCTION
Cp*Cp(CO)I2 (10 mol%)
Cu(OAc)2 (1.5 equiv.) / In(OTf)3 (25 mol%)
benzoquinone (1.25 equiv)
1,4-dioxane, 60 °C, 5 h
(2.00 equiv)
N
H
pym
ArSH
N
SAr
pym
R1
R1
Scheme 17 Cobalt-catalyzed C-H thiolation through dehydrogenative cross-coupling.39
7 Preparation of Organozinc Reagents
Organozinc reagents belong to the first organometallic reagents and were discovered in 1848 by
Edward Frankland.40 By mixing ethyl iodide with granulated zinc in a sealed glass tube, ethyl zinc
iodide and diethyl zinc were generated as a colorless liquid.
From there on a lot of progress has been made and organozinc reagents have found large
application in many processes due to their high functional group tolerance combined with a
high reactivity.29,41 Nevertheless, organozinc compounds have one major drawback. They are
often highly sensitive to moisture and air, which limits practical use in the laboratory and on an
industrial scale. An approach for that problem was made by Bernhardt et al. by the synthesis of
solid arylzinc pivalates of type RZnOPiv·MgX2.42 These aryl zinc reagents are prepared from the
corresponding bromides in a one pot synthesis using Mg and Zn(OPiv)2·2LiCl (see Scheme 18).
R1 = SMe:     77%
R1 = CO2Et:  59%
R1 = CN:       64%
1) Mg (2.5 equiv)
    Zn(OPiv)2·2LiCl (1.0–2.0 equiv)
THF, rt, 20 min–2 h
2) solvent evaporation
(Het)ArBr (Het)ArZnOPiv
R1
ZnOPiv ZnOPiv
57%
OCONEt2
NN
ZnOPiv
65%
MeO
OMe
NO
Me
ZnOPiv
71%
N
ZnOPiv
65%
Me
Scheme 18 Preparation of solid functionalized arylzinc pivalates.42
After solvent evaporation the aryl zinc pivalates are obtained as powders with enhanced air
and moisture stability. The solid zinc reagents can be weighed under air, with no significant
40E. von Frankland, Liebigs Ann. Chem. 1849, 71, 171–213.
41a) T. Harada in The Chemistry of Organozinc Compounds, (Hrsg.: I. M. Zvi Rappoport), John Wiley & Sons, Ltd,
Chichester, U.K., 2007, Kap. 15, S. 685–711; b) P. Knochel, H. Leuser, L.-Z. Cong, S. Perrone, F. F. Kneisel in
Handbook of Functionalized Organometallics, (ed.: P. Knochel), John Wiley & Sons, Ltd, New York, 2008, pp.
251–346; c) P. Knochel, M. I. Calaza, E. Hupe in Metal-Catalyzed Cross-Coupling Reactions, John Wiley & Sons,
Ltd, New York, 2008, pp. 619–670; d) A. D. Dilman, V. V. Levin, Tetrahedron Lett. 2016, 57, 3986–3992.
42S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205–9209.
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loss of activity and can be stored under argon for more than a month. These arylzinc pivalates
also underwent palladium-catalyzed Negishi cross-couplings in good to excellent yields (see
Scheme 19).
PEPPSI-i-Pr (2 mol%)
THF, rt, 2 h
Br
R2
(0.84 equiv)
(Het)ArZnOPiv
(Het)Ar
R2
EtO2C
NH2
CO2Et
69%
N
N
91%
NC
N N
71%
OMe
OMe
NO2
99%
CN
O N
MeMe
F
SMe
N
O
O
88%
Scheme 19 Palladium-catalyzed Negishi cross-coupling of aromatic organozinc pivalates.42
A few years later the origin of this enhanced air and moisture stability could be discovered by
X-ray crystallographic, NMR and ESI mass spectrometric studies. In fact, the proper writing of
these organometallics would be RZnCl·Mg(OPiv)2·LiCl and the enhanced stability towards air
was explained by the ability of Mg(OPiv)2 to bind H2O.
43 In the following years a broad range of
unsaturated zinc pivalates have been explored and applied to cross-coupling and electrophilic
quench reactions,44 including alkynyl zinc pivalates.45 Knochel and co-workers could generate
alkynyl zinc pivalates from terminal alkynes by deprotonation with TMPZnOPiv, a TMP base,
which directly introduces a ZnOPiv moiety. This class of unsaturated zinc pivalates showed a high
tolerance towards air and moisture (see Scheme 20).
43A. Hernán-Gómez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. Koszinowski, S. M. Manolikakes, R. E. Mulvey,
C. Schnegelsberg, Angew. Chem. Int. Ed 2014, 53, 2706–2710.
44a) C. I. Stathakis, S. Bernhardt, V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9428–9432; b)S. M.
Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. – Eur. J. 2014, 20, 12289–12297; c) M. Ellwart, P.
Knochel, Angew. Chem. Int. Ed. 2015, 54, 10662–10665; d) Y. Chen, C. Tüllmann, M. Ellwart, P. Knochel, Angew.
Chem. Int. Ed. 2017, 56, 9236–9239; e) J. R. Colombe, S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org.
Lett. 2013, 15, 5754–5757; f) Y.-H. Chen, M. Ellwart, V. Malakhov, P. Knochel, Synthesis 2017, 49, 3215–3223.
45Y.-H. Chen, C. P. Tüllmann, M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2017, 56, 9236–9239.
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THF, rt, 1–2 h
2) solvent evaporation
R1 H R1 ZnOPiv
1) TMPZnOPiv (1.2 equiv)
TMS:    90%
CO2Et:  82%
Cy:        73%
R1 =
EtO2C NC
90% 87%
S
90%
OTMSH
H
H
H
43%
Scheme 20 Preparation of functionalized solid alkynylzinc pivalates. The following yields of the
zinc pivalates were determined after 4 h under air.45
According to the aryl analogs the alkynyl zinc pivalates underwent palladium-catalyzed
Negishi-type cross-couplings with various aryl halides, leading to functionalized alkynes (see
Scheme 21).
THF, 25–60 °C, 6–48 h
R1 ZnOPiv
Pd(dba)2 (2 mol%)
DavePhos (4 mol%)
Hal
R2
(0.84 equiv)
R1 R2
TMS
COMe
89%
n-Bu
CHO
OMe
76%
N
92%
S
Scheme 21 Palladium-catalyzed Negishi cross-coupling of alkynylzinc pivalates.45
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8 Cobalt-Catalyzed Cross-Couplings using Organozinc Pivalates
The advantages of these solid organozinc compounds were used for cobalt-catalysis. Hammann
et al. reported in 2017 a broadly applicable cobalt-catalyzed cross-coupling of functionalized
bench-stable organozinc pivalates with unsaturated halides.46 Using (4-methoxy-phenyl) zinc
pivalate instead of the corresponding arylzinc chloride resulted in almost twice the amount of
arylated product (see Scheme 22).
THF, 40 °C, 16 h
CoCl2 (5 mol%)
(1.5 equiv)
NC
Br
F
MetMeO
NC
F
OMe
Met = ZnCl:     41% 
Met = ZnOPiv: 80%
THF, -40–40 °C, 16 h
CoCl2 (5 mol%)
(1.5 equiv)
R3
Hal
(Het)Ar-ZnOPiv
R1 R1
EtO2C
OMe
N
N
SMe
CO2Et CF3
80%, (E/Z = 97:3)85%61%
OMe
EtO2C
71%
R2
R3
R2
(Het)Ar
Scheme 22 Cobalt-catalyzed of functionalized organozinc pivalates unsaturated halides.46
The utilization of arylzinc pivalates made the additional use of ligands redundant. This protocol
not only allows the coupling of aryl halides or heterocyclic halides, but also cis-alkene iodides,
which proceed in a stereoselective manner and even alkynyl bromides were suitable coupling
partners.
Furthermore, the previous developed alkynylzinc pivalates could also be used in cobalt-catalyzed
C(sp)-C(sp)2-couplings with (hetero)aryl halides as electrophilic coupling partners.47A catalytic
system consisting of CoCl2·2LiCl and TMEDA enabled the alkynylation of various N-heterocycles
and aromatics (see Scheme 23). However, the reaction only allowed the coupling of bulky
alkynylzinc pivalates.
46J. M. Hammann, F. H. Lutter, D. Haas, P. Knochel, Angew. Chem. Int. Ed. 2017, 56, 1082–1086.
47 J. M. Hammann, L. Thomas, Y.-H. Chen, D. Haas, P. Knochel, Org. Lett. 2017, 19, 3847–3850.
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dioxane, rt, 8 h
CoCl22LiCl (20 mol%)
TMEDA (2.0 equiv)
(1.9–3.5 equiv)
(Het)Ar
R2
R2 ZnOPiv
Ph
O
R2
Me
OTES
Me
OTES
Me
i-Pr
Me
90%
81%
69%
R2 =
TIPS
EtO2C
75%
TIPS
ortho: 65%
meta: 84%
para:  95%
N
TIPS
81%
CF3
N
N
TIPS
52%
X = Cl, Br, I
(Het)Ar-X
Me
H
H
H
H
OTES
R2 = NC
75%
Scheme 23 Cobalt-catalyzed cross couplings of alkynylzinc pivalates with (hetero)aryl and
alkenyl halides.47
Apart from cobalt-catalyzed carbon-carbon bond formations, also cobalt-catalyzed amination
reactions using organozinc pivalates have been discovered.48 In 2018 Chen et al. reported a
CoCl2·2LiCl catalyzed electrophilic amination of O-benzoylhydroxylamines with various aryl and
heteroarylzinc pivalates. Remarkably, under this protocol (hetero)aryl zinc pivalates generated by
directed metalation with TMP-bases were suitable coupling partners. The key for the usage of this
organometal reagents under cobalt catalysis, was the addition of TMEDA, presumably TMEDA
prevents remaining TMP from a coordination with cobalt.
CoCl22LiCl (2.5 mol%)
(TMEDA 5.0 mol%)
THF, rt, 2 h
ZnOPiv
R3
BzO
N
R2
R1
N
R3 R1
R2
NC
N
O
93 %
N O
N
Me
H
O
80%
N
Me
MePh
MeO
97%
(1.1 equiv)
N
O
81%
CF3
Scheme 24 Cobalt-catalyzed electrophilic amination of (hetero)arylzinc pivalates with
N-hydroxylamine benzoates.48
48Y.-H. Chen, S. Graßl, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 1108–1111.
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9 Objectives
Organozinc compounds with their unique combination of high tolerance of sensitive functional
groups and high reactivity, are valuable organometallic reagents for transition-metal catalyzed
cross-couplings.29,41 Although they have found their way to cobalt-catalyzed cross-coupling
reactions, there is still a lack of convenient transformations.33 Therefore, the aim of this thesis was
the development of new cobalt-catalyzed cross-coupling protocols, using zinc organometallics for
the synthesis of new small molecules.
Alkynes play an important role in the synthesis of natural products and bioactive molecules,
furthermore they are components in functional materials, like polymers, dyes and organic
light-emitting diodes (OLEDs).22,49 Thus, methods for the introduction of the alkynyl unit
into organic molecules and especially stereoselective versions are highly desirable. Although
stereoselective cobalt-catalyzed cross-couplings using Grignard reagents have been reported,
no diastereoselective Negishi-type reactions are available. In addition, these protocols only gave
satisfactory diastereoselectivities for 1,2-substituted systems.
Y X
R1
X = I, Br
Y = CH, O
R2 ZnOPiv
Co catalysis
Y
R1
R2
Scheme 25 Cobalt-catalyzed diastereoselective C(sp)-C(sp3) cross-coupling.
The carbonyl group is a central motif in organic chemistry and a convenient way for the
construction of unsymmetrical ketones are acylation reactions.29a,50 One protocol for the synthesis
of functionalized ketones is the Fukuyama-coupling, using organothio ester and organozinc halides
under palladium catalysis.51 Due to the high price of palladium a cobalt-catalyzed acylation
reaction using organothio esters and air and moisture stable arylzinc pivalates is therefore highly
desirable.52
49a) S. Nakatsuji, K. Nakashima, S. Akiyama, H. Nakazumi, Dyes and Pigments 1994, 24, 37–57; b) M. Kivala, F.
Diederich, Acc. Chem. Res. 2009, 42, 235–248.
50D. S. Walter in Comprehensive Organic Functional Group Transformations, (Hrsg.: A. R. Katritzky, O. Meth-Cohn,
C. W. Rees), Elsevier Science, Oxford, 1995, S. 277–312.
51H. Tokuyama, S. Yokoshima, T. Yamashita, T. Fukuyama, Tetrahedron Lett. 1998, 39, 3189 –3192.
52a) World market price for palladium:1,865.37e/ozt, 59.98 e/g, 6383 e/mol and for cobalt: 27,277.82 e/t, 0.027 e/g,
1.59 e/mol, from http://www.infomine.com/investment/metal-prices, retrieved 25. March 2020; b) This project was
developed in cooperation with Ferdinand H. Lutter, see F. H. Lutter, L. Grokenberger, M. S. Hofmayer, P. Knochel,
Chem. Sci. 2019, 10, 8241–8245 and Ferdinand H. Lutter Dissertation, LMU Munich.
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R1 SR2
R1 = Alkyl, Aryl
(Het)ArZnOPiv
Co catalysis
O
R1 (Het)Ar
O
Scheme 26 Cobalt-catalyzed Fukuyama-type reaction.
Whereas many cobalt-catalyzed cross-couplings for the formation of C(sp3)-C(sp2) centers
focus on the use of unsaturated metallic reagents with alkyl electrophiles, the use of alkyl
organometallics is rare, especially the use of alkylzinc reagents.9 A general method for the
coupling of alkylzinc reagents with aryl halides under cobalt catalysis is higly appreciated
and also the use of secondary cyclohexyl zinc species for the alkylation of arylhalides in a
diastereoselective manner would be desirable.53
AlkZnCl
Co catalysisY
X = I, Br
Y = CH, O
X Y Alk
Scheme 27 Cobalt-catalyzed cross-coupling of alkylzinc reagents.
53This project was developed in cooperation with Ferdinand H. Lutter, see F. H. Lutter, L. Grokenberger, P. Spieß,
J. M. Hammann, K. Karaghiosoff, P. Knochel, Angewandte Chemie International Edition 2020, 59, 5546–5550 and
Ferdinand H. Lutter Dissertation, LMU Munich.
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1 Cobalt-Catalyzed Diastereoselective Cross-Couplings between
Alkynylzinc Pivalates and Functionalized Cyclic Iodides or
Bromides
1.1 Introduction
Transition-metal catalyzed diastereoselective cross-couplings represent an excellent way for
the stereoselective synthesis of organic molecules.19c,54 Although palladium-salts have been
employed for such stereoselective cross-couplings,55 the use of alternative, less expensive, and
less toxic transition-metals such as iron-salts56 or cobalt-salts,9,25,26,57 has recently attracted
a lot of attention. In most cross-coupling reactions, organomagnesium reagents, including
alkynylmagnesium halides, are the preferred nucleophiles.26,55e,56e,57c,58 As already previously
mentioned, the use of organozinc reagents can be advantageous for such cross-couplings
because of the high tolerance of functional groups of these organometallics.29b Particularly, the use
of organozinc pivalates of the type RZnOPivMgX2
42,44 enables fast and efficient cobalt-catalyzed
cross-couplings.46 Cheng et al. reported that alkynylzinc pivalates are readily prepared from
54a) S. Chemler, D. Trauner, S. Danishefsky, Angew. Chem. Int. Ed. 2001, 40, 4544–4568; b) D. A. Powell, T. Maki,
G. C. Fu, J. Am. Chem. Soc. 2005, 127, 510–511; c) A. H. Cherney, N. T. Kadunce, S. E. Reisman, Chem. Rev.
2015, 115, 9587–9652.
55a) K. C. Nicolaou, P. G. Bulger, D. Sarlah, Angew. Chem. Int. Ed. 2005, 44, 4442–4489; b) T. Thaler, B. Haag,
A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, Nat. Chem. 2010,
2, 125–130; c) T. Thaler, L.-N. Guo, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 2174–2177; d) S.
Seel, T. Thaler, K. Takatsu, C. Zhang, H. Zipse, B. F. Straub, P. Mayer, P. Knochel, J. Am. Chem. Soc. 2011,
133, 4774–4777; e) C. E. I. Knappke, A. Jacobi von Wangelin, Chem. Soc. Rev. 2011, 40, 4948–4962; f) L. Li,
C.-Y. Wang, R. Huang, M. R. Biscoe, Nat. Chem. 2013, 5, 607–612.
56 a) C. Bolm, J. Legros, J. Le Paih, L. Zani, Chem. Rev. 2004, 104, 6217–6254; b) B. D. Sherry, A. Fürstner, Acc. Chem.
Res. 2008, 41, 1500–1511; c) I. Bauer, H.-J. Knölker, Chem. Rev. 2015, 115, 3170–3387; For diastereoselective
reactions, see: d) M. Nakamura, K. Matsuo, S. Ito, E. Nakamura, J. Am. Chem. Soc. 2004, 126, 3686–3687; e)
A. K. Steib, T. Thaler, K. Komeyama, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 3303–3307; f) L. Adak,
S. Kawamura, G. Toma, T. Takenaka, K. Isozaki, H. Takaya, A. Orita, H. C. Li, T. K. M. Shing, M. Nakamura, J. Am.
Chem. Soc. 2017, 139, 10693–10701.
57 a) H. Ohmiya, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2006, 128, 1886–1889; b) H. Ohmiya, H. Yorimitsu, K.
Oshima, Org. Lett. 2006, 8, 3093–3096; c) J. M. Hammann, A. K. Steib, P. Knochel, Org. Lett. 2014, 16, 6500–6503.
58 a) T. Hatakeyama, Y. Okada, Y. Yoshimoto, M. Nakamura, Angew. Chem. Int. Ed. 2011, 50, 10973–10976; b)
C. W. Cheung, P. Ren, X. Hu, Org. Lett. 2014, 16, 2566–2569; c) O. Vechorkin, A. Godinat, R. Scopelliti, X. Hu,
Angew. Chem. Int. Ed. 2011, 50, 11777–11781.
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the corresponding alkynes. After solvent evaporation, solid organozinc pivalates are obtained
with enhanced air and moisture stability.45 Also, these organozinc pivalates undergo convenient
cobalt-catalyzed cross-couplings with aryl halides and heteroaryl halides.47
1.2 Design of the Procedure
In preliminary experiments, 3-isopropylcyclohexyl iodide (1a) was treated with
2-phenylethynyl-zinc pivalate (2a) at 0 ◦C under various conditions (see Table 1). First,
some low-cost transition-metal salts were tested without any additive or in the presence of
TMEDA.47 However, NiCl2,
58c,59 MnCl2,
60 FeCl2,
56e,58a, 58b and CuCl2
61 were unsuitable metal
catalysts for this coupling (entries 1–8). However, using 20 mol% of CoCl2 and TMEDA as an
additive provided 3a in 67% yield, but with a moderate diastereoselectivity (dr = 85:15, entry 10).
Table 1 Optimization of the reaction conditions for diastereoselective cross-coupling of
1,3-disubstituted cyclohexyl iodode 1a with alkynylzinc pivalate 2a.
Ph ZnOPiv
solvent, 0 °C, 8 h
Ii-Pr
1a
2a (equiv)
i-Pr
Ph
3a
catalyst (mol%)
additive (equiv)
Entry Catalyst Ligand 2a Solvent Yield of 3aa dra
(Loading [mol%]) (Amount [equiv]) [equiv] [%]
1 NiCl2 (20) – 1.5 THF 0 –
2 NiCl2 (20) TMEDA (2.0) 1.5 THF 0 –
3 MnCl2 (20) – 1.5 THF 0 –
4 MnCl2 (20) TMEDA (2.0) 1.5 THF 0 –
5 FeCl2(20) – 1.5 THF 0 –
6 FeCl2(20) TMEDA (2.0) 1.5 THF 0 –
7 CuCl2(20) – 1.5 THF 0 –
8 CuCl2(20) TMEDA (2.0) 1.5 THF 0 –
9 CoCl2 (20) – 1.5 THF 5 80:20
10 CoCl2 (20) TMEDA (2.0) 1.5 THF 67 85:15
11 CoBr2 (20) TMEDA (2.0) 1.5 THF 11 85:15
59a) H. Gong, M. R. Gagné, J. Am. Chem. Soc. 2008, 130, 12177–12183; b) J. Caeiro, J. Pérez Sestelo, L. A.
Sarandeses, Chem. – Eur. J. 2008, 14, 741–746; c) G. Xu, X. Li, H. Sun, J. Organomet. Chem. 2011, 696,
3011–3014.
60G. Cahiez, C. Duplais, J. Buendia, Angew. Chem. 2009, 121, 6859–6862.
61S. Thapa, B. Shrestha, S. K. Gurung, R. Giri, Org. Biomol. Chem. 2015, 13, 4816–4827.
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Entry Catalyst Ligand 2a Solvent Yield of 3aa dra
(Loading [mol%]) (Amount [equiv]) [equiv] [%]
12 CoCl2·2LiCl (20) TMEDA (2.0) 1.5 THF 62 85:15
13 CoCl2 (20) bipy
b (2.0) 1.5 THF 2 n.d
14 CoCl2 (20) neocuproine (2.0) 1.5 THF 38 88:12
15 CoCl2 (20) Me4DACH
c (2.0) 1.5 THF 86 (78)d 92:8
16 CoCl2 (20) Me4DACH (2.0) 1.5 THF 85
e 92:8
17 CoCl2 (5) Me4DACH (2.0) 1.5 THF 43 92:8
18 CoCl2 (10) Me4DACH (2.0) 1.5 THF 58 92:8
19 CoCl2 (30) Me4DACH (2.0) 1.5 THF 83 92:8
20 CoCl2 (20) Me4DACH (0.5) 1.5 THF 63 92:8
22 CoCl2 (20) Me4DACH (1.0) 1.5 THF 63 92:8
23 CoCl2 (20) Me4DACH (1.5) 1.5 THF 75 92:8
24 CoCl2 (20) Me4DACH (2.0) 1.5 dioxane 86 92:8
25 CoCl2 (20) Me4DACH (2.0) 1.5 DME 82 92:8
26 CoCl2 (20) Me4DACH (2.0) 1.5 t-BuOMe 79 91:9
27 CoCl2 (20) Me4DACH (2.0) 1.5 NMP 12 92:8
28 CoCl2 (20) Me4DACH (2.0) 1.5 DMPU 15 89:11
29 CoCl2 (20) Me4DACH (2.0) 1.5 2-MeTHF 83 91:9
30 CoCl2 (20) Me4DACH (2.0) 1.2 THF 76 92:8
31 CoCl2 (20) Me4DACH (2.0) 1.8 THF 78 92:8
32 CoCl2 (20) Me4DACH (2.0) 2.0 THF 19 92:8
33 CoCl2 (20) Me4DACH (2.0) 1.5 THF 56
f 92:8
a Determined by GC analysis. Tetradecane (C14H30) was used as internal standard. Reactions
were performed on a 0.5 mmol scale. Only the major diastereomer is shown.b 2,2’-Bipyridine. c
trans-N,N,N ’,N ’-Tetramethylcyclohexane-1,2-diamine. d Isolated yield of analytically pure product. e CoCl2
(99.99% purity) was used.f The reaction was performed at rt.
Other cobalt sources, such as CoBr2 or CoCl2·2LiCl, did not have beneficial effects (entries
11–12). The diastereoselectivity was improved by screening various N-heterocyclic ligands
(entries 13–15). Clearly, trans-N,N,N ’,N ’-tetramethylcyclohexane-1,2-diamine (Me4DACH) gave
the best results (entry 15). At this point, it was verified that no other traces of metal contaminations
22
II RESULTS AND DISCUSSION
are responsible for this catalysis. Thus, using CoCl2 (99.99% purity) led to 3a in 85% yield
(dr = 92:8, entry 16). With a decrease of the catalyst loading the yield of the coupling product 3a
significantly drops (entries 17–18). Also, a higher catalyst loading did not improve the reaction
outcome (entry 19). Furthermore, it was shown that less than 2.0 equivalents of Me4DACH lead
to significantly lower formation of product 3a (entries 20–23). Varying the solvent system and the
amount of the organometallic reagent 2a did not improve the reaction outcome (entries 24–32).
1.3 Cobalt-Catalyzed Diastereoselective Cross-Couplings of 1,3-Disubstituted
Cyclohexyl Iodides
With these optimized reaction conditions in hand, a range of coupling reactions of various
alkynylzinc pivalates of type 2 with 1,3-substituted cyclic alkyl iodides of type 1 was performed,
furnishing the thermodynamically favored cis-isomer 3 (see Table 2).62 The coupling of 1a with
bulky alkynes, such as zinc pivalates 2b or 2c, resulted in the corresponding coupling products
(3b or 3c) in 91%–95% yield and high diastereoselectivity (dr = 95:5–98:2, entries 1–2).
Table 2 Cross-coupling of 1,3-disubstituted cyclic (hetero)alkyl halides (1) with various
alkynylzinc pivalates (2).
R2 ZnOPiv
THF, 0 °C, 8 h
IR1
1
2 (1.5 equiv)
R1
R2
3
NMe2Me2N
Me4DACH
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3: yielda (dr)
i-Pr I
PivOZn TIPS
i-Pr
TIPS
1 1a (99:1) 2b 3b: 95% (95:5)
PivOZn
TESO i-Pr
TESO
2 1a (99:1) 2c 3c: 91% (98:2)
62The stereochemistry of 3a and 3b was confirmed by literature NMR data. See T. Thaler, L.-N. Guo, P. Mayer,
P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 2174–2177.
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Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3: yielda (dr)
CF3 I
PivOZn
Me
Me
OTMS
CF3
Me Me
OTMS
3 1b (99:1) 2d 3d: 62% (90:10)
I
MeO Me Me
OTMS
MeO
4 1c (99:1) 2d 3e: 78% (98:2)
O
Ph I
PivOZn Ph O
Ph
Ph
5 1d (99:1) 2a 3f: 76% (93:7)
i-Pr
H
Me
Me
I
PivOZn F i-Pr
H
Me
Me
F
6 1e (85:15) 2e 3g: 60% (94:6)
a Isolated yield of analytically pure product. The diastereoselectivity (dr) was determined by GC analysis
from the crude mixture.
Also, the propargylic alcohol derivative 2d was successfully coupled with cyclic iodides
bearing a trifluoromethyl 1b and an aryl group 1c, providing 3d and 3e in 62%–78% yield,
respectively, with a diastereomeric ratio of up to 98:2 (entries 3–4). The pyran derivative 3f was
obtained by coupling of the heterocyclic iodide 1d with 2a in 76% yield and diastereomeric ratio
of 93:7 (entry 5).
Remarkably, the cross-coupling of iodide 1e, derived from the natural product (+)-nootkatone,63
proceeded smoothly with alkynylzinc pivalate 2e, furnishing 3g in 60% yield (dr = 96:4, entry 6).
63X. Mu, Y. Shibata, Y. Makida, G. C. Fu, Angew. Chem. Int. Ed. 2017, 56, 5821–5824.
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1.4 Cobalt-Catalyzed Diastereoselective Cross-Couplings of 1,4-Disubstituted
Cyclohexyl Halides
Furthermore, this cobalt-catalyzed cross-coupling was applied to 1,4-disubstituted cyclohexyl
halides, leading to the corresponding trans-coupling products (see Table 3).64 Thus, 4-phenyl
cyclohexyl iodide (1f) reacted smoothly with various alkynylzinc pivalates (2f, 2g, 2h, 2b), resulting
in the products 3h–3k in 68%–96% yield (dr = 90:10–99:1, entries 1–4).
Table 3 Cross-coupling of 1,4-disubstituted cyclohexyl halides (1) with various alkynylzinc
pivalates (2).
R2 ZnOPiv
THF, 0 °C, 8 h
I
1
2 (1.5 equiv) R2
3
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
R1 R1
Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3: yielda (dr)
Ph
I PivOZn
Cl Ph
Cl
1 1f (92:8) 2f 3h: 68% (90:10)
PivOZn
Me
Me
OTES Ph
Me Me
OTES
2 1f (92:8) 2g 3i: 95% (99:1)
PivOZn Ph
3 1f (92:8) 2h 3j: 71% (95:5)
PivOZn TIPS Ph
TIPS
4 1f (92:8) 2b 3k: 96% (98:2)
64The stereochemistry of the product 3o was determined by crystal structure analysis, see appendix.
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Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3: yielda
I
EtO2C
PivOZn
Me
OTES
i-Pr EtO2C
Me OTES
i-Pr
5 1g (68:32) 2i 3l: 71% (90:10)
I
N
Me
Me
PivOZn
N
Me
Me
6 1h (90:10) 2j 3m: 83% (95:5)
X
t-Bu PivOZn TMS t-Bu
TMS
7 1i: X = Br (99:1) 2k 3n: 71% (90:10)
8 1j: X = I (99:1) 2k 3n: 84% (90:10)
PivOZn OMe
t-Bu
OMe
9 1j (99:1) 2l 3o: 73% (94:6)
a Isolated yield of analytically pure product. The diastereoselectivity (dr) was determined by GC analysis
from the crude mixture.
Also, an ester function was tolerated in this cross-coupling reaction and the iodoester
1g was converted to the trans-alkyne 3l in 71% yield (dr = 90:10, entry 5). Furthermore, pyrrole
derivative 1h was coupled with 2j, furnishing the trans-pyrrole-substituted cyclohexane derivative
3m in 83% yield and a dr of 95:5 (entry 6). 4-(tert-Butyl)cyclohexyl bromide (1i) reacts readily
with the silylated alkynylzinc pivalate 2k, leading to the trans-1,4-cyclohexane derivative 3n (71%,
dr = 90:10, entry 7). Also, the corresponding cyclohexyl iodide 1j undergoes such couplings with
alkynylzinc pivalates 2k and 2l, providing the products 3n and 3o in 73%–84% yields and a
diastereoselectivity up to 94:6 (entries 8–9).
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1.5 Cobalt-Catalyzed Diastereoselective Cross-Couplings of 1,2-Disubstituted
Cyclic (Hetero)alkyl Halides
Moreover, this cross-coupling was performed with 1,2-substituted cyclic halides and
bromo-glycosides (see Table 4).56f,25a TBS-protected iodo- or bromohydrins 1k and 1l were
successfully coupled with alkynylzinc pivalate 2b, leading to the thermodynamically preferred
trans-substituted product 3p in 60%–78% yield (dr = 99:1, entry 1).65 Similarly, iodohydrin 1k
reacted with 2a to give the trans-1,2- disubstituted cyclohexane derivative 3q in 72% yield (dr =
94:6, entry 3). Bicyclic bromide 1m bearing a ketone moiety was converted to the alkynylated
product 3r in 62% yield (dr = 99:1, entry 4).
Table 4 Cross-coupling of 1,2-disubstituted cyclic (hetero)alkyl halides (1) with various
alkynylzinc pivalates (2)
Y
R2 ZnOPiv
THF, 0 °C, 8 h
1, Y = CH, O
2 (1.5 equiv)
Y
3
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
I
R1 R1
R2
Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3a: yielda (dr)
X
OTBS PivOZn TIPS OTBS
TIPS
1 1k: X = I (99:1) 2b 3p: 77%b (99:1)
2 1l: X = Br (99:1) 2b 3p: 60% (99:1)
PivOZn Ph OTBS
Ph
3 1k (99:1) 2a 3q: 72% (96:4)
O
Br
OTBS
H
H PivOZn
O
OTBS
Cy
H
H
4 1m (99:1) 2m 3r: 62% (99:1)
65The stereochemistry of 3p was confirmed by literature NMR data. See J. M. Hammann, D. Haas, C.-P. Tüllmann,
K. Karaghiosoff, P. Knochel, Org. Lett. 2016, 18, 4778–4781.
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Entry Electrophile Zinc reagent PivOZn-R Product
1 (dr) 2 3a: yielda
O
I
OTBS
PivOZn
Cl
O
OTBS
Cl
5 1n (99:1) 2n 3s: 63% (99:1)
TsN
I
OTBS
PivOZn OMe TsN
OTBS
OMe
6 1o (99:1) 2l 3t: 75% (99:1)
O
AcO
OAc
OAc
Br
AcO
O
AcO
OAc
OAc
AcO
OMe
7 1p (99:1) 2l 3u: 54% (94:6)
O
AcO
OAc
OAc
Br
AcO
PivOZn TMS
O
AcO
OAc
OAc
AcO
TMS
8 1p (99:1) 2k 3v: 52% (95:5)
a Isolated yield of analytically pure product. The diastereoselectivity (dr) was determined by GC analysis
from the crude mixture. b 5 mmol scale.
This cobalt-catalyzed cross-coupling was further extended to five-membered heterocyclic
halohydrins 1n and 1o (entries 5–6). The coupling of the TBS-protected cyclic iodohydrin 1n
with alkynylzinc pivalate 2n afforded the substituted tetrahydrofuran 3s in 63% yield (dr = 99:1,
entry 5). Coupling of the iodopyrrolidine derivative 1o with 2l afforded the trans-1,2-disubstituted
heterocycle 3t in 75% yield and high diastereoselectivity (dr = 99:1, entry 6). Remarkably,
this diastereoselective cross-coupling could also be performed using the bromo-glycoside
1p. Thus, galactose derivative 1p was successfully cross-coupled under cobalt catalysis with
alkynylzinc pivalates 2l and 2k, furnishing the α-C-glycosides 3u and 3v in 52%–54% yields
and high α/β-selectivity (α/β = 94:6–95:5, entries 7–8). The stereochemical outcome of these
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cobalt-catalyzed cross-couplings with bromo-glycosides could be explained with the formation of
an anomeric α-radical intermediate.9b,25a,66 The reaction between the allyl-protected iodohydrin
1q and the alkynylzinc pivalate 2k led to the bicyclic product 3w in 68% yield (dr = 95:5; see
Scheme 28).67 This result indicates a radical pathway for this cross-coupling.
O O O O
TMS
3w: 68% yield (dr = 95:5)
I
1q
H
H
TMS ZnOPiv
THF, 0 °C, 8 h
2k (1.5 equiv)
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
Scheme 28 Diastereoselective cyclization of iodide 1q with alkynylzinc pivalate 2k.
1.6 Cobalt-Catalyzed Diastereoselective Cross-Couplings with Steroid
Derivatives
Finally, silylated alkynylzinc reagent 2k was coupled with steroid derivatives (see Scheme 29).
The iodinated cholesteryl derivative (1r) was succesfully cross-coupled with 2k leading to the
alkynylated steroid derivative 3x in 75% yield (dr = 98:2, see Scheme 29 a).68 Remarkably, the
use of an iodo-epiandrosterone derivative 1s containing a ketone moiety also proceeded smoothly
in 84% yield affording steroid 3y (see Scheme 29 b).
i-Pr
Me
Me
Me
I
H
H
H
i-Pr
Me
Me
Me
H
H
H
TMS 3x: 75% yield (dr = 99:1)
TMS ZnOPiv
THF, 0 °C, 8 h
2k (1.5 equiv)
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
1r
Me
Me
I
H
H
H
OMe
Me
H
H
H
TMS
3y: 84% yield (dr = 92:8)
TMS ZnOPiv
THF, 0 °C, 8 h
2k (1.5 equiv)
CoCl2 (20 mol%)
Me4DACH (2.0 equiv)
1s
O
a)
b)
HH
Scheme 29 Diastereoselective cross-coupling of steroid derivatives 1r and 1s with alkynylzinc
pivalate 2k
66a) R. M. Adlington, J. E. Baldwin, A. Basak, R. P. Kozyrod, J. Chem. Soc., Chem. Commun. 1983, 944–945; b)
J. Dupuis, B. Giese, D. Rüegge, H. Fischer, H.-G. Korth, R. Sustmann, Angew. Chem. Int. Ed. Engl. 1984, 23,
896–898; c) H. Abe, S. Shuto, A. Matsuda, J. Am. Chem. Soc. 2001, 123, 11870–11882; d) G. Li, D.-C. Xiong,
X.-S. Ye, Synlett 2011, 2011, 2410–2414; e) K. Wakabayashi, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2001,
123, 5374–5375; f) K. O. T. Tsuji, H. Yorimitsu, Angew. Chem. Int. Ed. 2002, 41, 4137–4139.
67The stereochemistry of 3w was determined by NOESY-NMR spectroscopy. See Appendix.
68The stereochemistry of 3x was determined by crystal structure analysis. See Appendix.
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2 Cobalt-Catalyzed Acylation-Reactions of (Hetero)arylzinc
Pivalates with Thiopyridyl Ester Derivatives
2.1 Introduction
The carbonyl group is a central functionality in organic chemistry and the performance of
acylation reactions employing organometallic reagents represents a general access to various
ketones.29a,69 A major drawback of these reactions is the moderate chemoselectivity or the use
of expensive catalysts.29a,69 Acid chlorides are the most common acylation reagents.29a,31,69,70
However, their preparation requires harsh conditions, thus lowering the functional group tolerance.
In contrast, the use of thioesters is a valuable alternative since Fukuyama showed in his pioneering
work that these acylating reagents react readily with organozinc halides in the presence of a
palladium catalyst.51. Additionally, Seki,71 Rovis,72 Fleischer,73 and others74 showed that these
reactions can be performed using various transition-metal catalysts. Recently, the knochel group
has shown that organozinc pivalates (RZnOPiv) are an attractive class of zinc organometallics
due to their enhanced air- and moisture stability and their excellent compatibility with various
transition-metal catalyzed transformations.42,44,45,75 Especially, cobalt-catalyzed reactions have
proven to be advantageous.46,47,48,76
2.2 Design of the Procedure
Although most thioesters are readily available from the corresponding acid chlorides and thiols, the
thioesters were directly synthesized from caboxylic acids of type 4 using Mukaiyama’s method77
into the corresponding thioesters 5 under exceedingly mild and neutral conditions.
69 D. A. Shirley, Organic Reactions, Wiley-VCH, Weinheim, 2011.
70a) P. Knochel, R. D. Singer, Chem. Rev. 1993, 93, 2117–2188; b) C. K. Reddy, P. Knochel, Angew. Chem. Int.
Ed. Engl. 1996, 35, 1700–1701; c) Handbook of Functionalized Organometallics, (Ed.: P. Knochel), Wiley- VCH,
Weinheim, 2005; d) S.-H. Kim, R. D. Rieke, Tetrahedron Lett. 2011, 52, 1523 –1526.
71T. Shimizu, M. Seki, Tetrahedron Lett. 2002, 43, 1039 –1042.
72Y. Zhang, T. Rovis, J. Am. Chem. Soc. 2004, 126, 15964–15965.
73P. H. Gehrtz, P. Kathe, I. Fleischer, Chem. – Eur. J. 2018, 24, 8774–8778.
74a) M. Onaka, Y. Matsuoka, T. Mukaiyama, Chem. Lett. 1981, 10, 531–534; b) C. Cardellicchio, V. Fiandanese, G.
Marchese, L. Ronzini, Tetrahedron Lett. 1985, 26, 3595 –3598; c) W. Oppolzer, C. Darcel, P. Rochet, S. Rosset, J.
De Brabander, Helvetica Chimica Acta 1997, 80, 1319–1337; d) B. Li, R. A. Buzon, C. K.-F. Chiu, S. T. Colgan, M. L.
Jorgensen, N. Kasthurikrishnan, Tetrahedron Lett. 2004, 45, 6887 –6890; e) K. Kunchithapatham, C. C. Eichman,
J. P. Stambuli, Chem. Commun. 2011, 47, 12679–12681; f) A. H. Cherney, S. E. Reisman, Tetrahedron 2014, 70,
3259 –3265, g) R. Haraguchi, S.-g. Tanazawa, N. Tokunaga, S.-i. Fukuzawa, Org. Lett. 2017, 19, 1646–1649.
75a) C. P. Tüllmann, Y.-H. Chen, R. J. Schuster, P. Knochel, Org. Lett. 2018, 20, 4601–4605; b) M. S. Hofmayer,
F. H. Lutter, L. Grokenberger, J. M. Hammann, P. Knochel, Org. Lett. 2019, 21, 36–39.
76a) M. S. Hofmayer, J. M. Hammann, F. H. Lutter, P. Knochel, Synthesis 2017, 49, 3925–3930; b) L. Thomas, F. H.
Lutter, M. S. Hofmayer, K. Karaghiosoff, P. Knochel, Org. Lett. 2018, 20, 2441–2444; c) F. H. Lutter, S. Graßl,
L. Grokenberger, M. S. Hofmayer, Y.-H. Chen, P. Knochel, ChemCatChem 2019, 11, 5188–5197.
77a) T. Endo, S. Ikenaga, T. Mukaiyama, Bull. Chem. Soc. Jpn. 1970, 43, 2632–2633; b) T. Mukaiyama, M. Araki,
H. Takei, J. Am. Chem. Soc. 1973, 95, 4763–4765; c) T. Hofmann, P. Schieberle, J. Agric. Food. Chem. 1998, 46,
616–619.
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R1 OH
O
R1: 1°, 2°, 3° alkyl, benzyl, (hetero)aryl
PySSPy (1.0–1.1 equiv) 
PPh3 (1.0–1.5 equiv)
MeCN, reflux 3 h or 0 °C 16 h R SPy
O
CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF, 0°C or rt, 4 h
(Het)Ar-ZnOPiv
6 (1.9 equiv)
R (Het)Ar
O
4 5 7
Scheme 30 Preparation of thiolpyridyl ester of type 5 from carboxylic acids 4 and
cobalt-catalyzed acylation with organozinc pivalates 6, affording ketones of type 7.
In preliminary experiments, S-(pyridin-2-yl)-cyclohexanecarbothioate (5a) was treated with
4-(methoxyphenyl)zinc pivalate (6a) under various conditions (see Table 5). In the absence
of a catalyst, ketone 7a was obtained in only 9% yield (entry 1). Although palladium and nickel are
well-known metal catalysts for the Fukuyama acylation, the use of cheaper6e and more abundant
catalysts is highly desirable. Whereas, MnCl2, CrCl2 , FeCl2 or CuCl2 gave unsatisfying results
(entries 2–5), CoCl2 proved to be an excellent catalyst for this transformation (entry 6). Its catalytic
efficiency could be further improved by the addition of various ligands.
Table 5 Optimization of the reaction conditions for the acylation of thioester 5a with arylzinc 6a.
SPy
O catalyst (mol%)
ligand (mol%)
solvent, rt, 4 h
6a (equiv)
O
5a 7a
MeO ZnOPiv
OMe
Entry Catalyst Ligand Equivalents of Solvent Yield of 7aa
(Loading [mol%]) (Amount [mol%]) 6a [%]
1 – – 1.5 THF 9
2 MnCl2 (10) – 1.9 THF traces
3 CrCl2 (10) – 1.9 THF traces
4 FeCl2 (10) – 1.9 THF 50
5 CuCl2 (10) – 1.9 THF 29
6 CoCl2 (10) – 1.9 THF 67
7 CoCl2 (10) PPh3 (20) 1.9 THF 63
8 CoCl2 (10) TMEDA (10) 1.9 THF 64
9 CoCl2 (10) neocuproine (10) 1.9 THF 49
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Entry Catalyst Ligand Equivalents of Solvent Yield of 7aa
(Loading [mol%]) (Amount [mol%]) 6a [%]
10 CoCl2 (10) bipy
b (10) 1.9 THF 71
11 CoCl2 (10) dtbbpy
c (10) 1.9 THF 90 (88)d (87)e
12 CoCl2
f (10) dtbbpy (10) 1.9 THF 86
13 CoCl2 (5) dtbbpy (5) 1.9 THF 81
14 CoCl2 (20) dtbbpy (20) 1.9 THF 92
15 CoCl2 (10) dtbbpy (10) 1.5 THF 85
16 CoCl2 (10) dtbbpy (10) 2.5 THF 87
17 CoCl2 (10) dtbbpy (10) 1.9 MeCN 89
18 CoCl2 (10) dtbbpy (10) 1.9 1,4-dioxane 90
19 CoCl2 (10) dtbbpy (10) 1.9 2-MeTHF 87
20 CoCl2 (10) dtbbpy (10) 1.9 THF 80
g
21 CoCl2 (10) dtbbpy (10) 1.9 THF 80
h
22 CoBr2 (10) dtbbpy (10) 1.9 THF 86
23 Co(acac)2 (10) dtbbpy (10) 1.9 THF 86
24 Co(acac)3 (10) dtbbpy (10) 1.9 THF 84
25 CoCl2 (10) dtbbpy (10) 1.9 THF 8
i
26 CoCl2 (10) dtbbpy (10) 1.9 THF 53
j
a Determined by GC analysis. Tetradecane (C14H30) was used as internal standard. Reactions were
performed on a 0.25 mmol scale. b 2,2’-Bipyridine. c 4,4’-Di-tert-butyl-2,2’-dipyridyl.d isolated yield. e
Reaction was performed on a 5 mmol scale. f CoCl2 (99.99% purity) was used.
g The corresponding zinc
species with ZnCl was used. h The solid zinc pivalate 6a was weighed out on the bench and added to the
reaction mixture under air. i The corresponding thioethyl ester RC(O)SEt was used. j The corresponding
thiophenyl ester RC(O)SPh was used.
After a short screening it became clear that 4,4’-di-tert-butyl-2,2’-dipyridyl (dtbbpy) gave
the best results leading to the ketone 7a in 88% isolated yield (entry 11). At this point, it was
verified that no other metal contaminations are responsible for this catalysis. Thus, using CoCl2
(99.99% purity) in combination with a new stirring bar and a reaction vessel.78 led to 7a in
86% yield (entry 12). Using half the amount of CoCl2 led to a slightly reduced yield (entry 13)
78E. O. Pentsak, D. B. Eremin, E. G. Gordeev, V. P. Ananikov, ACS Catal. 2019, 9, 3070–3081.
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and a higher catalyst loading did not increase the yield significantly (entry 14). A variation of
the equivalents of the zinc species (6a) resulted in a decrease of the product yield (entries
15–16). Variation of the reaction solvent did not improve the product formation, as MeCN,
1,4-dioxane and 2-MeTHF nearly gave similar yields of product 7a (87-90% yield, entries 17–19).
Also, CoCl2 was superior to other cobalt sources like CoBr2, Co(acac)2 and Co(acac)3 (entries
22–24). Furthermore, a screening revealed that RC(O)SPy thioesters are the preferable acylation
reagents, since other thioesters of type RC(O)SEt or RC(O)SPh afforded the product 7a in 8% or
53% yield (entries 25–26).
2.3 Cobalt-Catalyzed Acylation of Alkylthiopyridyl Esters
In a typical experiment palmitic acid (4b) was treated with 2,2’-dipyridyl disulfide (1.1 equiv)
and PPh3 (1.5 equiv) in acetonitrile (0.3 M) under reflux for 3 h. Purification using flash column
chromatography afforded 5b in 98% yield. The required zinc pivalate 6b was prepared by treating
1-bromo-3,4-(methylene-dioxy)benzene 8 with Mg (1.2 equiv) and anhydrous LiCl (1.2 equiv) for
2 h at 0 ◦C leading to the corresponding arylmagnesium derivative (91% yield).79 Transmetalation
with Zn(OPiv)2 (1.0 equiv) afforded the zinc organometallic 6b in 93% yield.
79 The thioester 5b
reacted with 3,4-(methylene-dioxy)-1-phenylzinc pivalate (6b) in the presence of 10% CoCl2 and
10% dtbbpy in THF (25 ◦C, 4 h) furnishing after standard workup and chromatographic purification
the ketone 7b in 90% yield (see Table 6, entry 1).
Table 6 Ketones of type 7 obtained by acylation of varios alkylthiopyridyl esters 5 with
(hetero)arylzinc pivalates 6.
Alk SPy
O
CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF rt, 4 h
6 (1.9 equiv)
Alk (Het)Ar
O
5 7
(Het)Ar-ZnOPiv
N N
t-But-Bu
dtbbpy
Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 6 7: yielda
H31C15
O
SPy O
OPivOZn H31C15
O
O
O
1 5b 6b 7b: 90%
79 The yield was determined by iodometric titration, see: A. Krasovskiy, P. Knochel, Synthesis 2006, 2006, 890–891.
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Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 6 7: yielda
N
Me
PivOZn C15H31
O
N
Me
2 5b 6c 7c: 74%
O
SPy
CF3
PivOZn
O
CF3
3 5c 6d 7d: 84%
O
SPy
NMe2
PivOZn
O
NMe2
4 5c 6e 7e: 95%
O
SPy
F
PivOZn
O
F
5 5a 6f 7f: 60%
CN
PivOZn F
O
CN
F
6 5a 6g 7g: 79%
O
SPy CF3PivOZn
O
CF3
7 5d 6h 7h: 61%
CN
PivOZn F
O
CN
F
8 5d 6g 7i: 81%
O
OMe
Me
Me Me
SPy
3 CNPivOZn
O
OMe
Me
CN
Me Me
3
9 5e 6i 7j: 72%
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Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 6 7: yielda
O
OMe
Me
Me Me
SPy
3 OTBSPivOZn
O
OMe
Me
OTBS
Me Me
3
10 5e 6j 7k: 78%
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product.
According to this procedure various ketones of type 7 were prepared. Hence, the heterocyclic
indolylzinc pivalate (6c) was acylated with palmitic S-pyridyl thioate (5b) furnishing ketone 7c
in 74% yield (entry 2). Additionally, secondary thioesters derived from cyclobutane- (4a) and
cyclohexanecarboxylic acid (4a) were employed to this acylation procedure leading to the
corresponding ketones 7d–7g in 60–95% yield (entries 3–6). Tertiary S-pyridyl thioesters 5d and
5e derived from 1-adamantanecarboxylic acid (4d) and the lipid regulating drug gemfibrozil.80 4e
reacted smoothly with various functionalized arylzinc pivalates affording acylation products 7h–7k
in 61– 81% yield (entries 7–10).
2.4 Cobalt-Catalyzed Acylation of (Hetero)arylthiopyridyl Esters
Furthermore, this acylation reaction was extended to aryl- and heteroaryl-S-pyridyl thioesters
(Table 6). Thus, (4-(ethoxycarbonyl)-phenyl)-zinc pivalate (6k) prepared via I/Mg- exchange
using i-PrMgCl·LiCl followed by transmetalation with Zn(OPiv)275c was readily acylated with
S-pyridyl thioester 5f affording the benzophenone derivative 7l in 71% yield (entry 1). Also,
2-benzothiophenylzinc pivalate (6l) generated via directed metalation of benzothiophene using
TMPMgCl·LiCl and subsequent transmetalation with Zn(OPiv)275c underwent a cobalt catalyzed
acylation reaction with 5f leading to the ketone 7m in 68% yield (entry 2). Various substituted
aryl thioesters (5g, 5h) and ferrocenyl (5i) derivatives reacted successfully with functionalized
(hetero)arylzinc pivalates affording the diaryl ketones 7n–7r in 81–96% yield (entries 3–7).
80P. A. Todd and A. Ward, Drugs, 1988, 36, 314–339.
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Table 7 Ketones of type 7 obtained by acylation of (hetero)aryl thiopyridyl esters 5 with
(hetero)arylzinc pivalates 6.
(Het)Ar SPy
O CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF rt, 4 h
6 (1.9 equiv)
(Het)Ar (Het)Ar
O
5 7
(Het)Ar-ZnOPiv
Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 6 7: yielda
SPy
O
CO2Et
PivOZn
O
CO2Et
1 5f 6k 7l: 71%
PivOZn
S S
O
2 5f 6l 7m: 68%b
SPy
O
Cl
PivOZn
OMe
F O
OMeCl
F
3 5g 6m 7n: 92%
SPy
O
MeO
SMePivOZn
O
MeO
SMe
4 para: 5h 6n para: 7o: 96%
ortho: 5h’ 6n ortho: 7o’: 71%
F
PivOZn
O
FMeO
5 5h 6f 7p: 86%
Fe O
SPy
OCF3
PivOZn
Fe O
OCF3
6 5i 6o 7q: 81%
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Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 6 7: yielda
Fe O
SPy
N
Me
PivOZn
Fe O
N
Me
7 5i 6c 7r: 84%
N
SPy
O OCF3
PivOZn
O
N
OCF3
8 5j 6o 7s: 68%
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product. b TMEDA was
used instead of dtbbpy.
Additionally, 4-trifluoro-methoxyphenylzinc pivalate (6o) was acylated using quinoline thioester
5j furnishing ketone 7s in 68% yield (entry 8). Unfortunately, ortho-functionalized arylzinc
pivalates, like (2-(trifluoromethyl)phenyl)zinc pivalate or (2-cyanophenyl)zinc pivalate did not
gave satisfactory results. Also, several electron poor N-heterocyclic organozinc pivalates, like
isoxazol-, pyridazine- and pyrimidine derivatives were unsuitable zinc-reagents in this acylation
procedure.
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2.5 Cobalt-Catalyzed Acylation of α-chiral Thiopyridyl Esters
The synthesis of α-chiral ketones is of great interest51,72,74c,74f,81 but often challenging under
basic conditions due to epimerization. Also, reactions under pH-neutral conditions have been
reported by Liebeskind et al. for the synthesis of highly enantiopure peptidyl ketones.82
Also, the applicability of this cobalt-catalyzed acylation to the synthesis of optically enriched
α-chiral ketones was tested. Using α-chiral S-pyridyl thioesters at 0 ◦C afforded several α-chiral
ketones with high stereoretention (Table 8). Thus, S-pyridyl thioester 5k prepared from N-Boc
protected (S)-proline was treated with arylzinc reagents 6a and 6b leading to the corresponding
α-chiral ketones (7t–7u) in 72–82% yield and >99% ee (entries 1 and 2). Furthermore, thioester 5l
derived from enantiopure (S)-ibuprofen reacted smoothly with the functionalized arylzinc pivalates
6p and 6n in 71–89% yield and 94–97% ee (entries 3–4).
Table 8 Preparation of α-chiral ketones of type 7 obtained by acylation of thiopyridyl esters 5
with (hetero)arylzinc pivalates 6.
SPy
O CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF 0 °C,  4 h
6 (1.9 equiv)
Ar
O
5 7
Ar-ZnOPiv
R1
R2
R1
R2
Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 (ee) 6 7: yielda
O
N
Boc
SPy PivOZn
OMe O
N
Boc
OMe
1 5k (>99%) 6a 7t: 72%, >99% ee
O
OPivOZn
O
N
Boc
O
O
2 5k 6b 7u: 82%, >99% ee
81a)G. T. Crisp, T. P. Bubner, Synth. Commun. 1990, 20, 1665–1670, b)G. Cahiez, E. Metais, Tetrahedron Lett. 1995,
36, 6449 –6452, c)T. Fukuyama, H. Tokuyama, Aldrichimica Acta 2004, 37, 101–110, d) A. H. Cherney, N. T.
Kadunce, S. E. Reisman, J. Am. Chem. Soc. 2013, 135, 7442–7445, e) R. Oost, A. Misale, N. Maulide, Angew.
Chem. Int. Ed. 2016, 55, 4587–4590.
82a)H. Li, H. Yang, L. S. Liebeskind, Org. Lett. 2008, 10, 4375–4378; b)L. S. Liebeskind, H. Yang, H. Li, Angew. Chem.
Int. Ed. 2009, 48, 1417–1421.
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Entry Thiopyridyl ester Zinc reagent PivOZn-R Product
5 (ee) 6 7: yieldb
O
Me
i-Pr
SPy
OMe
PivOZn
O
Me
i-Pr
OMe
3 5l (98%) 6p 7v: 89%, 97% ee
SMePivOZn
O
Me
i-Pr
SMe
4 5l 6n 7w: 71%, 94% ee
Me SPy
O
Me
PivOZn
O
NMe2
Me
O
Me O
NMe2
5 5m (98%) 6q 7x: 69%, >95% ee
PivOZn NMe2 Me
O
Me
NMe2
6 5m 6r 7y: 84%, 98% ee
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product.
Also, arylzinc pivalates6q and 6r bearing an amide or dimethylamino functionality were
acylated using optically pure S-(pyridin-2-yl)-(S)-2-methylbutanethioate (5m) furnishing the
α-chiral ketones 7x and 7y in 69–84% yield and 95–98% ee (entries 5–6).
2.6 Mechanistic Experiments
To gain insights into the reaction mechanism, radical trapping experiments were carried
out. Thus, to a standard acylation setup of the developed protocol using S-pyridyl thioester
5a with arylzinc and organozinc pivalate 6a, various amounts of the radical trapping agent
2,2,6,6-tetramethylpiperidinyloxyl (TEMPO) were added (see Table 9). With 10% of the trapping
reagent a decrease of the yield by 19% was observed for the acylation product 7a (entry 2).
To ensure, that TEMPO does not react with the arylzinc species, 6a was stirred with equimolar
amounts of TEMPO. Iodolysis of the reaction mixture after 4 h led to 99% of iodinated 6a,
determined using GC-analysis with an internal standard (C14H30). However, using 1.5 equivalents
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of TEMPO the product formation is almost completely suppressed, affording 7a on only 6%
yield. This may indicate the involvement of radical intermediates within this acylation reaction.
Performing the reaction with a Co(I) catalyst led to only a small decrease in yield of product
7a compared to the corresponding Co(II) catalyst system, this result also supports a radical
mechanism (entries (5–6).
Table 9 Optimization of the reaction conditions for the acylation of thioester 5a with arylzinc 6a.
SPy
O
TEMPO (XX mol%)
catalyst (10 mol%)
ligand (10 mol%)
THF, rt, 4 h
6a (1.9 euqiv)
O
5a 7a
MeO ZnOPiv
OMe
N
Me
Me
Me
Me
O
TMEPO
Entry Catalyst Ligand TEMPO [mol%] Yield of 7aa [%]
1 CoCl2 dtbbpy 0 90
2 CoCl2 dtbbpy 10 71
3 CoCl2 dtbbpy 150 6
4 Co powder dtbbpy 0 2
5 CoCl(PPh3)3 - 0 64
6 CoCl2(PPh3)3 - 0 73
a Determined by GC analysis. Tetradecane (C14H30) was used as internal standard. Reactions were
performed on a 0.25 mmol scale.
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2.7 Synthesis of the Antilipidemic Drug Fenofibrate
The utility of this acylation was demonstrated in the synthesis of the antilipidemic drug fenofibrate83
(7z, Scheme 31). Alkylation of 4-iodophenol (9) with isopropyl 2-bromo-2-methyl-propanoate
(10) affords the corresponding iodoaryl ether 11 in 70% yield. 11 was treated with Mg, LiCl and
Zn(OPiv)2 generating the arylzinc pivalate 6s in 72% yield (see Scheme 31).
42 Using the new
cobalt-catalyzed acylation procedure, fenofibrate (7z) was obtained in 65% yield.
I
OH
Br
Me Me
Oi-Pr
O
9 (1.0 euqiv) 10 (1.0 euqiv)
+
KOH (1.0 equiv)
EtOH, reflux, 24 h
I
OR
11, 70% yield
Mg (1.2 equiv)
LiCl (1.2 equiv)
Zn(OPiv)2 (1.0 equiv)
THF, rt, 4 h
PivOZn
OR
6s, 72% yield
R
SPy
O
Cl
5g
CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF, rt, 4 h
O
Cl O
Me Me
Oi-Pr
O
7z: 65% yield
fenofibrate
6s (1.9 equiv)
Scheme 31 Synthesis of fenofibrate (7z) using the cobalt-catalyzed acylation.
83K. F. C. G. M. Keating, Drugs 2007, 67, 121–153.
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3 Cobalt-Catalyzed Cross-Couplings of Functionalized Alkylzinc
Reagents with (Hetero)aryl Halides
3.1 Introduction
The transition-metal catalyzed construction of new C-C bonds is of utmost importance in modern
organic chemistry and finds wide application in academic and industrial processes.84 Especially,
Negishi cross-couplings are among the most versatile methods for the formation of carbon-carbon
bonds to create highly functionalized scaffolds. Albeit, various examples of palladium- 29b,85
or nickel-catalyzed29b,85e,86 C(sp2)-C(sp3) cross-couplings using alkylzinc reagents have been
reported, the search for cheaper and more abundant alternative catalytic systems is highly
desirable. As already mentioned above, cobalt-salts have been found to display several beneficial
characteristics.9,76c,87 In comparison to palladium, cobalt is a fairly cheap metal and for many
transformations no sophisticated ligands are required for an efficient catalysis.55a,b,87 Cobalt
salts are especially well suited catalysts for various types of reactions utilizing organozinc
reagents as nucleophilic coupling partners55a,b,87 including acylations,31,32,34,88 cross-coupling
reactions12,16,20,21,23,28,34,46,47,76,89or aminations.37,48,90
3.2 Design of the Procedure
In a preliminary experiment, 6-chloronicotinonitrile (12a) was treated with (2-(1,3-dioxan-2-yl)
ethyl)zinc chloride (13a) under various conditions (see Table 10). In the absence of a catalyst, the
desired coupling product 14a could not be detected. Various metal halides such as MnCl2, CuCl2,
FeCl2 or CrCl2 were tested. However, no catalytic activity was observed for this cross-coupling
(entries 2–5). As expected, NiCl2 was able to catalyze the reaction leading to 14a in 51% yield
84Modern Drug Synthesis, (eds. J. J. Li, D. S. Johnson), John Wiley & Sons, Ltd New York, 2010.
85 a) C. Dai, G. C. Fu, J. Am. Chem. Soc. 2001, 123, 2719–2724; b) C. Han, S. L. Buchwald, J. Am. Chem. Soc. 2009,
131, 7532–7533; c) S. Çalimsiz, M. G. Organ, Chem. Commun. 2011, 47, 5181–5183; d) Z. Qureshi, C. Toker,
M. Lautens, Synthesis 2017, 49, 1–16; e) R. Jana, T. P. Pathak, M. S. Sigman, Chem. Rev. 2011, 111, 1417–1492;
f) Y. Yang, K. Niedermann, C. Han, S. L. Buchwald, Org. Lett. 2014, 16, 4638–4641.
86a) V. B. Phapale, D. J. Cárdenas, Chem. Soc. Rev. 2009, 38, 1598–1607; b) A. Joshi-Pangu, M. Ganesh, M. R.
Biscoe, Org. Lett. 2011, 13, 1218–1221; c) J. Cornella, J. T. Edwards, T. Qin, S. Kawamura, J. Wang, C.-M. Pan, R.
Gianatassio, M. Schmidt, M. D. Eastgate, P. S. Baran, J. Am. Chem. Soc. 2016, 138, 2174–2177; d) E. C. Hansen,
C. Li, S. Yang, D. Pedro, D. J. Weix, J. Org. Chem. 2017, 82, 7085–7092.
87 C. Gosmini, A. Moncomble, Isr. J. Chem. 2010, 50, 568–576.
88a) I. Kazmierski, M. Bastienne, C. Gosmini, J.-M. Paris, J. Périchon, J. Org. Chem. 2004, 69, 936–942; b) A. Rérat,
C. Michon, F. Agbossou-Niedercorn, C. Gosmini, Eur. J. Org. Chem. 2016, 2016, 4554–4560.
89a) J. Yan, N. Yoshikai, ACS Catal. 2016, 6, 3738–3742; b) A. D. Benischke, I. Knoll, A. Rérat, C. Gosmini, P. Knochel,
Chem. Commun. 2016, 52, 3171–3174; c) R. Sallio, M. Corpet, L. Habert, M. Durandetti, C. Gosmini, I. Gillaizeau,
J. Org. Chem. 2017, 82, 1254–1259; d) X.-G. Liu, C.-J. Zhou, E. Lin, X.-L. Han, S.-S. Zhang, Q. Li, H. Wang,
Angew. Chem. Int. Ed 2018, 57, 13096–13100.
90S. Graßl, Y.-H. Chen, C. Hamze, C. P. Tüllmann, P. Knochel, Organic Letters 2019, 21, 494–497.
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(entry 6). However, CoCl2 also proved to be a suitable catalyst for this transformation affording the
desired alkylated heterocycle 14a in 52% yield (entry 7). Various ligands were tested to further
improve the reaction outcome (entries 8–11). Thus, using the unsubstituted 2,2’-bipyridine led to
the best coupling yield of 66% (entry 8). Increasing the amount of ligand furnished 14a in 75%
isolated yield (entry 12).
Table 10 Optimization of the reaction conditions for the cross-coupling of 12a with alkylzinc
reagent 13a.
catalyst (mol%)
ligand (mol%)
solvent, T, 16 h
O
O
ZnCl
13a (equiv)
14a
N Cl
NC
12a
N
NC
O
O
Entry Catalyst Ligand Equiv of Solvent T Yield of 14aa
(Loading [mol%]) (Amount [mol%]) 13a [◦C] [%]
1 – – 1.5 THF 0 0
2 MnCl2 (10) – 1.5 THF 0 0
3 CuCl2 (10) – 1.5 THF 0 0
4 FeCl2(10) – 1.5 THF 0 0
5 CrCl2(10) – 1.5 THF 0 0
6 NiCl2 (10) – 1.5 THF 0 51
7 CoCl2 (10) – 1.5 THF 0 52
8 CoCl2 (10) bipy
b (10) 1.5 THF 0 66
9 CoCl2(10) dtbbpy
c (10) 1.5 THF 0 63
10 CoCl2(10) neocuproine (10) 1.5 THF 0 65
11 CoCl2(10) TMEDA (10) 1.5 THF 0 39
12 CoCl2 (10) bipy (20) 1.5 THF 0 80 (75)
e
13 CoCl2 (10)
f bipy (10) 1.5 THF 0 82
14 CoBr2 (10) bipy (20) 1.5 THF 0 78
15 Co(acac)2 (10) bipy (20) 1.5 THF 0 79
16 Co(acac)3 (10) bipy (20) 1.5 THF 0 71
17 CoCl2 (2.5) bipy (5) 1.5 THF 0 51
18 CoCl2 (5.0) bipy (10) 1.5 THF 0 73
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Entry Catalyst Ligand Equiv of Solvent T Yield of 14aa
(Loading [mol%]) (Amount [mol%]) 13a [◦C] [%]
19 CoCl2 (20) bipy (40) 1.5 THF 0 12
20 CoCl2 (10) bipy (20) 1.2 THF 0 62
21 CoCl2 (10) bipy (20) 1.7 THF 0 81
22 CoCl2 (10) bipy (20) 1.5 toluol 0 56
23 CoCl2 (10) bipy (20) 1.5 MeCN 0 79
24 CoCl2 (10) bipy (20) 1.5 Et2O 0 79
25 CoCl2 (10) bipy (20) 1.5 t-BuOMe 0 76
26 CoCl2 (10) bipy (20) 1.5 THF -10 65
27 CoCl2 (10) bipy (20) 1.5 THF 25 65
a Determined by GC analysis. Tetradecane (C14H30) was used as internal standard. Reactions were
performed on a 0.25 mmol scale. b 2,2’-Bipyridine. c 4,4’-Di-tert-butyl-2,2’-dipyridyl. d 20 mol% of bipy
was used.e Isolated yield of the reaction performed on a 1.00 mmol scale. f CoCl2 (99.99% purity) was used.
At this point it was verified that no other metal contaminants are responsible for this
catalysis. Using CoCl2 (99.99% purity) in combination with a new stirring bar
78 and reaction
vessel afforded the pyridine derivative 14a in 82% yield (entry 13). Variation of the cobalt-species
(entries 14–16), catalyst loading (entries 17–19), the amounts of metal species (entries 20–21),
reaction solvent (22–25) and the reaction temperature (26–27) did not further improve the yield.
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3.3 Cobalt-Catalyzed Cross-Couplings of functionalized Alkylzinc Reagents with
Heteroaryl Halides
With these results in hand the scope of this cross-coupling reaction was examined. N-hetero-cyclic
halides of type 12 were coupled with various functionalized alkylzinc reagents of type 13 (see
Table 11). Thus, the reaction of 12a with (3-phenylpropyl)zinc chloride (13b) afforded 14b in 73%
yield (entry 1). Also, the corresponding bromopyridine 12b was coupled with zinc species 13c,
derived from natural product (1R)-(–)-nopol and 13d bearig a TMS-protected alkyne group led
to the coupling products 14c and 14d in 62–75% yield (entries 2–3). Several alkylzinc reagents
bearing various functional groups were excellent substrates for this cross-coupling.
Table 11 Pyridines of type 14 obtained by cross-coupling of various substituted halopyridines
12 with primary alkylzinc reagents 13.
CoCl2 (10 mol%)
bipy (20 mol%)
THF, 0 °C, 16 h
R2
ZnX
13 (1.5 equiv)
14
N X
12
N R2
R1 R1
Entry Electrophile Zinc reagent AlkylZnX Product
12 13 14: yielda
N
NC
Cl PhClZn
Ph
N
N
N
NC
Ph
1 12a 13b 14b: 73%
N
NC
Br
ClZn
Me Me
N
Me MeNC
2 12b 13c 14c: 75%
N
NC
Br TMS
ClZn
Ph
N
N
N
TMS
NC
3 12b 13d 14d: 62%
N
F3C
Br BrZn CN
Ph
N
N
N
CN
F3C
4 12b 13e 14e: 87%b
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Entry Electrophile Zinc reagent AlkylZnX Product
12 13 14: yielda
N
F3C
Br
N
Me
Me
ClZn
Ph
N
N
N
N
Me
Me
F3C
5 12c 13f 14f: 87%
N
EtO2C
Cl BrZn OAc
Ph
N
N
N OAc
EtO2C
6 12d 13g 14g: 66%b
N
EtO2C
Cl
ClZn
Me Me
N
EtO2C Me Me
7 12d 13c 14h: 76%
N
EtO2C
Cl Me Me
MeClZn
N
EtO2C
Me
MeMe
8 12d 13h 14i: 83%
N Cl
CO2Et
S
ClZn
Ph
N
N
N
S
CO2Et
9 12e 13i 14j: 78%
N Br
CO2Me
TMS
ClZn
Ph
N
N
N
CO2Me
TMS
10 12f 13d 14k: 83%
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product. b 20% CoCl2,
40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent were used.
Zinc organometallics containing a nitrile group (13e), a pyrrole protected amine (13f) or an
acetate group (13g ) were successful substrates in this reaction, furnishing the alkylated pyridines
14e–14g in 66–87% yield (entries 4–6). The reactions of zinc species 13c and zinc species
dervived from (S)-citronellol (13h) with ethyl 6-chloronicotinate (12d) afforded 14h and 14i in
76–83% yield (entries 7–8). Also, using 2-halonicotinic esters 12e and 12g in combination with
zinc reagents bearing a thiophene (13i) or an alkyne moiety (13d) coupled smoothly leading to
14j and 14k in 78–83% yield (9–10).
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Furthermore, other N-heterocyclic halides were suitable electrophiles in this coupling (see
Table 12). The reaction of 2-bromoquinoline (12h) with zinc species 13a, 13c and 13f lead to
quinoline derivatives 14l, 14m and 14n 75–95%yield (entries 1–3). 14n could also be synthesized
starting from the corresponding chloride 12i in 82% yield (entry 4). Methyl- and chloro-substituted
2-chloroquinolines 12j and 12k were alkylated with zinc species 13e and 13g affording the
quinoline derivatives 14o and 14p in 70% and 58% yield (entries 5–6).
Table 12 Products of type 14 obtained by cross-coupling of various substituted N-heterocycles
12 with primary alkylzinc reagents 13.
CoCl2 (10 mol%)
bipy (20 mol%)
THF, 0 °C, 16 h
R2
ZnX
13 (1.5 equiv)
14
N
Y
X
12
N
Y
R2
Entry Electrophile Zinc reagent AlkylZnX Product
12 13 15: yielda
N Br O
OClZn
Ph
N
N
N
O
O
1 12h 13a 14l: 95%
N Br
ClZn
Me Me
N
Me Me
2 12h 13c 14m: 75%
N X
N
Me
Me
ClZn
Ph
N
N
N
N
Me
Me
3 12h: X = Br 13f 14n: 85%
4 12i: X = Cl 13f 14n: 82%
N Cl
Me
BrZn CN
Ph
N
N
N
CN
Me
5 12j 13e 14o: 70%b
N Cl
Cl
BrZn OAc
Ph
N
N
N
Cl
OAc
6 12k 13g 14p: 58%b
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Entry Electrophile Zinc reagent AlkylZnX Product
12 13 14: yielda
N
Br S
ClZn
Ph
N
N
N S
7 12l 13i 14q: 61%
N
N
MeO
MeO
Cl
ClZn
Ph
N
N
N
N
MeO
MeO
8 12m 13j 14r: 60%
N
N
Br S
ClZn
Ph
N
N
N
N
S
9 12n 13i 14s: 71%
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product. b 20% CoCl2,
40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent were used.
Moreover 2-bromoisoquinoline (12l) and (2-(thiophen-3-yl)ethyl)zinc chloride (13i) led to
14q in 61% yield (entry 7). In addition, the coupling of (but-3-en-1-yl)zinc chloride(13j) and
quinazoline 12m afforded 14r in 60% yield (entry 8). Pyrimidine 14s was obtained in 71%
yield by cross-coupling of 2-bomopyriminide (12n) and zinc species 13i in 71% yield (entry
9). However, the reaction with less activated heterocyclic halides like 2-bromopyridine or
2-bromo-6-methoxypyridine led to poor coupling results.
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3.4 Cobalt-Catalyzed Cross-Couplings of functionalized Alkylzinc Reagents with
Aryl Halides
Next, this cobalt catalyzed cross-coupling was extended to various electron-deficient aryl halides
as electrophilic coupling partners (see Table 13). Thus, (2-(1,3-dioxan-2-yl)ethyl)zinc chloride (13a)
was coupled with 4-bromo-2-fluorobenzonitrile (12o) and ethyl 4-iodobenzoate (12p) furnishing
14t-14u in 66-82% yield (entries 1–2). Benzophenone was successfully alkylated in ortho- and
para-position, respectively, starting from the corresponding halides 12q and 12r, leading to 14v
and 14w in 70–85% yield (entries 3–4).
Table 13 Products of type 14 obtained by cross-coupling of various substituted aryl halides 12
with alkylzinc reagents 13.
CoCl2 (10 mol%)
bipy (20 mol%)
THF, 0 °C, 16 h
R2
ZnX
13 (1.5 equiv)
14
X
12
R1
R1
R2
Entry Electrophile Zinc reagent AlkylZnX Product
12 13 14: yielda
Br
F
NC
O
OClZn
Ph
N
N
F
O
O
NC
1 12o 13a 14t: 66%
I
EtO2C
O
O
EtO2C
2 12p 13a 14u: 82%b
Cl
Ph
O
Ph
N
N
O
O
O
3 12q 13a 14x: 70%
Ph
O
Br O
OClZn
Ph
N
N
O
O
O
4 12r 13a 14v: 85%
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Entry Electrophile Zinc reagent AlkylZnX Product
12 13 14: yielda
O
F Cl BrZn CO2Et
Ph
N
N
O
CO2Et
F
5 12s 13k 14w: 73%b
Ph
O
Br
ClZn
Ph
N
N
Ph
O
6 12r 13l 14y: 70%c
Cl
Ph
O
O
7 12q 13l 14z: 71%c
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product. b 20% CoCl2,
40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent were used.
c Dtbbpy was used instead of bipy. The reaction was performed at rt.
The cross-coupling of zinc reagent 13k containing an ester moiety with fluoro functionalized
chlorobenzophenone 12s led to 14y in 73% yield (entry 5). Also, cyclopropylzinc chloride 13l was
used in this procedure, affording the benzophenones 14y and 14z in 70–71% yield (6-7).
3.5 Diastereoselective Cobalt-Catalyzed Cross-Couplings of functionalized
Alkylzinc Reagents with Heteroaryl Halides
Encouraged by the results with the secondary cyclopropylzinc reagent 13l, the cross-coupling
of various substituted six-membered cycloalkylzinc reagents was examined. In the past, several
diastereoselective Csp3-Csp2 Negishi-type cross-couplings using palladium55b-d, 91 and nickel
salts92 have been reported. Also, a cobalt-catalyzed version applying bis-arylzinc reagents is
91a) P. Knochel, C. Diène, Comptes Rendus Chimie 2011, 14, 842 –850; b) R. J. Mycka, S. Duez, S. Bernhardt,
J. Heppekausen, P. Knochel, F. F. Fleming, J. Org. Chem. 2012, 77, 7671–7676; c) K. Moriya, P. Knochel, Org. Lett.
2014, 16, 924–927.
92a) H. Gong, M. R. Gagné, J. Am. Chem. Soc. 2008, 130, 12177–12183; b) H. Gong, R. Sinisi, M. R. Gagné, J. Am.
Chem. Soc. 2007, 129, 1908–1909.
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known.20 However, this methodology only allows the coupling of 1,2-substituted cycloalkyl iodides
with (hetero)aryl zinc reagents in a diastereoselective manner. To overcome this limitation, the
problem was approached by using substituted cycloalkylzinc species with heteroaryl halides
as coupling partners. Previous studies have shown that the carbon-zinc bond is prone for
epimerization in the presence of metal salts.55b,c Thus, a highly diastereoselective cross-coupling
is only enabled by a fast transmetalation of the thermodynamically more stable alkylzinc species
to the transition-metal catalyst.55b To evaluate the scope of a diastereoselective cross-coupling
using substituted cyclohexylzinc reagents, 2-methylcyclo-hexylzinc iodide (13m) was coupled with
6-bromonicotinonitrile (12b) (see Table 14). A short screening revealed that a catalytic system
of 10% CoCl2 and 20% 4,4’-di-tert-butyl-2,2’-dipyridyl in acetonitrile led to the best yield and
diastereomeric ratio (entry 7).
Table 14 Optimization of the reaction conditions for the cross-coupling of 12b with alkylzinc
reagent 13m.
CoCl2 (10 mol%)
ligand (20 mol%)
solvent, T, 16 h
ZnI
13m (1.5 equiv)
14aa
N Br
NC
12b
N
NC
Me
Me
Entry Ligand T [◦C] Solvent dr Yield of 14aaa [%]
1 - rt THF 40:60 13
2 neocuproine rt THF 69:31 6
3 bipyb rt THF 91:9 33
4 bipy 0 THF 91:9 24
5 dtbbpyc rt THF 90:10 28
6 bipy rt MeCN 79:21 81
7 dtbbpy rt MeCN 91:9 85 (80)d
a Determined by GC analysis. Tetradecane (C14H30) was used as internal standard. Reactions were
performed on a 0.25 mmol scale.b 2,2’-Bipyridine. c 4,4’-Di-tert-butyl-2,2’-dipyridyl.d Isolated yield of
analytically pure product.
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Hence, the coupling of various 1,3-, and 1,4-functionalized cycloalkylzinc reagent with
N-heterocyclic bromides was examined (see Table 15). The reaction of bromide 12b
with 3-methylcyclohexylzinc iodide (13m) led to the thermodynamically more stable
cis-1,3-disubstituted cyclohexane 14aa in 80% yield and diastereoselectivity of 91:9 (see Table 15,
entry 7). However, using the corresponding zinc reagent 13n bearing the bulkier iso-propyl residue
led to 14ab in 63% yield and an improved diastereomeric ratio of 96:4 (see Table 15, entry
1). Additionally, this zinc reagent was coupled with pyrimidine 12t furnishing 14ac (52% yield,
dr = 94:693) (entry 2). Also, 1,4-substituted cyclohexylzinc reagents could be used in this protocol.
Table 15 Products of type 14 obtained by diastereoselective cross-coupling of various
substituted pyridyl halides (12) with 1,3- and 1,4-substituted secondary alkylzinc
reagents (13).
CoCl2 (10 mol%)
dtbbpy (20 mol%)
MeCN, rt, 16 h
ZnI
13 (1.5 equiv)
14
N
Y
X
12
R1
N
Y
R1
R2
R2
Entry Electrophile Zinc reagent AlkylZnI Product
12 13 14: yielda (dr)
N
NC
Br
i-Pr ZnI
Ph
N
N
N
CN
i-Pr
1 12b 13n 14ab: 63% (96:4)
N
N
Br
i-Pr ZnI
Ph
N
N
N
N
i-Pr
2 12t 13n 14ac: 52% (94:6)
N
F3C
Br
ZnI
EtO2C
Ph
N
N
EtO2C
N
CF3
3 12c 13o 14ad: 51% (80:20)
93The stereochemistry of 14ac was determined by NOESY-NMR spectroscopy, see Appendix.
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Entry Electrophile Zinc reagent AlkylZnI Product
12 13 14: yielda
N
F3C
Br
ZnI
N
Ph
N
N
N
N
CF3
4 12c 13p 14ae: 54% (98:2)
N
N
Br
ZnI
CF3
Ph
N
N
N
N
F3C
5 12t 13q 14af: 73% (98:2)
N
N
Br
ZnI
Ph Ph
N
N
6 12t 13r 14ag: 67% (96:4)
N
N
Br
Cl
ZnI
N N
N
N
Cl
7 12u 13p 14ah: 64% (91:1)
a Reactions were performed on a 0.5 mmol scale. Isolated yield of analytically pure product. The major
diastereomer is shown. b 20% CoCl2, 40% dtbbpy and 1.9 equiv of the corresponding alkylzinc reagent
were used. c Dtbbpy was used instead of bipy. The reaction was performed at rt.
Thus, the cross-coupling of zinc reagents bearing an ester (13o) or a pyrrole (13p) substituent
with trifluoromethylated bromopyridine 12c led to the corresponding trans-1,4-bifunctionalized
cyclohexanes 14ad and 14ae in 51-54% yield (dr = 80:20–98:2,94 entries 3–4). Bromopyrimidine
(12t) could also be coupled with 1,4-substituted cyclohexylzinc iodides 13q and 13r affording the
functionalized cyclohecyl reagents 14af and 14ag in 54–73% yield and 96:4–98:2 dr (entries
5–6). Additionally, the 2-bromopyrimidine derivative 12u was cross-coupled with zinc species 13p
leading to the polyfunctional pyrimidine 14ah in 64% yield and 91:1 dr (entry 7).
94The stereochemistry of 14ae was determined by crystal structure analysis, see Appendix.
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Remarkably, 2-bromopyrimidine (12t) could be coupled with complex alkylzinc reagents prepared
from steroid and sesquiterpene derivatives (see Scheme 32). The reaction of cholesterylzinc
chloride 13s with 2-bromopyrimide (12t) furnished 14ai in 78% yield and a diastereomeric ratio of
98:2. Also, the corresponding coupling using zinc reagent 13t derived from a reduced nootkaton
derivative proceeded in a highly diastereoselective fashion leading to 14aj in 52% yield (dr = 98:2).
i-Pr
Me
Me
Me
ClZn
H
H
H
i-Pr
Me
Me
Me
H
H
H
14ai: 78% yield (dr = 98:2)
MeCN, rt, 16 h
13s (1.5 equiv)
CoCl2 (10 mol%)
dtbbpy (20 mol%)
N
N
Br
N
N
12t
N
N
Br
12t
MeCN, rt, 16 h
13t (1.5 equiv)
CoCl2 (10 mol%)
dtbbpy (20 mol%)
i-Pr
H
Me
Me
i-Pr
H
Me
Me
N
N
14aj: 52% yield (dr = 98:2)
IZn
Scheme 32 Cobalt-catalyzed diastereoselective cross-coupling of 12t with zinc organometallics
13s and 13t derived from cholesterol and nootkatone. The major diastereomers
are shown.
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Finally, this cobalt-catalyzed cross-coupling was further extended to alkynyl bromides (see
Scheme 33). (Bromoethynyl)-benzene (16a) reacted smoothly with alkylzinc chloride 13a
affording the alkylated alkyne 14ak in 55% yield. Interestingly, the coupling of the TIPS
protected alkyne 16b with the 1,4 phenyl substituted cyclohexylzinc reagent 13r furnished the
1,4-trans-alkynylated cyclohexane derivative 14al in 54% yield and dr = 99:1.
Ph Br
16a
CoCl2 (10 mol%)
bipy (20 mol%)
THF, 0 °C, 16 h
O
O
ZnCl
13a (1.5 equiv)
O
O
Ph
14ak: 55% yield
TIPS Br
16b
CoCl2 (10 mol%)
dtbbpy (20 mol%)
MeCN, rt, 16 h
ZnCl
13r (1.5 equiv)
TIPS
14al: 54% yield (dr = 99:1)
Ph
Ph
Scheme 33 Cobalt-catalyzed cross-coupling of alkynyl bromides with primary and secondary
alkylzinc reagents.
To gain an insight into the reaction mechanism, radical-trapping experiments using
2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) were performed. Previous studies and as
we have seen in chapter 2.5 TEMPO is able to significantly inhibit cobalt-catalyzed reactions,
which might indicate an involvement of radical intermediates within the course of this reaction.25a
Thus, to a standard coupling setup of 12a with 13a 2.0 equivalents of TEMPO were added.
However, the coupling product 14a was obtained in comparable yield to the standard conditions,
without the radical trapping agent. This indicates that this new cobalt-catalyzed cross-coupling
might not proceed via radical intermediates.
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4 Summary
This work focused on the application of sp-, sp2- and sp3-hybridized organozinc reagents in
cobalt-catalyzed carbon-carbon bond formation.
First, a broad range of bench stable alkynylzinc pivalates underwent cobalt-catalyzed
cross-coupling reactions with 1,2- 1,3-, and 1,4-substituted five- and six-membered cyclic
(hetero)alkyl halides with predictable diastereoselectivity. This protocol allowed the coupling
of alkynes bearing silyl, alkyl and aryl moieties and was not limited to the use of bulky alkynes, in
contrast to the prior developed C(sp)-C(sp2) coupling. Several functional groups like silyl ethers,
trifluoromethyl, ester, pyrrol, halides and even ketone moieties could be tolerated under these
conditions. Additionally, alkynyl-substituted glycosides were prepared with excellent α-selectivity
and also steroids could be alkynylated in high diastereoselectivity. Radical trapping experiments
indicated an involvement of radicals during the course of the reaction.
Me4DACH (2.0 equiv)
CoCl2 (20 mol%)
THF, 0 °C, 8 h
X = I, Br; Y = CH, O
Y X
R1
Y
R1
R2
R2 ZnOPiv
(1.5 equiv)
Me2N NMe2
Me4DACH
O
AcO
OAc
OAc
AcO
OMe
54%; a:ß = 94:6
OMe
Me
H
H
H
TMS
H
84%; dr = 92:8
Me
Me
i-Pr
H
F
60%; dr = 94:6
O
Ph
Ph
76%; dr = 93:7
N
71%; dr = 90:10 75%; dr = 99:1
Me
Me
TsN
OTBS
OMe
Selected examples:
Scheme 34 Cobalt-catalyzed diastereoselective cross-coupling between alkynylzinc pivalates
and functionalized cyclic iodides and bromides.
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Moreover, a cobalt-catalyzed acylation procedure of primary, secondary and tertiary alkyl, benzyl
and (hetero)aryl pyridyl thioesters with bench stable (hetero)arylzinc pivalates was developed.
These thioesters were readily prepared from the corresponding carboxylic acids under mild
conditions allowing their synthesis in the presence of various sensitive functional groups and
stereocenters. Therefore, several α-chiral ketones could be prepared with high retention of
configuration (94% to >99% ee). Furthermore, this protocol was applied to the synthesis of the
antilipidemic drug fenofibrate. Due to a complete suppression of the acylation reaction using the
radical trapping reagent TEMPO the mechanism proceeds propaply via radical intermediates.
R OH
O
R1: 1°, 2°, 3° alkyl, benzyl, (hetero)aryl
PySSPy (1.0–1.1 equiv) 
PPh3 (1.0–1.5 equiv)
MeCN, reflux 3 h or 0 °C 16 h R SPy
O
CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF, 0°C or rt, 4h
(Het)ArZnOPiv
(1.9 euqiv)
R (Het)Ar
O
Me
Me O
O
3
CN
MeMe
72%
Fe O
N
Me
84%
O
Me
i-Pr
OMe
89%; 97% ee
N
Boc O
O
O
82%; >99% ee
O
CO2Et
71%
O
Cl
MeMe
Oi-Pr
O
65%
N N
t-But-Bu
dtbbpy
Selected examples:
Scheme 35 Cobalt-catalyzed acylation-reaction between (hetero)arylzinc pivalates and
thiopyridyl ester derivatives.
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Finally, a cobalt-catalyzed cross-coupling of various substituted primary and secondary alkylzinc
reagents with aryl and heteroaryl halides was developed. Under these mild conditions a broad
range of functional groups like trifluoromethyl, halides and also sensitive groups like nitrile, ester,
and ketone moieties were tolerated. Couplings using 1,3- and 1,4-functionalized cyclohexylzinc
reagents proceeded in a diastereoselective manner with a diastereomeric ratio up to 98:2. In
addition, the coupling of secondary and primary alkylzinc reagents with alkynyl bromides was
possible, providing the alkylated alkynes. Addition of TEMPO did not result in an inhibition of the
reaction, therefore it can be assumed that the catalytic cycle does not involve radical formation.
bipy or dtbbpy (20–40 mol%)
CoCl2 (10–20 mol%)
THF or MeCN, 
0 °C or rt, 16 h
X = Cl, Br, I; Y = CH, N
(1.5–1.9 equiv) N N
bipy
Y X
R1
Alk-ZnCl
Y Alk
R1
N
CF3 NC
F
O
O
O
CO2Et
F
73%
66%
CN
87%
N S
61%
N
CO2Et
TMS
83%
N
CF3
N
54%; dr = 98:2
Me
Me
H
H
H
H
Me
i-Pr
N
N
78%; dr = 98:2
Selected examples:
Scheme 36 Cobalt-catalyzed cross-coupling between functionalized alkylzinc reagents and
(hetero)aryl halides.
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III EXPERIMENTAL PART
1 General Considerations
Unless otherwise indicated, all reactions were carried out in flame-dried glassware under argon
atmosphere using Schlenk technique with rubber septum and manetic stirring bars. Syringes
used to transfer reagents and solvents were purged with argon prior to use.
1.1 Solvents
CH2Cl2 was predried over CaCl2 and distilled from CaH2 under nitrogen atmosphere.
DME was distilled under nitrogen atmosphere.
DMPU was distilled under nitrogen atmosphere.
dioxane was distilled from sodium benzophenone ketyl under nitrogen atmosphere.
t-BuOMe was distilled from sodium benzophenone ketyl under nitrogen atmosphere.
NMP was distilled under nitrogen atmosphere.
MeCN was used from acros extra dry
MeTHF was used from acros extra dry
THF was used from acros extra dry over molecular sieves
Solvents for reaction workups and column chromatography were distilled prior to use.
1.2 Reagents
TMEDA was predried over CaH2 (12 h) and distilled from sodium benzophenone ketyl under
argon atmosphere.
TMPH was distilled from CaH2 under argon prior to use.
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i-PrMgCl·LiCl Magnesium turnings (2.67 g, 110 mmol) and anhydrous LiCl (4.66 g, 100 mmol)
were placed in an argon-flushed flask and THF (50 mL) was added. A solution of i-PrCl (9.13 mL,
100 mmol) in THF (50 mL) was slowly added at 25 ◦C. The reaction starts within a few minutes.
After addition, the reaction mixture was stirred for 12 h at 25 ◦C. The grey solution of i-PrMgCl·LiCl
was cannulated to another flask under argon and removed in this way from excess of magnesium.
A yield of ca. 95–98% of i-PrMgCl·LiCl is obtained.95
ZnCl2 solution in THF (1 M) was prepared by adding anhydrous THF to dry ZnCl2 (40.8 g,
300 mmol), which was prior to use dried in a Schlenk-flask under high vacuum at 150 ◦C for
4 h. The suspension was left stirring overnight at 25 ◦C and after 12 h the salts had completely
dissolved. The stirring was stopped and the solution was left for some hours to become completely
clear. The solution was stored over 4 Å under argon upon use.
CoCl2·2LiCl solution in THF (1 M) was prepared by drying LiCl (8.5 g, 200 mmol) in a
Schlenk-flask under high vacuum at 130 ◦C for 3 h. After cooling to 25 ◦C, anhydrous CoCl2
(13.0 g, 100 mmol) was added and the salts were further heated to 130 ◦C for 5 h under high
vacuum. After cooling to 25 ◦C anhydrous THF (100 mL) was added. The mixture was vigorously
stirred until all solids were dissolved and the reagent was obtained as a dark blue solution.
Preparation of TMPMgCl·LiCl A 250 mL Schlenk -flask was charged with i-PrMgCl·LiCl (100 mL,
120 mmol, 1.2 M in THF). Freshly distilled TMPH (23.9 mL, 126 mmol) was added dropwise at
25 ◦C and the mixture was stirred for 48 h.
Zn(OPiv)2 A dry, tared, 500 mL round-bottomed flask equipped with a magnetic stirring bar and
a septum was charged with toluene (250 mL, 0.2 M). Pivalic acid (12.5 mL, 11.3 g, 110 mmol,
2.2 equiv) was added to form a colorless solution. Zinc oxide (4.07 g, 50 mmol, 1.0 equiv) was
added in 1 g portions at 25 ◦C over 15 min to form a colorless suspension. The flask was equipped
with a Dean-Stark apparatus (10 mL) wrapped in aluminum foil and topped with a reflux condenser
(20 cm) and the suspension was stirred under nitrogen at reflux in an oil bath for 16 h. A viscous
colorless suspension was obtained after 12 h. After cooling to 25 ◦C, the mixture was concentrated
by rotary evaporation (50 ◦C/50 mmHg). The remaining pivalic acid and water were removed in
vacuo from the reaction mixture using a vacuum line (0.1 mmHg) and a liquid nitrogen cold trap
(1000 mL). The white solid was warmed to 100 ◦C in an oil bath and dried for at least 6 h. Zinc
pivalate (13.1–13.2 g, 48.9–49.7 mmol, 98–99% yield), was obtained as a puffy amorphous white
95A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333–3336
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solid.96
EtMgBr A dry and argon-flushed 250 mL Schlenk-flask, equipped with a stirring bar and a
septum, was charged with magnesium turnings (2.88 g, 120 mmol) in THF (90 mL). Bromoethane
(10.8 g, 100 mmol) was added dropwise at -20 ◦C and the reaction mixture was shortly heated to
reflux and again cooled to -20 ◦C. This procedure was repeated until the reaction started. After
disappearance of the Mg turnings the dark-grey solution was titrated by using a stoichiometric
amount of iodine (100 mg) in THF (2 mL) and a concentration of 1.03 M was determined.
1.3 Chromatography
Flash column chromatography was performed using silica gel 60 (40 – 63µm 230 – 400 mesh
ASTM) from Merck.
Thin layer chromatography (TLC) was performed using aluminium plates covered with SiO2
(Merk 60, F-254) and visulized either by UV detection, by staining with KMnO4 solution
(1.5 g KMnO4, 10 g K2CO3, 1.25 mL 10% NaOH solution in 200 mL H2O) or PMA stain
(Molybdophosphoric acid 10 g in Ethanol 200 mL).
1.4 Analytical Data
NMR spectra were recorded on Varian VXR 400S, Bruker Avance III HD 400 MHz and Bruker
AMX 600 instruments. Chemical shifts (δ) are reported in parts per million (ppm) relative to the
residual solvent peak CHCl3 (δH = 7.26, δC = 77.0) or DMSO-d6 (δH = 2.50, δC = 39.5) (For
the characterization of the observed signal multiplicities the following abbreviations were used:
s(singulet), d (doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet), br (broad).
Mass spectra and high resolution mass spectra (HRMS) were recorded on a Finnigan MAT
95Q (EI) or a Thermo Finnigan LTQ FT instrument (ESI). Electron impact ionization (EI) was
concucted with an electron energy of 70 eV. Elektrospray ionization (ESI) was conducted with
an IONMax ion-source equiped with an ESI head. It was performed with a voltage of 4 kV at the
spray capillary tube, a heating filament temperature of 250 ◦C and a nitrogen flow of 25 units.
Gas Chromatography (GC) was performed with maschines of the types Hewlett-Packard
6890 or 5890 Series II (Hewlett Packard, 5% phenylmethylpolysiloxane; column length: 15 m,
diameter: 0.25 mm; film thickness: 0.25µ). For the combination of gas chromatography with mass
96M. Ellwart, Y.-H. Chen, V. Malakhov, P. Knochel, Org. Synth 2018, 95, 127–141
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spectroscopic detection, a GC-MS from Hewlett Packard of type 6890/MSD 5973 was used.
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a Perkin Elmer Spectrum
BX-59343 instrument. For detection a Smiths Detection Dura Sampl/R II Diamond ATR sensor
was used. The absorption bands (ν̃) are reported in wave numbers (cm-1).
Melting points (m.p.) were measured using a Büchi B-540 apparatus and are uncorrected.
Single Crystal X-Ray Diffraction Studies The crystals were introduced into perfluorinated oil
and a suitable single crystal was carefully mounted on the top of a thin glass wire. Data collection
was performed with an Oxford Xcalibur 3 diffractometer equipped with a Spellman generator
(50 kV, 40 mA) and a Kappa CCD detector, operating with Mo-Kα radiation (λ = 0.71071 ). Data
collection and data reduction were performed with the CrysAlisPro software. Absorption correction
using the 13 1415 multiscan method was applied. The structures were solved with SHELXS-97,
refined with SHELXL-97 and finally checked using PLATON. Details for data collection and
structure refinement are summarized in the appendix section.
Enantiomeric Excess (ee) of chiral products were determined via chiral HPLC analysis on a
Shimadzu Prominence 20A HPLC system. For developing a chiral resolution method, different
chiral normal phase columns (Daicel Chemical Industries Chiralcel OD-H, OJ, OB-H or Chiralpak
AS-H, ADH) were tested with n-heptane and i-PrOH as mobile phase (isocratic) using a racemic
mixture of the compound.
Optical Rotation were resorded on Anton Paar MCP 500 polarimeter. The specific rotation is
calculated as follows:
[α]ϕλ =
[α]·100
c·d
Thereby, the wavelength λ is report ed in nm and the measuring temperature ϕ ◦C, α represents
the recorded optical rotation, c the concentration of the analyte in 10 mg/mL and d the length of
the cuvette in dm. Thus, the specific rotation is given in 10-1·deg·cm2·g-1. Usage of the sodium D
line (λ= 589 nm) is indicated by D instead of the wavelength in nm. The respective concentration
as well as the solvent is reported at the relevant section of the experimental section.
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2 Cobalt-Catalyzed Diastereoselective Cross-Couplings between
Alkynylzinc Pivalates and Functionalized Cyclic Iodides or
Bromides
2.1 Preparation of Starting Materials
Triethyl((2-methylbut-3-yn-2-yl)oxy)silane (17)
Me
Me
OTES
Triethyl((2-methylbut-3-yn-2-yl)oxy)silane (17) was prepared according to literature procedure
from 2-methylbut-3-yn-2-ol and chlorotriethylsilane.97
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.39 (s, 1H), 1.49 (s, 6H), 0.94 (t, J = 7.9 Hz, 9H), 0.67 (q,
J = 7.9 Hz, 6H).
((3,5-Dimethylhex-1-yn-3-yl)oxy)triethylsilane (18)
Me
OTES
i-Pr
((3,5-Dimethylhex-1-yn-3-yl)oxy)triethylsilane (18) was prepared according to literature procedure
from 3,5-dimethylhex-1-yn-3-ol and chlorotriethylsilane.97
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.40 (s, 1H), 1.92 (dh, J = 13.1, 6.5 Hz, 1H), 1.64 – 1.50
(m, 2H), 1.46 (s, 3H), 0.96 (t, J = 7.6 Hz, 15H), 0.68 (qd, J = 7.8, 2.1 Hz, 6H).
Triethyl((1-ethynylcyclohexyl)oxy)silane (19)
TESO
Triethyl((1-ethynylcyclohexyl)oxy)silane (19) was prepared from 1-ethynylcyclohexan-1-ol and
chlorotriethylsilane according to literature procedure.97
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.45 (s, 1H), 1.83 (dt, J = 10.4, 5.4 Hz, 2H), 1.71 – 1.07
(m, 8H), 0.97 (t, J = 7.9 Hz, 9H), 0.68 (q, J = 7.9 Hz, 6H).
97D. L. J. Clive, W. Yang, A. C. MacDonald, Z. Wang, M. Cantin, J. Org. Chem. 2001, 66, 1966–1983.
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Preparation of Iodides TP1:
R1
OH
I2 (1.20 equiv)
PPh3 (1.10 equiv)
NMI (1.25 equiv)
CH2Cl2, 0 °C to rt, overnight
R1
I
1
A dry round bottom flask equipped with a magnetic stirring bar was charged with I2 (1.20 equiv)
which was dissolved in CH2Cl2 (0.5 M) and cooled to 0
◦C. PPh3 (1.10 equiv) was carefully added
at this temperature. The resulting suspension was stirred for 1.5 h. Then, N-methylimidazole
(1.25 equiv) was added. After 10 min of stirring, the respective cyclohexanol (1.00 equiv) was
added. The reaction mixture was stirred at this temperature for 4h, befor it was let warm to
ambient temperature and stirred overnight.The reaction mixture was quenched with sat. aq.
NaS2O3 solution. The phases were separated and the aq. layer was extracted 3x with CH2Cl2.
The combined organic layers were washed with brine and dried over MgSO4. The solvents were
evaporated and the crude product was subjected to column chromatography furnishing the
analytically pure cyclohexyl iodide 1.98
1-Iodo-3-isopropylcyclohexane (1a)
i-Pr I
1-Iodo-3-isopropylcyclohexane (1a) was prepared according to TP1 from
3-isopropylcyclohexan-1-ol (12.07 g, 85 mmol), which was prepared according to literature
procedure55b and was obtained as a slightly pink oil (15.09 g, 60 mmol, 70% yield). The analytical
data is in full consictency with the data reported in literature.55c
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.93 (qt, J = 3.3, 2.0 Hz, 1H), 2.05 (ddtt, J = 14.5, 10.5,
3.5, 1.8 Hz, 2H), 1.81 – 1.58 (m, 4H), 1.53 – 1.38 (m, 2H), 1.29 (ddd, J = 14.4, 11.0, 3.4 Hz, 1H),
1.13 – 1.00 (m, 1H), 0.86 (d, J = 6.6, 6H).
98G. L. Lange, C. Gottardo, Synth. Commun. 1990, 20, 1473–1479.
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1-Iodo-3-(trifluoromethyl)cyclohexane (1b)
CF3 I
1-Iodo-3-(trifluoromethyl)cyclohexane (1t) was prepared according to TP1 from 3-(trifluoromethyl)
cyclohexan-1-ol (1 g, 6.0 mmol) and was obtained as a colorless oil (533 mg, 1.9 mmol, 32%
yield).
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.89 (p, J = 3.6 Hz, 1H), 2.72 – 2.54 (m, 1H), 2.25 (dtt,
J = 14.6, 3.5, 2.1 Hz, 1H), 1.99 – 1.92 (m, 1H), 1.75 (tq, J = 10.4, 3.7 Hz, 2H), 1.67 – 1.43 (m, 2H),
1.36 (qd, J = 12.6, 4.2 Hz, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 127.8 (q, J = 278.7 Hz), 39.4 – 38.3 (m), 35.54, 35.4 –
34.7 (m), 31.9, 24.6 (t, J = 2.8 Hz), 21.3.
FT-IR (ATR, cm-1): ν̃ = 2951, 1431, 1392, 1339, 1287, 1259, 1248, 1212, 1166, 1105, 1094,
1075, 903.
MS (EI, 70 eV): m/z (%) = 151 (47), 131 (40), 127 (100), 111 (31), 109 (31), 103 (16).
HR-MS (EI, 70 eV): [C7H10F3], calcd.: 151.0740; found: 151.0727 [M
+-I].
1-(3-Iodocyclohexyl)-4-methoxybenzene (1c)
I
MeO
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum,
was charged with dry LiCl (168 mg, 4.0 mmol) and CuI (380 mg, 2.0 mmol) in THF (20 mL). The
reaction mixure was cooled to 0 ◦C and 2-cyclohexenone (1.92 g, 20 mmol) and TMSCl (2.16 g,
20 mmol) were added and stirring was continued for 1 h. After cooling the reaction mixture
to -78 ◦C (4-methoxyphenyl)magnesium bromide, which was preparred according to literature
procedure,26 was added drop wise over 15 min. The stirring was continued for 4 h, the reaction
mixture was quenched with saturated aq. NH4Cl solution (20 mL) and was allowed to warm to
rt. Most of the solvents were removed under reduced pressure. The residue was extracted with
EtOAc (3 x 20 mL). The combined organic phase was washed several times with saturated aq.
NH4Cl solution until the aq. phase remained colorless. The solvent was removed on the rotary
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evaporator and the crude product was treated with a mixture of EtOH and H2O (1:1, 5 mL) and
HCl (2 M, 3 mL) and was stirred at rt overnight. The reaction mixture was extracted with EtOAc (3
x 20 mL) and the combined organic phases were dried (MgSO4). The solvent was removed via
rotary evaporation to give 3-(4-methoxyphenyl)cyclohexanone as a colorless liquid and was used
without further purification. LiAH4 (230 mg, 6.1 mmol) was suspended in Et2O (6 mL) and the
suspension was heated to reflux for 1 h. After cooling to 0 ◦C, 3-(4-methoxyphenyl)cyclohexanone
in Et2O (1.6 mL) was added dropwise. The reaction mixture was heated to reflux for 12 h the
suspension was cooled to 0 ◦C and carefully quenched via addition of aq. NaOH solution (1 M,
0.5 mL). Celite (2 g) and H2O (1.5 mL) were added and the suspension was stirred for 2 h at
rt and filtered. The precipitate was washed with Et2O and the solvent was removed via rotary
evaporation to give 3-(4-methoxyphenyl)cyclohexanole as a colorless liquid (2.62 g, 64%) and
was used without further purification. Following TP1 1-(3-Iodocyclohexyl)-4-methoxybenzene (1c)
was prepared from 3-(4-methoxyphenyl)cyclohexanole (2.62 g, 12.7 mmol). A colorless oil (2.28 g,
5.0 mmol, 39% yield) was obtained.
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.22 – 7.02 (m, 2H), 6.92 – 6.69 (m, 2H), 3.79 (s, 3H),
3.10 (tt, J = 11.8, 3.4 Hz, 1H), 2.23 (dddd, J = 14.5, 5.3, 3.2, 2.0 Hz, 1H), 2.11 (dtt, J = 14.7, 3.4,
1.5 Hz, 1H), 2.02 – 1.83 (m, 2H), 1.80 – 1.61 (m, 2H), 1.61 – 1.38 (m, 2H), 0.92 – 0.79 (m, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 158.1, 138.3, 128.1, 113.9, 55.4, 43.9, 39.2, 36.5, 36.1,
33.8, 23.1.
FT-IR (ATR, cm-1): ν̃ = 2932, 1610, 1512, 1464, 1443, 1295, 1262, 1245, 1178, 1148, 1107,
1036, 904, 851, 825.
MS (EI, 70 eV): m/z (%) = 316 (3), 254 (100), 188 (11), 184 (14), 169 (9), 134 (46), 128 (19), 127
(79), 121 (29).
HR-MS (EI, 70 eV): [C13H17OI], calcd.: 316.0324; found: 316.0320.
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4-Iodo-2-phenyltetrahydro-2H-pyran (1d)
O
Ph I
4-Iodo-2-phenyltetrahydro-2H-pyran (1d) was prepared according to literature procedure.99
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.32 – 7.17 (m, 5H), 4.44 – 4.30 (m, 1H), 4.26 (dd,
J = 11.1, 2.2 Hz, 1H), 3.95 (ddd, J = 11.8, 4.4, 2.5 Hz, 1H), 3.65 – 3.45 (m, 1H), 2.50 (ddt, J = 13.1,
3.8, 1.8 Hz, 1H), 2.38 – 2.10 (m, 3H).
(1R,4aS,7R,8aS)-3-Iodo-7-isopropyl-1,8a-dimethyldecahydronaphthalene (1e)63
i-Pr
H
Me
Me
I
(+)-Nootkatone (20.0 mmol, 4.40 g) and Pd/C (10%, 700 mg) were suspended in EtOAc (35 mL)
in a 250 mL round- bottom flask charged with a stirring bar. A H2 balloon was attached to the
flask was stirred for 72 h until full reduction of the olefinic double bonds was detected according to
GC-MS and NMR analysis of a crude reaction aliquot. The reaction mixture was filtered through
a short silica plug using EtOAc as eluent. After solvent evaporation the obtained pale yellow
oil was dissolved in MeOH (50 mL), cooled to 0 ◦C, NaBH4 was added portion wise and the
reaction mixture was stirred overnight. The reaction mixture was quenched with HCl (1.0 M)
and extracted with CH2Cl2. After solvent evaporation the crude product was purified by flash
column chromatogrpahy using silica gel (9:1 hexanes/EtOAc), affording the corresponding alcohol
as a colorless oil. (1S,2S,4aS,8aS)-6-iodo-2-isopropyl-1,8a-dimethyldecahydronaphthalene
was prepared according to TP1 from the corresponding alcohol and was obtained as pink oil
(14.8 mmol, 4.95 g, 75% over 3 steps). The analytical data is in full consistency with the data
reported in the literature.63
dr = 85:15.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.88 (tt, J = 4.0, 2.1 Hz, 1H), 1.72 (ddt, J = 13.8, 10.3,
3.2 Hz, 2H), 1.67 – 1.54 (m, 4H), 1.40 – 1.10 (m, 6H), 0.98 (ddt, J = 14.3, 12.3, 5.2 Hz, 1H), 0.79
(dd, J = 6.8, 4.3 Hz, 6H), 0.75 (dd, J = 6.7, 4.2 Hz, 3H), 0.63 (s, 3H).
99J. Yadav, B. S. Reddy, G. N. Kumar, T. Swamy, Tetrahedron Lett. 2007, 48, 2205–2208.
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(4-Iodocyclohexyl)benzene (1f)
Ph
I
(4-Iodocyclohexyl)benzene (1f) was prepared accprding to TP1 from 4-phenylcyclohexan-1-ol
(3.5 g, 20 mmol) and was obtained as colorless crystals (34.81 g, 16.8 mmol, 84% yield). The
analytical data is in full consictency with the data reported in literature.63
dr = 92:8.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.37 – 6.99 (m, 5H), 2.49 (m, 1H), 2.11 (ddt, J = 8.7, 7.0,
3.3 Hz, 2H), 1.96 (qd, J = 12.5, 3.2 Hz, 2H), 1.88 – 1.54 (m, 4H), 0.85 – 0.70 (m, 1H).
Ethyl 4-iodocyclohexane-1-carboxylate (1g)
I
EtO2C
Ethyl 4-iodocyclohexane-1-carboxylate (1g) was prepared accroding to TP1 from ethyl
4-hydroxy-cyclohexane-1-carboxylate (1.72 g, 10 mmol) and was obtained as a colorless oil
(1 g, 3.5 mmol, 35% yield) was obtained. The analytical data is in full consictency with the data
reported in literature.91c
dr = 68:32.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.14 – 3.96 (m, 3H), 2.54 – 2.42 (m, 2H), 2.41 – 2.28 (m,
2H), 2.24 – 2.13 (m, 1H), 2.13 – 2.00 (m, 2H), 1.96 – 1.88 (m, 2H), 1.28 – 1.11 (m, 3H).
1-(4-Iodocyclohexyl)-2,5-dimethyl-1H-pyrrole (1h)
I
N
Me
Me
1-(4-Iodocyclohexyl)-2,5-dimethyl-1H-pyrrole (1h) was prepared according to TP1 from
4-(2,5-dimethyl-1H-pyrrol-1-yl)cyclohexan-1-ol (1.93 g, 10 mmol), which was prepared according
to literature procedure100 and was obtained as light red crystals (860 mg, 28%).
100H. Cho, R. Madden, B. Nisanci, B. Török, Green Chem. 2015, 17, 1088–1099.
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dr = 90:10.
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.76 (s, 2H), 4.88 (t, J = 3.2 Hz, 1H), 3.94 (tt, J = 12.7,
4.0 Hz, 1H), 2.53 (qd, J = 12.8, 3.4 Hz, 2H), 2.37 (s, 6H), 2.22 (dt, J = 15.1, 3.0 Hz, 2H), 1.86 –
1.63 (m, 4H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 128.0, 106.4, 55.2, 36.5, 34.1, 28.1, 14.5.
FT-IR (ATR, cm-1): ν̃ = 2940, 2890, 2864, 2832, 1516, 1439, 1428, 1394, 1347, 1291, 1231,
1212, 1191, 1161, 1084, 1021, 944, 977, 904, 873, 821, 790.
MS (EI, 70 eV): m/z (%) = 303 (10), 254 (53), 176 (7), 128 (37), 127 (100), 96 (8), 94 (17), 79
(11).
HR-MS (EI, 70 eV): [C12H18NI], calcd.: 303.0484; found: 303.0478.
1-(tert-Butyl)-4-bromocyclohexane (1i)
1-(tert-Butyl)-4-bromocyclohexane (1i) was preparedfrom 4-(tert-butyl)cyclohexan-1-ol according
to literature procedure.101
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.68 (p, J = 3.0 Hz, 1H), 2.19 – 2.07 (m, 2H), 1.75 (tdd,
J = 14.6, 4.5, 3.1 Hz, 2H), 1.68 – 1.51 (m, 4H), 1.10 – 0.95 (m, 1H), 0.87 (d, J = 7.4 Hz, 9H).
1-(tert-Butyl)-4-iodocyclohexane (1j)
1-(tert-Butyl)-4-iodocyclohexane (1j) was prepared according to TP1 from
4-(tert-butyl)cyclohexan-1-ol (12.8 g, 20 mmol) and was obtained as colorless crystals
(2.48 mg, 47%). The analytical data is in full consictency with the data reported in literature.63
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.88 (dd, J = 3.6, 2.2 Hz, 1H), 2.12 (dt, J = 13.9, 2.7 Hz,
2H), 1.70 – 1.43 (m, 7H), 1.06 (ddd, J = 11.3, 7.6, 3.5 Hz, 1H), 0.89 (s, 9H).
101Mundy, B P.; Stewart, C. A. e-Eros, 2008, Phosphorus(V) bromide, 1
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tert-Butyl((2-iodocyclohexyl)oxy)dimethylsilane (1k)
tert-Butyl((2-iodocyclohexyl)oxy)dimethylsilane (1k) was prepared from cylcohexene,
N-iodosuccinimide and water, followed by TBS-protection, according to literature procedure.102,97
The analytical data is in full consictency with the data reported in literature.26
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.53 – 4.39 (m, 1H), 3.36 (s, 1H), 2.32 – 2.20 (m, 1H),
1.96 – 1.84 (m, 1H), 1.79 – 1.60 (m, 3H), 1.57 – 1.30 (m, 3H), 0.95 (s, 9H), 0.14 (s, 3H), 0.08 (s,
3H).
tert-Butyl((2-bromocyclohexyl)oxy)dimethylsilane (1l)
tert-Butyl((2-bromocyclohexyl)oxy)dimethylsilane (1l) was prepared according to literature
procedure from cylcohexene, N-bromosuccinimide and water, followed by TBS-protection.57c
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 3.90 (ddd, J = 9.6, 7.6, 4.1 Hz, 1H), 3.73 – 3.63 (m, 1H),
2.36 – 2.25 (m, 1H), 2.09 – 1.95 (m, 1H) 1.88 – 1.58 (m, 4H), 1.43 – 1.23 (m, 3H), 0.90 (s, 9H),
0.12 (s, 3H), 0.08 (s, 3H).
(trans-2-bromo-3-((tert-butyldimethylsilyl)oxy)bicyclo[3.2.0]heptan-6-one (1m)
O
Br
OTBS
H
H
(trans)-3-Bromo-4-((tert-butyldimethylsilyl)oxy)bicyclo[3.2.0]heptan-6-one (2m) was prepared
from (trans)-2-bromo-3-hydroxybicyclo[3.2.0]heptan-6-one, which was prepared according to
literature procedure,103 by TBS protection.97
102M Smietana, V Gouverneur, C Mioskowski, Tetrahedron Letters 2000, 41, 193–195
103J. M. Kelly, F. J. Leeper, Tetrahedron Lett. 2012, 53, 819–821.
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dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.52 (d, J = 3.7 Hz, 1H), 4.21 (s, 1H), 3.78 (dddd, J = 10.2,
6.1, 1.9, 0.9 Hz, 1H), 3.35 – 3.20 (m, 1H), 3.19 – 3.13 (m, 2H), 2.48 (ddd, J = 13.6, 9.5, 3.8 Hz,
1H), 2.17 (dt, J = 14.0, 0.8 Hz, 1H), 0.85 (s, 9H), 0.08 (s, 2H), 0.06 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 210.6, 82.29, 63.6, 58.4, 53.3, 39.1, 38.0, 25.7, 17.9,
–4.9, –5.1.
FT-IR (ATR, cm-1): ν̃ = 2928, 1781, 1471, 1253, 1165, 1074, 1026, 1017, 1005, 906, 871, 837,
825, 809, 777.
MS (EI, 70 eV): m/z (%) = 318 (4), 263 (67), 261 (51), 221 (97), 139 (79), 137 (76), 79 (56), 75
(100=, 73 (100), 57 (48), 55 (22).
HR-MS (EI, 70 eV): [C13H23O3BrSi], calcd.: 318.0651; found: 318.0651.
tert-Butyl((4-iodotetrahydrofuran-3-yl)oxy)dimethylsilane (1n)
O
I
OTBS
tert-Butyl((4-iodotetrahydrofuran-3-yl)oxy)dimethylsilane (1n) was prepared from 2,5-dihydrofuran,
N-iodosuccinimide and water, followed by TBS-protection, according to literature procedure.102,97
The analytical data is in full consictency with the data reported in literature.57c
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.58 (dt, J = 4.42, 2.21 Hz, 1H), 4.17 – 4.36 (m, 2H), 3.97
– 4.10 (m, 2H), 3.66 (dd, J = 9.3, 2.1 Hz, 1H), 0.87 (s, 9H), 0.01 – 0.14 (m, 6H).
3-((tert-Butyldimethylsilyl)oxy)-4-iodo-1-tosylpyrrolidine (1o)
TsN
I
OTBS
3-((tert-Butyldimethylsilyl)oxy)-4-iodo-1-tosylpyrrolidine (1o) was prepared from
1-tosyl-2,5-dihydro-1H-pyrrole, N-iodosuccinimide and water, followed by TBS-protection,
according to literature produre .102
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.70 (m, J = 8.3 Hz, 2H), 7.30 (m, J = 8.6 Hz, 2H), 4.34 (dt,
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J = 4.7, 2.4 Hz, 1H), 3.77 – 3.96 (m, 3H), 3.63 -3.71 (m, 1H), 3.17 (dd, J = 10.2, 1.9 Hz, 1H), 2.40
(s, 3H), 0.73 (s, 9H), -0.08 -0.02 (m, 6H).
The 1H-NMR spectra data are in agreement with literature.57c
2-(Allyloxy)-3-iodotetrahydro-2H-pyran (1q)
2-(Allyloxy)-3-iodotetrahydro-2H-pyran (1q) was prepared according to literature procedure from
3,4-dihydro-2H-pyran, N-iodosuccinimide and allyl alcohol.104
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.87 (dddd, J = 16.9, 10.3, 6.1, 5.2 Hz, 1H), 5.27 (dq,
J = 17.2, 1.7 Hz, 1H), 5.15 (dq, J = 10.4, 1.4 Hz, 1H), 4.62 (d, J = 5.3 Hz, 1H), 4.20 (ddt, J = 12.9,
5.3, 1.5 Hz, 1H), 4.05 (ddd, J = 8.1, 5.3, 4.3 Hz, 1H), 4.02 – 3.94 (m, 1H), 3.94 – 3.88 (m, 1H),
3.52 (ddd, J = 11.2, 7.4, 3.5 Hz, 1H), 2.32 (ddt, J = 14.9, 7.8, 4.1 Hz, 1H), 1.96 (dtd, J = 14.0, 8.3,
4.0 Hz, 1H), 1.71 (dtt, J = 14.2, 7.3, 3.8 Hz, 1H), 1.61 – 1.41 (m, 1H).
3-Iodo-epiandrosterone (1u)
I
OMe
Me
H
H
H
H
3-Iodo epiandrosterone (1u) was prepared according to TP1 from epiandrosterone (2.0 g, 7 mmol)
and was obtained as colorless crystals (2.2 g, 79%). The analytical data is in full consictency with
the data reported in literature.105
dr = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.93 (p, J = 3.0 Hz, 1H), 2.43 (ddd, J = 19.2, 8.8, 1.1 Hz,
1H), 2.14 – 1.99 (m, 1H), 1.99 – 1.86 (m, 2H), 1.85 – 1.61 (m, 7H), 1.61 – 1.39 (m, 5H), 1.30
(dddd, J = 18.4, 13.6, 7.2, 2.9 Hz, 5H), 1.07 (qd, J = 12.2, 5.1 Hz, 1H), 0.85 (s, 3H), 0.81 (s, 3H).
104C. Ollivier, P. Renaud, J. Am. Chem. Soc. 2001, 123, 4717–4727.
105E. Keinan, M. Sahai, R. Shvily, Synthesis 1991, 1991, 641–643.
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2.2 Cobalt-Catalyzed Diastereoselective Cross-Couplings between Alkynylzinc
Pivalates and Functionalized CyclicIodides or Bromides
Preparation of alkynylzinc pivalates (TP2):
R1 H
1) EtMgBr (1.1 equiv)
2) Zn(OPiv)2 (1.1 equiv)
THF, 0 °C to rt
R1 ZnOPiv
2
The corresponding alkyne (1.0 equiv, 1.0 mmol) and THF (0.5 mL) were added to a dry and
argon-flushed 10 mL Schlenk -flask, equipped with a stirring bar and a septum. EtMgBr (1.1 equiv)
was added dropwise at room temperature and stirred until a reaction aliquot quenched with
I2 in THF showed full conversion of the starting material determined by GC. Solid Zn(OPiv)2
(1.1 equiv) was added in one portion at 0 ◦C and the reaction mixture was stirred at ambient
temperature for 15 min.
Cobalt-catalyzed cross-coupling of alkynylzinc pivalates (TP3):
Me4DACH (2.0 equiv)
CoCl2 (20 mol%)
THF, 0 °C, 8 h
1
X = I, Br; Y = CH, O
Y X
R1
Y
R1
R2
R2 ZnOPiv
2 (1.5 equiv)
3
A dry and argon-flushed 10 mL Schlenk-tube, equipped with a stirring bar and a septum, was
charged with anhydrous CoCl2 (0.1 mmol, 13 mg, 20 mol%, dried in vacuo at 400
◦C prior to
use), the respective halide (0.5 mmol, 1.0 equiv), THF (1.0 mL) and Me4DACH (1 mmol, 0.19 mL,
2.0 equiv) were added. The reaction mixture was cooled to 0 ◦C with an ice bath and the THF
solution of the appropriate alkynylzinc pivalate (0.6 M, 0.75 mmol, 1.5 equiv) was added dropwise.
The reaction was stirred and monitored by GC-analysis (tetradecane, C14H30 was used as an
internal standard). After 8 h, saturated aq. NH4Cl solution (10 mL) was added, the phases were
separated and the aq. phase was extracted with EtOAc (3 x 25 mL). The combined organic layers
were dried over MgSO4. The solvents were evaporated and the residue was subjected to column
chromatography on silica yielding the respective title compound.
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cis-3-Isopropylcyclohexyl)ethynyl)benzene (3a)
Following TP3 1-iodo-3-isopropylcyclohexane (1a, 126 mg, 0.5 mmol, 1.0 equiv) was coupled
with 2-phenylethynylzinc pivalate (2a, 1.0 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 88 mg, 0.39 mmol, 78%, dr = 92:8, colorless oil.
Purification: i-hexane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.43 – 7.36 (m, 2H), 7.31 – 7.20 (m, 3H), 2.43 (tt, J = 11.4,
3.6 Hz, 1H), 2.12 – 1.95 (m, 2H), 1.81 (dq, J = 12.9, 3.3 Hz, 1H), 1.68 (ddq, J = 12.6, 3.5, 1.6 Hz,
1H), 1.47 (pd, J = 6.9, 4.7 Hz, 1H), 1.40 – 1.20 (m, 2H), 1.13 (tdd, J = 11.9, 9.8, 5.6 Hz, 2H), 0.97
(tdd, J = 11.9, 6.2, 3.7 Hz, 1H), 0.89 (d, J = 6.8 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.7, 128.3, 127.6, 124.2, 94.9, 80.0, 43.7, 36.6, 33.4,
33.0, 30.7, 29.1, 26.1, 19.9, 19.8.
FT-IR (ATR, cm-1): ν̃ = 2928, 2858, 1701, 1598, 1490, 1460, 1443, 1385, 1367, 1331, 1308,
1263, 1176, 1069, 1026, 934, 911, 886, 869, 847.
MS (EI, 70 eV): m/z (%) = 226 (8), 211 (100), 155 (63), 141 (99), 129 (51), 128 (50), 115 (51).
HR-MS (EI, 70 eV): [C17H22], calcd.: 226.1722; found: 226.1714.
Triisopropyl(((cis)-3-isopropylcyclohexyl)ethynyl)silane (3b)
Following TP3 1-iodo-3-isopropylcyclohexane (1a, 126 mg, 0.5 mmol, 1.0 equiv) was coupled
with triisopropylsilyl)ethynyl)zinc pivalate (2b, 1.0 mmol, 1.5 equiv) prepared according to TP2.
The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 145 mg, 0.48 mmol, 95%, dr = 95:5, colorless oil.
Purification: i-hexane.
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1H-NMR (400 MHz, CDCl3, ppm): δ = 2.24 (ddt, J = 11.4, 7.0, 3.6 Hz, 1H), 2.04 – 1.91 (m, 2H),
1.83 – 1.71 (m, 1H), 1.71 – 1.60 (m, 1H), 1.50 – 1.36 (m, 1H), 1.31 – 1.13 (m, 2H), 1.13 – 0.95
(m, 24H), 0.87 (d, J = 1.9 Hz, 3H), 0.85 (d, J = 2.0 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 114.3, 78.7, 43.7, 36.8, 33.7, 33.0, 31.2, 29.0, 26.1, 19.9,
19.8, 18.8, 11.4.
FT-IR (ATR, cm-1): ν̃ = 2933, 2873, 1458, 1448, 1445, 1367, 1305, 1181, 1096, 1060, 1002, 867,
820, 739, 727, 723, 721.
MS (EI, 70 eV): m/z (%) = 306 (1), 263 (100), 221 (17), 207 (22), 193 (12), 179 (11), 151 (10), 73
(15), 59 (10).
HR-MS (EI, 70 eV): [C20H38Si], calcd.: 306.2743; found: 306.2732.
Triethyl((1-(((cis)-3-isopropylcyclohexyl)ethynyl)cyclohexyl)oxy)silane (3c)
Following TP3 1-iodo-3-isopropylcyclohexane (1a, 126 mg, 0.5 mmol, 1.0 equiv) was coupled
with ((1-((triethylsilyl)oxy)cyclohexyl)ethynyl)zinc pivalate (2c, 1.0 mmol, 1.5 equiv) prepared
according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 165 mg, 0.46 mmol, 91%, dr = 98:2, colorless oil.
Purification: i-hexane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.23 (ddq, J = 12.2, 7.0, 3.8 Hz, 1H), 1.98 – 1.85 (m, 2H),
1.84 – 1.70 (m, 3H), 1.70 – 1.38 (m, 9H), 1.35 – 1.17 (m, 3H), 1.11 – 1.02 (m, 2H), 0.96 (t,
J = 7.9 Hz, 10H), 0.86 (d, J = 6.8 Hz, 6H), 0.67 (q, J = 7.9 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 89.6, 83.9, 69.5, 43.7, 41.8, 36.6, 33.4, 33.0, 30.2, 29.1,
26.1, 25.6, 23.4, 19.8, 19.8, 7.3, 6.4.
FT-IR (ATR, cm-1): ν̃ = 2938, 2863, 2171, 1462, 1385, 1367, 1097, 1061, 1062, 1017, 995, 918,
882, 810, 667.
MS (EI, 70 eV): m/z (%) = 334 (22), 333 (92), 215 (57), 187 (53), 145 (69), 131 (52), 117 (48),
105 (42), 103 (92), 79 (43), 75 (100).
HR-MS (EI, 70 eV): [C23H42OSi], calcd.: 362.3005; found: 362.3001.
75
III EXPERIMENTAL PART
Trimethyl((2-methyl-4-((cis)-3-(trifluoromethyl)cyclohexyl)but-3-yn-2-yl)oxy)silane (3d)
Following TP3 1-iodo-3-(trifluoromethyl)cyclohexane (1b, 139 mg, 0.5 mmol, 1.0 equiv) was
coupled with (3-methyl-3-((trimethylsilyl)oxy)but-1-yn-yl)zinc pivalate (2d, 1.0 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 95 mg, 0.31 mmol, 62%, dr = 90:10, orange oil.
Purification: i-hexane:ethyl acetate = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.27 (tt, J = 11.9, 3.6 Hz, 1H), 2.14 (dtt, J = 12.9, 3.6,
1.6 Hz, 1H), 2.10 – 1.79 (m, 4H), 1.44 (s, 6H), 1.40 – 1.15 (m, 4H), 0.18 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.6 (q, J = 278.6 Hz), 128.8, 126.0, 123.3, 86.0, 85.6,
66.6, 42.0, 41.8 (q, J = 26.7 Hz) 41.5, 41.2, 33.5, 32.3, 31.4 (q, J = 2.5 Hz) , 28.7, 24.5, 24.3 (q,
J = 2.6 Hz), 2.1.
FT-IR (ATR, cm-1): ν̃ = 2925, 1359, 1327, 1283, 1273, 1248, 1210, 1166, 1111, 1099, 1072,
1032, 902, 877, 838, 752, 686.
MS (EI, 70 eV): m/z (%) = 291 (100), 161 (16), 105 (51), 91 (38), 75 (53).
HR-MS (EI, 70 eV): [C15H25F3O2Si], calcd.: 291.1398; found: 291.1389 [M
+-CH3].
((4-((cis)-3-(4-Methoxyphenyl)cyclohexyl)-2-methylbut-3-yn-2-yl)oxy)trimethylsilane (3e)
Following TP3 1-(3-iodocyclohexyl)-4-methoxybenzene (1v, 158 mg, 0.5 mmol, 1.0 equiv) was
coupled with (3-methyl-3-((trimethylsilyl)oxy)but-1-yn-yl)zinc pivalate (2d, 0.75 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 134 mg, 0.39 mmol, 78%, dr = 98:2, colorless oil.
Purification: i-hexane:ethyl acetate = 99:1.
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.15 – 7.10 (m, 2H), 6.88 – 6.82 (m, 2H), 3.79 (s, 3H),
2.44 (m, 2H), 2.10 (dtt, J = 12.9, 3.5, 1.8 Hz, 1H), 2.05 – 1.96 (m, 1H), 1.85 (tdd, J = 12.6, 5.4, 2.4
Hz, 3H), 1.44 (s, 9H), 0.18 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 158.0, 139.1, 127.8, 113.9, 87.0, 85.3, 66.7, 55.4, 43.1,
40.8, 33.8, 33.6, 32.7, 30.2, 26.3, 2.2.
FT-IR (ATR, cm-1): ν̃ = 2929, 2855, 1611, 1512, 1461, 1446, 1443, 1358, 1244, 1176, 1157,
1100, 1032, 914, 896, 839, 823, 753, 721, 686, 655.
MS (EI, 70 eV): m/z (%) = 254 (50), 239 (59), 223 (44), 211 (44), 179 (54), 155 (55), 121 (49),
121 (49), 91 (49), 91 (46), 75 (100).
HR-MS (EI, 70 eV): [C21H32O2Si], calcd.: 344.2172; found: 344.2167.
cis-2-Phenyl-4-(phenylethynyl)tetrahydro-2H-pyran (3f)
Following TP3 4-iodo-2-phenyltetrahydro-2H-pyran (1d, 144 mg, 0.5 mmol, 1.0 equiv) was
coupled with 2-phenylethynylzinc pivalate (2a, 0.75 mmol, 1.5 equiv) prepared according to TP2.
The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 99 mg, 0.38 mmol, 76%, dr = 93:7, pale yellow oil.
Purification: i-hexane:ethyl acetate = 98:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.32 – 7.21 (m, 6H), 7.21 – 7.10 (m, 4H), 4.24 (dd,
J = 11.4, 2.2 Hz, 1H), 4.09 (ddd, J = 11.7, 4.5, 1.7 Hz, 1H), 3.53 (td, J = 12.1, 2.4 Hz, 1H), 2.79 (tt,
J = 11.9, 3.9 Hz, 1H), 2.10 (ddt, J = 13.3, 3.9, 2.0 Hz, 1H), 1.87 (ddq, J = 13.4, 4.1, 2.1 Hz, 1H),
1.83 – 1.74 (m, 1H), 1.68 (dt, J = 13.4, 11.6 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 142.3, 131.7, 128.5, 128.3, 127.9, 127.7, 126.0, 123.6,
92.3, 81.0, 79.4, 68.0, 40.1, 32.4, 28.6.
FT-IR (ATR, cm-1): ν̃ = 2930, 2856, 1730, 1731, 1601, 1492, 1451, 1372, 1240, 117, 1091, 1068,
1026, 970, 939, 899, 859, 836, 807, 777, 757.
MS (EI, 70 eV): m/z (%) = 262 (42), 218 (40), 185 (28), 141 (37), 128 (100), 115 (64), 91 (28), 77
(32).
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HR-MS (EI, 70 eV): [C19H18O], calcd.: 262.1358; found: 262.1353.
(1R,3S,4aR,7R,8aS)-3-((4-Fluorophenyl)ethynyl)-7-isopropyl-1,8a dimethyldecahydro
naphthalene (3g)
Following TP3 (1R,3R,4aS,7R,8aS)-3-iodo-7-isopropyl-1,8a dimethyldecahydronaphthalene
(1e, 174 mg, 0.5 mmol, 1.0 equiv) was coupled with ((4-fluorophenyl)ethynyl)zinc pivalate (2e,
0.75 mmol, 1.5 equiv) prepared according to TP2. The solution was stirred for 8 h and was
worked-up as usual.
Isolated yield: 98 mg, 0.30 mmol, 60%, dr = 94:6, colorless oil.
Purification: i-hexane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.50 (dd, J = 7.5, 5.8 Hz, 2H), 7.06 – 6.97 (m, 2H), 2.44 (p,
J = 8.0 Hz, 2H), 1.77 (dt, J = 12.6, 7.8 Hz, 2H), 1.72 – 1.57 (m, 4H), 1.51 – 1.13 (m, 10H), 0.90 (d,
J = 6.1 Hz, 4H), 0.87 (d, J = 2.2 Hz, 6H), 0.86 (s, 2H), 0.74 – 0.65 (m, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.2 (d, J = 162.1) 161.2, 91.6, 83.3, 46.6, 39.9, 37.3,
35.7, 34.9, 32.3, 28.7, 28.4, 28.0, 22.9, 18.9, 15.8.
FT-IR (ATR, cm-1): ν̃ = 2953, 2925, 2858, 1601, 1506, 1463, 1441, 1384, 1367, 1231, 1155,
1091, 1014, 905, 834, 816.
MS (EI, 70 eV): m/z (%) = 326 (36), 201 (50), 188 (80), 173 (90), 159 (100), 146 (91), 133 (45),
95 (49).
HR-MS (EI, 70 eV): [C23H31F], calcd.: 326.2410; found: 326.2403.
Optical rotation: [α]ϕλ = 33.8 (c = 0.81, CHCl3).
78
III EXPERIMENTAL PART
1-Chloro-3-(((trans)-4-phenylcyclohexyl)ethynyl)benzene (3h)
Following TP3 (4-iodocyclohexyl)benzene (1f, 143 mg, 0.5 mmol, 1.0 equiv) was coupled with
((3-chlorophenyl)ethynyl)zinc pivalate (2f, 0.75 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 100 mg, 0.34 mmol, 68%, dr = 90:10, colorless crystals.
Purification: i-hexane.
m.p.: 67.2 – 68.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.32 (d, J = 1.8 Hz, 1H), 7.27 – 7.09 (m, 8H), 2.55 – 2.35
(m, 2H), 2.10 (dd, J = 13.4, 3.6 Hz, 2H), 1.94 – 1.83 (m, 2H), 1.48 (ttd, J = 25.5, 13.0, 3.2 Hz, 4H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.1, 134.1, 131.7, 129.9, 129.5, 128.5, 127.9, 126.9,
126.2, 125.8, 95.7, 79.22, 43.6, 33.7, 33.4, 30.1.
FT-IR (ATR, cm-1): ν̃ = 3018, 2932, 2857, 1704, 1592, 1560, 1493, 1475, 1448, 1214, 1092,
1077, 1028, 961, 882, 812.
MS (EI, 70 eV): m/z (%) = 268 (9), 266 (27), 164 (16), 156 (14), 153 (9), 130 (11), 129 (100), 128
(13), 115 (16), 91 (11).
HR-MS (EI, 70 eV): [C20H19Cl], calcd.: 294.1175; found: 294.1170.
Triethyl((2-methyl-4-((trans)-4-phenylcyclohexyl)but-3-yn-2-yl)oxy)silane (3i)
Following TP3 (4-iodocyclohexyl)benzene (1f, 139 mg, 0.5 mmol, 1.0 equiv) was coupled with
(3-methyl-3-((triethylsilyl)oxy)but-1-yn-1-yl)zinc pivalate (2g, 0.75 mmol, 1.5 equiv) prepared
according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 169 mg, 0.48 mmol, 95%, dr = 99:1, colorless oil.
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Purification: i-hexane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.26 – 7.17 (m, J = 7.4, 6.9 Hz, 2H), 7.12 (d, J = 7.4 Hz,
3H), 2.43 (tt, J = 11.7, 3.5 Hz, 1H), 2.28 – 2.14 (m, 1H), 2.06 – 1.94 (m, 2H), 1.84 (d, J = 11.0 Hz,
2H), 1.50 – 1.30 (m, 10H), 0.91 (t, J = 7.9 Hz, 9H), 0.61 (q, J = 7.9 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.3, 128.5, 126.9, 126.2, 86.5, 85.5, 66.3, 43.7, 33.8,
33.6, 33.4, 29.5, 7.2, 6.2.
FT-IR (ATR, cm-1): ν̃ = 2931, 2873, 1494, 1448, 1376, 1357, 1300, 1242, 1157, 1096, 1034,
1011, 975, 907, 894, 789, 740, 725, 697.
MS (EI, 70 eV): m/z (%) = 327 (18), 209 (19), 196 (45), 156(50), 155 (25), 129 (26), 115 (39),
103 (43), 94 (24), 91 (60), 79 (100), 75 (46).
HR-MS (EI, 70 eV): [C22H33OSi], calcd.: 341.2306; found: 341.2294 [M
+-Me].
((trans)-4-(Cyclopropylethynyl)cyclohexyl)benzene(3j)
Following TP3 (4-iodocyclohexyl)benzene (1f, 139 mg, 0.5 mmol, 1.0 equiv) was coupled with
(cyclopropylethynyl)zinc pivalate (2h, 0.75 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 80 mg, 0.36 mmol, 71%, dr = 95:5, colorless crystals.
Purification: i-hexane.
m.p.: 70.8 – 72.4 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.40 – 7.30 (m, 2H), 7.25 (d, J = 7.3 Hz, 3H), 2.54 (ddd,
J = 11.6, 8.2, 3.4 Hz, 1H), 2.29 (td, J = 11.5, 3.7 Hz, 1H), 2.20 – 2.08 (m, 2H), 2.02 – 1.88 (m, 2H),
1.67 – 1.41 (m, 4H), 1.37 – 1.22 (m, 1H), 0.79 (dt, J = 8.0, 3.2 Hz, 2H), 0.69 (dt, J = 5.2, 3.1 Hz,
2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.3, 128.5, 126.9, 126.1, 83.1, 80.0, 43.7, 33.9, 33.8,
29.6, 8.3, -0.3.
FT-IR (ATR, cm-1): ν̃ = 2928, 1699, 1490, 1447, 1023, 976, 888, 814.
MS (EI, 70 eV): m/z (%) = 223 (2), 196 (16), 195 (21), 181 (33), 167 (36), 156 (17), 155 (24), 117
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(17), 115 (33), 91 (46), 79 (100).
HR-MS (EI, 70 eV): [C17H19], calcd.: 223.1492; found: 223.1479 [M
+-Me].
Triisopropyl(((trans)-4-phenylcyclohexyl)ethynyl)silane (3k)
Following TP3 (4-iodocyclohexyl)benzene (1f, 139 mg, 0.5 mmol, 1.0 equiv) was coupled with
triisopropylsilyl)ethynyl)zinc pivalate (2b, 0.75 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 163 mg, 0.48 mmol, 96%, dr = 98:2, colorless oil.
Purification: i-hexane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.28 – 7.17 (m, 2H), 7.12 (d, J = 7.3 Hz, 3H), 2.44 (tt,
J = 11.7, 3.5 Hz, 1H), 2.26 (tt, J = 11.7, 3.7 Hz, 1H), 2.06 (dd, J = 13.4, 3.6 Hz, 2H), 1.84 (dd,
J = 12.0, 3.1 Hz, 2H), 1.56 – 1.30 (m, 6H), 1.00 (d, J = 5.1 Hz, 19H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.3, 128.5, 127.0, 126.9, 126.2, 113.7, 79.3, 43.7, 33.8,
33.7, 30.5, 18.8, 11.4.
FT-IR (ATR, cm-1): ν̃ = 2929, 2890, 2862, 2175, 1462, 1449, 1444, 1072, 1017, 995, 882, 753,
697, 685, 670, 657.
MS (EI, 70 eV): m/z (%) = 298 (23), 297 (100), 156 (27), 155 (28), 141 (21), 131 (41), 117 (34),
115 (34), 91 (43), 75 (31).
HR-MS (EI, 70 eV): [C20H29Si], calcd.: 297.2044; found: 297.2033 [M
+-i-Pr].
Ethyl (trans)-4-(3,5-dimethyl-3-((triethylsilyl)oxy)hex-1-yn-1-yl)cyclohexane-1-carboxylate
(3l)
Following TP3 ethyl 4-iodocyclohexane-1-carboxylate (1g, 141 mg, 0.5 mmol, 1.0 equiv)
was coupled with (3,5-dimethyl-3-((triethylsilyl)oxy)hex-1-yn-1-yl)zinc pivalate (2i, 0.75 mmol,
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1.5 equiv) prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 139 mg, 0.35 mmol, 71%, dr = 90:10, yellow oil.
Purification: i-hexane:ethyl acetate = 97:3.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.11 (q, J = 7.1 Hz, 2H), 2.24 (tdt, J = 11.2, 7.9, 3.3 Hz,
2H), 2.03 – 1.94 (m, 4H), 1.93 – 1.81 (m, 1H), 1.58 – 1.32 (m, 9H), 1.24 (t, J = 7.1 Hz, 3H), 0.99 –
0.91 (m, 15H), 0.65 (dtd, J = 8.4, 7.4, 1.3 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.9, 86.9, 85.4, 69.2, 60.4, 54.1, 42.5, 32.2, 31.9, 31.9,
29.1, 28.3, 25.0, 24.7, 24.6, 14.4, 7.2, 6.3.
FT-IR (ATR, cm-1): ν̃ = 2950, 2873, 1733, 1450, 1414, 1367, 1300, 1378, 1162, 1136, 1072,
1039, 1022, 970, 740, 724, 671.
MS (EI, 70 eV): m/z (%) = 365 (44), 337 (70), 188 (13), 173 (69), 1313 (50), 117 (40), 103 (97),
75 (100).
HR-MS (EI, 70 eV): [C22H39O3Si], calcd.: 379.2674; found: 379.2662 [M
+-Me].
1-((trans)-4-(Cyclohex-1-en-1-ylethynyl)cyclohexyl)-2,5-dimethyl-1H-pyrrole (3m)
Following TP3 1-(4-iodocyclohexyl)-2,5-dimethyl-1H-pyrrole (1h, 152 mg, 0.5 mmol, 1.0 equiv)
was coupled with (cyclohex-1-en-1-ylethynyl)zinc pivalate (2j, 0.75 mmol, 1.5 equiv) prepared
according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 117 mg, 0.42 mmol, 83%, dr = 95:5, pale yellow oil.
Purification: i-hexane:ethyl acetate = 97:3.
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.04 (tt, J = 3.8, 1.7 Hz, 1H), 5.73 (s, 2H), 3.92 (tt, J = 12.0,
4.0 Hz, 1H), 2.45 – 2.32 (m, 1H), 2.28 (s, 6H), 2.19 – 2.05 (m, 6H), 2.01 – 1.86 (m, 4H), 1.69 –
1.46 (m, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 133.8, 127.9, 120.9, 106.4, 90.4, 82.4, 55.6, 33.5, 31.7,
29.7, 29.7, 25.7, 22.5, 21.7, 14.6.
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FT-IR (ATR, cm-1): ν̃ = 2928, 2858, 1517, 1444, 1396, 1349, 1292, 1237, 1212, 1189, 1166,
1135, 1086, 1019, 988, 978, 917, 899, 839, 815, 799, 786, 780.
MS (EI, 70 eV): m/z (%) = 282 (21), 281 (93), 266 (81), 129 (39), 128 (31), 115 (46), 94 (91), 91
(100).
HR-MS (EI, 70 eV): [C20H27N], calcd.: 281.2143; found: 281.2138.
(((trans)-4-(tert-Butyl)cyclohexyl)ethynyl)trimethylsilane (3n)
Following TP3 1-(tert-butyl)-4-bromocyclohexane (1i: 109 mg, 0.5 mmol, 1.0 equiv), or
1-(tert-butyl)-4-iodocyclohexane (1j: 133 mg, 0.5 mmol, 1.0 equiv was coupled with
((4-methoxyphenyl) ethynyl)zinc pivalate (2k, 0.75 mmol, 1.5 equiv) prepared according
to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: starting from 1i: 99 mg, 0.42 mmol, 84%, dr = 90:10, colorless oil.
Isolated yield: starting from 1j: 84 mg, 0.36 mmol, 71%, dr = 90:10, colorless oil
Purification: i-hexane
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.14 (tt, J = 12.0, 3.7 Hz, 1H), 2.06 – 1.96 (m, 2H), 1.75
(ddd, J = 9.1, 4.6, 2.6 Hz, 2H), 1.42 – 1.22 (m, 2H), 1.04 – 0.88 (m, 3H), 0.82 (s, 9H), 0.14 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 112.2, 83.2, 47.4, 33.7, 32.5, 30.9, 27.6, 27.0, 0.4.
FT-IR (ATR, cm-1): ν̃ = 2941, 2858, 1365, 1248, 1211, 862, 837, 758, 696, 665.
MS (EI, 70 eV): m/z (%) = 236 (1), 221 (49), 147 (39), 119 (39), 105 (20), 91 (18), 73 (100), 41
(20).
HR-MS (EI, 70 eV): [C15H28Si], calcd.: 236.1960; found: 236.1953.
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1-(((trans)-4-(tert-Butyl)cyclohexyl)ethynyl)-4-methoxybenzene (3o)
Following TP3 1-(tert-butyl)-4-iodocyclohexane (1j, 133 mg, 0.5 mmol, 1.0 equiv) was coupled
with ((4-methoxyphenyl) ethynyl)zinc pivalate (2l, 0.75 mmol, 1.5 equiv) prepared according to
TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 99 mg, 0.37 mmol, 73%, dr = 94:6, colorless crystals.
Purification: i-hexane:ethyl acetate = 99:1.
m.p.: 83.6 – 85.4 ◦C. 1H-NMR (400 MHz, CDCl3, ppm): δ = 7.39 – 7.28 (m, 2H), 6.85 – 6.73 (m,
2H), 3.79 (s, 3H), 2.32 (tt, J = 12.0, 3.7 Hz, 1H), 2.17 – 2.03 (m, 2H), 1.87 – 1.72 (m, 2H), 1.47 –
1.34 (m, 2H), 1.14 – 0.94 (m, 3H), 0.85 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.1, 133.0, 116.3, 113.9, 93.2, 79.8, 55.4, 47.5, 33.9,
32.6, 30.6, 27.6, 27.1.
FT-IR (ATR, cm-1): ν̃ = 2937, 2858, 1605, 1509, 1466, 1441, 1364, 1287, 1245, 1364, 1287,
1245, 1181, 1172, 1031, 904, 831.
MS (EI, 70 eV): m/z (%) = 270 (18), 160 (100), 159 (64), 145 (25), 134 (24), 129 (38).
HR-MS (EI, 70 eV): [C19H26O], calcd.: 270.1984; found: 270.1980.
tert-Butyldimethyl(((trans)-2-((triisopropylsilyl)ethynyl)cyclohexyl)oxy)silane (3p)
Following TP3 tert-butyl((2-bromocyclohexyl)oxy)dimethylsilane (1l, 146 mg 0.5 mmol, 1.0 equiv)
was coupled with triisopropylsilyl)ethynyl)zinc pivalate (2b, 0.75 mmol, 1.5 equiv) prepared
according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Large scale experiment:
A dry and argon-flushed 50 mL Schlenk-tube, equipped with a stirring bar and a septum, was
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charged with anhydrous CoCl2 (1.0 mmol, 130 mg, 20 mol%), tert-butyl((2-iodocyclohexyl)oxy)
dimethylsilane (1k, 1.70 g, 5.0 mmol, 1.0 equiv), THF (10 mL), and 20 (10 mmol, 1.9 mL, 2.0 equiv)
were added. The reaction mixture was cooled to 0 ◦C with an ice bath and the THF solution of
triisopropylsilyl)ethynyl)zinc pivalate (2b, 0.58 M, 7.5 mmol, 1.5 equiv), prepared according to
TP2 was added dropwise. The reaction was stirred and monitored by GC-analysis (tetradecane,
C14H30 was used as an internal standard). After 8 h, saturated aq. NH4Cl solution (100 mL) was
added, the phases were separated and the aq. phase was extracted with EtOAc (3 x 200 mL).
The combined organic layers were dried over MgSO4. The solvents were evaporated and the
residue was subjected to column chromatography on silica yielding 3p.
Isolated yield: starting from 1k: 1.54 g, 3.85 mmol, 77%; dr = 99:1, colorless oil.
Isolated yield: starting from 1l: 118 mg 0.30 mmol, 60%; dr = 99:1, colorless oil.
Purification: i-hexane:ethyl acetate = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 3.77 – 3.63 (m, 1H), 2.44 (td, J = 6.8, 4.2 Hz, 1H), 2.03 –
1.83 (m, 1H), 1.77 – 1.59 (m, 2H), 1.53 – 1.41 (m, 1H), 1.31 (tdd, J = 16.4, 11.7, 6.2 Hz, 4H), 1.06
(d, J = 4.7 Hz, 21H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 114.3, 78.7, 43.7, 36.8, 33.8, 33.0, 31.2, 29.0, 26.1, 19.9,
19.8, 18.8, 11.4.
FT-IR (ATR, cm-1): ν̃ = 2932, 2890, 2861, 1694, 1471, 1462, 1360, 1250, 1157, 1104, 1064,
1022, 1005, 996, 943, 919, 70, 834, 811, 773, 689, 668.
MS (EI, 70 eV): m/z (%) = 296 (19), 295 (100), 269 (35), 253 (87), 225 (18), 211 (12).
HR-MS (EI, 70 eV): [C23H45OSi2], calcd.: 393.3014; found: 393.2999 [M
+-Me].
tert-Butyldimethyl(((trans)-2-(phenylethynyl)cyclohexyl)oxy)silane (3q)
Following TP3 tert-butyl((2-iodocyclohexyl)oxy)dimethylsilane (1k, 170 mg, 0.5 mmol, 1.0 equiv)
was coupled with 2-phenylethynylzinc pivalate (2a, 0.75 mmol, 1.5 equiv) prepared according to
TP2. The solution was stirred for 8 h and was worked-up as usual.
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Isolated yield: 113 mg, 0.36 mmol, 72%, dr = 96:4, yellow oil.
Purification:i-hexane:ethyl acetate = 99:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.42 – 7.35 (m, 2H), 7.32 – 7.23 (m, 3H), 3.67 (td, J = 8.0,
3.5 Hz, 1H), 2.52 (td, J = 8.8, 3.8 Hz, 1H), 2.15 – 2.01 (m, 1H), 1.93 (ddd, J = 9.9, 6.0, 3.1 Hz, 1H),
1.70 (ddt, J = 16.7, 11.0, 6.3 Hz, 2H), 1.48 (ddd, J = 13.3, 9.7, 3.7 Hz, 1H), 1.31 (ddd, J = 18.8,
14.6, 9.6 Hz, 3H), 0.91 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.7, 128.3, 127.6, 124.3, 93.2, 81.7, 73.3, 38.5, 34.4,
30.5, 26.0, 24.3, 23.5, 18.3, -4.4, -4.4.
FT-IR (ATR, cm-1): ν̃ = 2928, 2855, 1490, 1471, 1461, 1442, 1360, 1248, 1130, 1098, 1060,
1039, 1039, 1022, 1005, 937, 875, 833, 814, 773, 753, 689.
MS (EI, 70 eV): m/z (%) = 257 (100), 183 (89), 181 (48), 159 (25), 141 (56), 115 (22), 75 (95), 73
(20).
HR-MS (EI, 70 eV): [C20H29OSI], calcd.: 313.1993; found: 313.1982 [M
+-Me].
4-((tert-Butyldimethylsilyl)oxy)-3-(cyclohexylethynyl)bicyclo[3.2.0]heptan-6-one (3r)
O
OTBS
Cy
H
H
Following TP3 (3-bromo-4-((tert-butyldimethylsilyl)oxy)bicyclo[3.2.0]heptan-6-one (1w, 159 mg,
0.5 mmol, 1.0 equiv) was coupled with (cyclohexylethynyl)zinc pivalate (2m, 0.75 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 107 mg, 0.31 mmol, 62%, dr = 99:1, yellow oil.
Purification: i-hexane:ethyl acetate = 96:4.
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.34 – 4.29 (m, 1H), 3.67 (ddt, J = 9.3, 7.7, 2.0 Hz, 1H),
3.19 – 3.01 (m, 2H), 2.98 – 2.88 (m, 1H), 2.82 (dd, J = 2.1, 1.0 Hz, 1H), 2.31 (s, 1H), 2.25 – 2.05
(m, 2H), 1.78 – 1.46 (m, 5H), 1.43 – 1.18 (m, 5H), 0.83 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 212.8, 88.0, 81.3, 80.8, 63.6, 52.5, 45.1, 39.9, 36.5, 33.0,
29.1, 26.0, 25.7, 24.9, 17.9, -4.9.
FT-IR (ATR, cm-1): ν̃ = 2928, 2855, 1779, 1471, 1463, 1449, 1362, 1255, 1215, 1179, 1093,
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1070, 1027, 1005, 963, 937, 903, 835, 812, 774.
MS (EI, 70 eV): m/z (%) = 289 (49), 189 (15), 155 (16), 129 (32), 91 (37), 75 (100), 73 (52).
HR-MS (EI, 70 eV): [C20H31O2Si], calcd.: 331.2099; found: 331.2084 [M
+-Me].
tert-Butyl(((trans)-4-((2-chlorophenyl)ethynyl)tetrahydrofuran-3-yl)oxy)dimethylsilane
(3s)
Following TP3 tert-butyl((4-iodotetrahydrofuran-3-yl)oxy)dimethylsilane (1n, 164 mg, 0.5 mmol,
1.0 equiv) was coupled with ((2-chlorophenyl)ethynyl)zinc pivalate (2n, 0.75 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 106 mg, 0.32 mmol, 63%, dr = 99:1, yellow oil.
Purification: i-hexane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.27 (dd, J = 7.2, 2.2 Hz, 1H), 7.23 (dd, J = 7.9, 1.5 Hz,
1H), 7.11 – 7.00 (m, 2H), 4.39 (dt, J = 5.0, 3.1 Hz, 1H), 4.08 (dd, J = 8.2, 7.0 Hz, 1H), 3.91 (dd,
J = 9.2, 4.9 Hz, 1H), 3.74 (dd, J = 8.3, 5.4 Hz, 1H), 3.56 (dd, J = 9.2, 2.9 Hz, 1H), 2.97 (ddd,
J = 7.0, 5.4, 3.2 Hz, 1H), 0.76 (s, 9H), 0.00 (s, 3H), –0.02 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 136.0, 133.3, 129.3, 129.1, 126.5, 123.2, 94.1, 80.1, 78.8,
75.4, 72.5, 41.4, 25.9, 18.2, -4.5, -4.8.
FT-IR (ATR, cm-1): ν̃ = 2950, 2928, 2855, 1694, 1472, 1436, 1361, 1251, 1202, 1101, 1063,
1033, 1004, 940, 907, 862, 834, 831, 811, 777, 752, 722.
MS (EI, 70 eV): m/z (%) = 279 (18), 162 (12), 148 (12), 139 (31), 118 (8), 117 (100), 75 (40), 73
(31), 59 (8).
HR-MS (EI, 70 eV): [C18H24ClO2Si], calcd.: 335.1240; found: 335.1237 [M
+-H].
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(trans)-3-((tert-Butyldimethylsilyl)oxy)-4-((4-methoxyphenyl)ethynyl)-1-tosylpyrrolidine
(3t)
Following TP3 3-((tert-butyldimethylsilyl)oxy)-4-iodo-1-tosylpyrrolidine (1o, 241 mg, 0.5 mmol,
1.0 equiv) was coupled with ((4-methoxyphenyl)ethynyl)zinc pivalate (2l, 0.75 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 182 mg, 0.38 mmol, 75%, dr = 99:1, colorless crystals.
Purification: i-hexane:ethyl acetate = 95:5.
m.p.: 87.3 – 89.9 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.73 (d, J = 8.3 Hz, 2H), 7.30 – 7.25 (m, 3H), 7.20 (d,
J = 8.8 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 4.34 – 4.21 (m, 1H), 3.80 (s, 3H), 3.73 – 3.55 (m, 2H),
3.45 (dd, J = 9.5, 4.9 Hz, 1H), 3.24 – 3.12 (m, 1H), 2.89 (dt, J = 6.9, 4.6 Hz, 1H), 2.35 (s, 3H),
0.80 (s, 10H), 0.04 (s, 3H), 0.02 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.6, 143.6, 133.90 133.1, 129.8, 127.7, 114.9, 113.95,
85.5, 83.7, 76.2, 55.4, 54.7, 51.6, 39.5, 25.7, 21.6, 18.0, -4.6, -4.9.
FT-IR (ATR, cm-1): ν̃ = 2953, 2932, 2858, 1606, 1508, 1471, 1460, 1441, 1380, 1343, 1322,
1290, 1247, 1231, 1209, 1175, 1156, 1091, 1053, 1032, 1016, 1003, 955, 939, 914, 835, 816,
800, 776.
MS (EI, 70 eV): m/z (%) = 439 (30), 429 (73), 428 (100), 428 (100), 428 (97), 428 (92), 428 (93),
428 (76), 428 (83), 428 (88), 428 (89), 298 (43), 91 (23), 73 (31).
HR-MS (EI, 70 eV): [C26H35NO4SSi], calcd.: 485.2056; found: 485.2037.
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(1-(4-Methoxyphenyl)ethynyl)-2,3,4,6-tetra-O-acetyl-α-D-galactopyranose (3u)
Following TP3 1-bromo-2,3,4,6-tetra-O-Acetyl-α-D-galactopyranose (1p, 205 mg, 0.5 mmol,
1.0 equiv) was coupled with ((4-methoxyphenyl)ethynyl)zinc pivalate (2l, 0.75 mmol, 1.5 equiv)
prepared according to TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 125 mg, 0.27 mmol, 54%, α/β = 94:6, yellow oil.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.50 – 7.37 (m, 2H), 6.95 – 6.76 (m, 2H), 5.50 (dd, J = 3.4,
1.3 Hz, 1H), 5.42 (dd, J = 10.5, 3.3 Hz, 1H), 5.29 (d, J = 5.8 Hz, 1H), 5.24 (dd, J = 10.5, 5.8 Hz,
1H), 4.48 (td, J = 6.7, 1.3 Hz, 1H), 4.24 – 4.04 (m, 2H), 3.83 (s, 3H), 2.15 (s, 3H), 2.09 (s, 3H),
2.05 (s, 3H), 2.01 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.6, 170.4, 170.4, 170.3, 160.4, 133.7, 114.2, 113.7,
89.9, 80.3, 69.6, 69.0, 68.0, 67.3, 66.8, 61.8, 55.5, 21.0, 20.9, 20.9, 20.8.
FT-IR (ATR, cm-1): ν̃ = 3018, 1747, 1606, 1510, 1370, 1212, 1054, 834.
MS (EI, 70 eV): m/z (%) = 269 (21), 240 (37), 227 (100), 203 (11), 187 (13), 161 (16), 159 (30),
139 (11), 135 (15), 97 (21), 43 (28).
HR-MS (EI, 70 eV): [C23H26O10], calcd.: 462.1526; found: 462.1519.
Optical rotation: [α]ϕλ = 157.7 (c = 0.35, CHCl3).
(1-(Trimethylsilyl)ethynyl)-2,3,4,6-tetra-O-acetyl-α-D-galactopyranose (3v)
Following TP3 1-bromo-2,3,4,6-tetra-O-Acetyl-α-D-galactopyranose (1p, 205 mg, 0.5 mmol,
1.0 equiv) was coupled with (trimethylsilyl)ethynyl)zinc pivalate (2k, 0.75 mmol, 1.5 equiv) prepared
according to TP2. The solution was stirred for 8 h and was worked-up as usual.
89
III EXPERIMENTAL PART
Isolated yield: 111 mg, 0.26 mmol, 52%, α/β = 95:5, yellow oil.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.45 (dd, J = 3.4, 1.3 Hz, 1H), 5.29 (dd, J = 10.5, 3.3 Hz,
1H), 5.12 (dd, J = 10.5, 5.9 Hz, 1H), 5.06 (d, J = 5.9 Hz, 1H), 4.36 (td, J = 6.6, 1.3 Hz, 1H), 4.13
(dd, J = 11.3, 6.5 Hz, 1H), 4.04 (dd, J = 11.3, 6.7 Hz, 1H).2.11 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H),
1.99 (s, 3H), 0.20 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.5, 170.3, 170.2, 170.1, 97.9, 96.0, 69.5, 68.8, 67.8,
66.9, 66.4, 61.7, 20.9, 20.8, 20.8, 20.8, -0.2.
FT-IR (ATR, cm-1): ν̃ = 2962, 1745, 1431, 1369, 1220, 1121, 1091, 1057, 950, 908, 844, 761.
MS (EI, 70 eV): m/z (%) = 139 (10), 115 (10), 97 (17), 44 (12), 43 (100).
HR-MS (EI, 70 eV): [C19H28O9Si], calcd.: 428.1503; found: 428.1491.
Optical rotation: [α]ϕλ = 161.4 (c = 0.57, CHCl3)
Hexahydro-4H-furo[2,3-b]pyran-3-yl)prop-1-yn-1-yl)trimethylsilane (3w)
Following TP3 2-(allyloxy)-3-iodotetrahydro-2H-pyran (1q, 134 mg, 0.5 mmol, 1.0 equiv) was
coupled with (trimethylsilyl)ethynyl)zinc pivalate (2k, 0.75 mmol, 1.5 equiv) prepared according to
TP2. The solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 91 mg, 0.34 mmol, 68%, dr = 95:5, colorless solid.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.24 (d, J = 3.5 Hz, H), 3.83 (t, J = 8.1 Hz, H), 3.67 (tdd,
J = 10.9, 2.6, 0.6 Hz, 1H), 3.57 – 3.35 (m, 2H), 2.17 (dqd, J = 9.5, 8.0, 6.1 Hz, 1H), 2.02 – 1.84 (m,
2H), 1.65 (dtd, J = 10.1, 6.2, 3.6 Hz, 1H), 1.37 – 1.15 (m, 2H), 1.14 – 0.91 (m, 2H), 0.20 (s, H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 105.6, 102.1, 85.2, 69.4, 60.9, 40.3, 36.9, 23.4, 19.4,
18.5, 0.3.
FT-IR (ATR, cm-1): ν̃ = 3018, 2948, 2173, 1770, 1405, 1250, 1214, 1147, 1097, 1018, 945, 899,
843.
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MS (EI, 70 eV): m/z (%) = 209 (10), 139 (16), 125 (100), 97 (29), 91 (27), 79 (25), 75 (35), 73
(31).
HR-MS (EI, 70 eV): [C13H21O2Si], calcd.: 237.1316; found: 237.1305 [M
+-H].
(3β)-3-(Trimethylsilyl(ethynyl))cholest-5-ene (3x)
Following TP3 3-iodo cholest-5-ene (1r, 248 mg, 0.5 mmol, 1.0 equiv) was coupled with
(trimethylsilyl)ethynyl)zinc pivalate (2k, 0.75 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 175 mg, 0.38 mmol, 75%, dr = 98:2, colorless crystals.
Purification: i-hexane.
m.p.: 132.8 – 134.1 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.31 (dt, J = 5.5, 1.9 Hz, 1H), 2.39 – 2.13 (m, 3H), 2.07 –
1.90 (m, 2H), 1.89 – 1.73 (m, 4H), 1.69 – 0.94 (m, 21H), 0.91 (d, J = 6.5 Hz, 3H), 0.86 (dd, J = 6.6,
1.9 Hz, 7H), 0.66 (s, 3H), 0.14 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 141.5, 120.9, 111.6, 83.8, 56.9, 56.3, 50.3, 42.4, 39.9,
39.7, 39.1, 39.0, 36.9, 36.3, 35.9, 32.2, 32.0, 31.9, 29.9, 29.3, 28.4, 28.2, 24.4, 24.0, 23.0, 22.2,
21.0, 19.51, 18.9, 12.0, 0.4.
FT-IR (ATR, cm-1): ν̃ = 2932, 2864, 2848, 1466, 1436, 1374, 1247, 837, 802, 758.
MS (EI, 70 eV): m/z (%) = 466 (21), 281 (39), 225 (58), 209 (23), 207 (100), 145 (15), 95 (14), 91
(17), 73 (54).
HR-MS (EI, 70 eV): [C32H54Si], calcd.: 466.3995; found: 466.3983.
Optical rotation: [α]ϕλ = 9.4 (c = 1.04, CHCl3)
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(3β)-3-(Trimethylsilyl(ethynyl))epiandrosterone (3y)
OMe
Me
H
H
H
TMS
H
Following TP3 3-iodo epiandrosterone (1s, 248 mg, 0.5 mmol, 1.0 equiv) was coupled with
(trimethylsilyl)ethynyl)zinc pivalate (2k, 0.75 mmol, 1.5 equiv) prepared according to TP2. The
solution was stirred for 8 h and was worked-up as usual.
Isolated yield: 156 mg, 0.42 mmol, 84%, dr = 93:7, orange crystals.
Purification: i-hexane:ethyl acetate = 95:5.
m.p.: 115.9 – 118.0 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 2.51 – 2.33 (m, 1H), 2.23 (tt, J = 12.3, 4.1 Hz, 1H), 2.03
(dt, J = 19.0, 9.0 Hz, 1H), 1.96 – 1.84 (m, 1H), 1.83 – 1.70 (m, 3H), 1.71 – 1.58 (m, 2H), 1.49
(dddd, J = 17.8, 15.9, 8.1, 3.5 Hz, 4H), 1.42 – 1.14 (m, 6H), 1.09 – 0.97 (m, 1H), 0.97 – 0.87 (m,
2H), 0.82 (s, 3H), 0.80 (s, 3H), 0.67 (ddd, J = 12.0, 10.3, 3.9 Hz, 1H), 0.11 (s, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 221.28, 111.77, 83.25, 54.54, 51.55, 47.87, 46.39, 38.07,
35.91, 35.84, 35.32, 35.11, 31.64, 30.98, 30.93, 28.77, 28.33, 21.84, 20.28, 13.90, 12.36, 0.39.
FT-IR (ATR, cm-1): ν̃ = 2928, 2847, 2168, 1736, 1448, 1374, 1244, 1199, 1057, 1022, 1007, 900,
831, 758.
MS (EI, 70 eV): m/z (%) = 371 (16), 370 (40), 356 (36), 355 (100), 142 (10), 142 (10), 73 (39).
HR-MS (EI, 70 eV): [C32H54Si], calcd.: 370.2692; found: 370.2668.
Optical rotation: [α]ϕλ = 80.2 (c = 1.01, CHCl3)
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3 Cobalt-Catalyzed Acylation-Reactions of (Hetero)arylzinc
Pivalates with Thiopyridyl Ester Derivatives
3.1 Preparation of Starting Materials
Preparation of thiopyridyl esters TP4:77a
R1 OH
O
R1: 1°, 2°, 3° alkyl, benzyl, (hetero)aryl
PySSPy (1.1 equiv) 
PPh3 (1.5 equiv)
MeCN, reflux 3 h R1 SPy
O
4 5
The corresponding carboxylic acid 4 (1.0 equiv), PPh3 (1.5 equiv) and 2,2’-dipyridyl disulfide
(1.1 equiv) were added to a round bottom flask equipped with a magnetic stirring bar. The mixture
was dissolved in MeCN (0.3 M) and heated to reflux for 3 h. After solvent evaporation, the resulting
thiopyridyl ester was purified by column chromatography (SiO2, i-hexane/ethyl acetate) yielding
the pure thioester 5.
Preparation of α-chiral-thiopyridyl esters (TP5):
OH
O
PySSPy (1.0 equiv) 
PPh3 (1.0 equiv)
MeCN, 0 °C, 16 h SPy
O
4 5
R1
R2
R1
R2
The corresponding α-chiral-carboxylic acid 4 (1.0 equiv), PPh3 (1.0 equiv) and 2,2’-dipyridyl
disulfide (1.0 equiv) were added to a round bottom flask equipped with a magnetic stirring bar.
The mixture was dissolved in MeCN (0.3 M), cooled to 0 ◦C and stirred for 16 h. After solvent
evaporation, the resulting substrate was purified by column chromatography (SiO2, i-hexane/ethyl
acetate) yielding the corresponding thioester 5..
S-(Pyridin-2-yl) cyclohexanecarbothioate (5a)
O
SPy
S-(Pyridin-2-yl) cyclohexanecarbothioate (5a) was prepared according to TP4 from
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cyclohexanecarboxylic acid (4a, 2.21 g, 10.00 mmol) and was obtained as a yellow solid
(1.68 g, 7.60 mmol, 76% yield). The analytical data is in full consistency with the data reported in
the literature.106
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.61 (dd, J = 5.2, 1.9 Hz, 1H), 7.71 (tt, J = 7.7, 1.4 Hz, 1H),
7.59 (d, J = 7.9 Hz, 1H), 7.35 – 7.17 (m, 1H), 2.62 (tt, J = 11.4, 3.5 Hz, 1H), 2.08 – 1.96 (m, 2H),
1.81 (dt, J = 12.8, 3.4 Hz, 2H), 1.67 (dt, J = 12.6, 3.6 Hz, 1H), 1.53 (qd, J = 12.0, 3.3 Hz, 2H), 1.40
– 1.12 (m, 3H).
S-(Pyridin-2-yl) hexadecanethioate (5b)
H31C15
O
SPy
S-(Pyridin-2-yl) hexadecanethioate (5b) was prepared according to TP4 from palmitic acid (4b,
512 mg, 2.00 mmol) and was obtained as a yellow powder (684 mg, 1.96 mmol, 98% yield).
Purification: i-hexane:ethyl acetate = 8:2.
m.p.: 62.0 – 63.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 – 8.58 (m, 1H), 7.73 (td, J = 7.7, 1.9 Hz, 1H), 7.61
(dd, J = 7.9, 1.1 Hz, 1H), 7.33 – 7.26 (m, 1H), 2.69 (t, J = 7.5 Hz, 2H), 1.72 (p, J = 7.5 Hz, 2H),
1.25 (s, 24H), 0.87 (t, J = 6.7 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.8, 151.8, 150.5, 137.2, 130.3, 123.6, 44.4, 32.1, 29.9,
29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.1, 25.6, 22.9, 14.3.
FT-IR (ATR, cm-1): ν̃ = 2916, 2848, 1796, 1739, 1696, 1571, 1472, 1463, 1446, 1421, 1382,
1124, 1107, 1092, 1061, 1049, 981, 945, 905, 762, 718.
MS (EI, 70 eV): m/z (%) = 239 (9), 112 (32), 111 (100), 98 (16), 57 (11), 43 (25).
HR-MS (EI, 70 eV): [C21H35NOS], calcd.: 349.2439; found: 349.2432.
106B. Neises, W. Steglich, T. Van Ree, S. Afr. J. Chem. 1981, 34, 58-59.
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S-Pyridin-2-yl) cyclobutanecarbothioate (5c)
O
SPy
S-(Pyridin-2-yl) cyclobutanecarbothioate (5c) was prepared according to TP4 from
cyclobutanecarboxylic acid (4c, 200 mg, 2.00 mmol) and was obtained as a yellow oil
(305 mg, 1.58 mmol, 79%).
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 – 8.50 (m, 1H), 7.67 (td, J = 7.7, 1.9 Hz, 1H), 7.55 (dt,
J = 8.0, 1.1 Hz, 1H), 7.24 – 7.18 (m, 1H), 3.43 (pd, J = 8.5, 1.0 Hz, 1H), 2.45 – 2.27 (m, 2H), 2.20
(dtdd, J = 12.6, 8.3, 4.2, 2.3 Hz, 2H), 2.02 – 1.72 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.4, 151.6, 150.4, 137.1, 130.2, 123.4, 47.0, 26.0,
18.0.
FT-IR (ATR, cm-1): ν̃ = 2986, 2944, 1698, 1572, 1562, 1448, 1420, 1334, 1280, 1245, 1186,
1139, 1105, 1059, 1046, 988, 956, 885, 813, 763, 722, 677.
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11).
HR-MS (EI, 70 eV): [C10H12NOS], calcd.: 194.0634; found: 194.0634 [M
++H].
S-(Pyridin-2-yl)-adamantane-1-carbothioate (5d)
O
SPy
S-(Pyridin-2-yl)-adamantane-1-carbothioate (5d) was prepared according to TP4 from
adamantane-1-carboxylic acid (4d, 360 mg, 2.00 mmol) and was obtained as a pale yellow
powder (464 mg, 1.70 mmol, 85% yield).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
m.p.: 73.2 – 75.6 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.62 (dd, J = 5.0, 1.9 Hz, 1H), 7.71 (td, J = 7.7, 1.9 Hz, 1H),
7.55 (d, J = 7.9 Hz, 1H), 7.35 – 7.17 (m, 1H), 2.09 (p, J = 3.1 Hz, 3H), 2.00 (d, J = 3.0 Hz, 6H),
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1.83 – 1.63 (m, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.5, 152.0, 150.5, 137.0, 131.1, 123.4, 49.6, 39.3, 36.5,
28.3.
FT-IR (ATR, cm-1): ν̃ = 2909, 2848, 1689, 1572, 1562, 1449, 1421, 1342, 1280, 1250, 1188,
1138, 1116, 1102, 1084, 1045, 986, 946, 918, 822, 795, 760, 742, 724, 671.
MS (EI, 70 eV): m/z (%) = 273 (2), 244 (6), 136 (8), 135 (100), 93 (8), 79 (9).
HR-MS (EI, 70 eV): [C16H19NOS], calcd.: 273.1187; found: 273.1176.
S-pyridin-2-yl) 3-(2,5-dimethylphenoxy)-2,2-dimethylpropanethioate (5e)
O
OMe
Me
Me Me
SPy
3
S-(Pyridin-2-yl) 3-(2,5-dimethylphenoxy)-2,2-dimethylpropanethioate (5e) was prepared according
to TP4 from 3-(2,5-dimethylphenoxy)-2,2-dimethylpropanoic acid (4e, 444 mg, 2.00 mmol) and
was obtained as a yellow oil (617 mg, 1.96 mmol, 98% yield).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.64 (ddd, J = 4.8, 2.0, 0.8 Hz, 1H), 7.73 (td, J = 7.7,
2.0 Hz, 1H), 7.53 (dt, J = 8.0, 1.0 Hz, 1H), 7.29 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 7.00 (d, J = 7.4 Hz,
1H), 6.69 – 6.64 (m, 1H), 6.61 (d, J = 1.5 Hz, 1H), 3.95 (t, J = 5.4 Hz, 2H), 2.31 (s, 3H), 2.19 (s,
3H), 1.91 – 1.79 (m, 4H), 1.36 (s, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.6, 157.0, 151.9, 150.6, 137.1, 136.6, 131.0, 130.4,
123.7, 123.5, 120.8, 112.0, 67.8, 50.6, 37.6, 25.4, 25.0, 21.6, 16.0.
FT-IR (ATR, cm-1): ν̃ = 2966, 2922, 1693, 1614, 1583, 1573, 1563, 1509, 1448, 1419, 1389,
1366, 1285, 1263, 1156, 1129, 1044, 1000, 988, 931, 906, 803, 764, 724.
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11).
HR-MS (EI, 70 eV): [C20H25NO2S], calcd.: 344.1679; found: 344.1678 [M
++H].
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S-(Pyridin-2-yl) benzothioate (5f)
SPy
O
S-(Pyridin-2-yl) benzothioate (5f) was prepared according to TP4 from 4-chlorobenzoic acid
(4f, 1.22 g, 10.0 mmol) and was obtained as a yellow solid (1.81 g, 8.40 mmol, 84% yield). The
analytical data was in full consistency with the data reported in the literature.107
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.72 – 8.62 (m, 1H), 8.08 – 7.97 (m, 2H), 7.79 (td, J = 7.7,
1.9 Hz, 1H), 7.73 (dt, J = 8.0, 1.0 Hz, 1H), 7.67 – 7.56 (m, 1H), 7.49 (t, J = 7.7 Hz, 2H), 7.33 (ddt,
J = 7.1, 4.8, 1.0 Hz, 1H).
S-(Pyridin-2-yl) 4-chlorobenzothioate (5g)
SPy
O
Cl
S-(Pyridin-2-yl) 4-chlorobenzothioate (5g) was prepared according to TP4 from 4-chlorobenzoic
acid (4f, 1.55 g, 10.0 mmol) and was obtained as a yellow needles (1.64 g, 6.60 mmol, 66% yield).
The analytical data was in full consistency with the data reported in the literature.108
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.03 – 7.92 (m, 2H),
7.79 (td, J = 7.7, 1.9 Hz, 1H), 7.71 (dt, J = 7.9, 1.0 Hz, 1H), 7.51 – 7.41 (m, 2H), 7.34 (ddd, J = 7.6,
4.9, 1.2 Hz, 1H).
S-Pyridin-2-yl) 4-methoxybenzothioate (5h)
SPy
O
MeO
S-(Pyridin-2-yl) 4-methoxybenzothioate (5h) was prepared according to TP4 from
4-methoxybenzoic acid (4h, 304 mg, 2.00 mmol) and was obtained as a yellow solid
107C. M. Lemon, E. Karnas, M. G. Bawendi, D. G. Nocera, Inorg. Chem. 2013, 52, 10394–10406.
108M. Ociepa, O. Baka, J. Narodowiec, D. Gryko, Adv. Synth. Catal. 2017, 359, 3560–3565.
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(338 mg, 1.38 mmol, 69% yield). The analytical data was in full consistency with the data reported
in the literature.109
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.59 (ddt, J = 3.6, 2.6, 1.4 Hz, 1H), 7.93 (dd, J = 9.0,
2.2 Hz, 2H), 7.77 – 7.59 (m, 2H), 7.25 (dtd, J = 6.8, 3.2, 1.6 Hz, 1H), 6.89 (dd, J = 9.1, 2.6 Hz, 2H),
3.81 (s, 3H).
S-Pyridin-2-yl) 2-methoxybenzothioate (5h’)
SPy
O
OMe
S-(Pyridin-2-yl) 2-methoxybenzothioatewas (5h’) prepared according to TP4 from
2-methoxybenzoic acid (4h’, 304 mg, 2.00 mmol) and was obtained as a yellow oil (470 mg,
1.92 mmol, 96% yield). The analytical data was in full consistency with the data reported in the
literature.110
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.74 – 8.58 (m, 1H), 7.86 (dd, J = 8.0, 1.7 Hz, 1H), 7.80 –
7.70 (m, 2H), 7.51 (ddd, J = 7.9, 7.0, 1.8 Hz, 1H), 7.30 (ddd, J = 6.7, 4.8, 1.9 Hz, 1H), 7.07 – 6.98
(m, 2H), 3.96 (s, 3H).
S-(Pyridin-2-yl) ferrocenecarbothioate(5n)
Fe O
SPy
S-(Pyridin-2-yl) ferrocene (5n) prepared according to TP4 from ferrocene monocarboxylic acid
(4i, 460 mg, 2.00 mmol) and was obtained as red crystals (588 mg, 1.22 mmol, 91% yield).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
m.p.: 84.6 – 86.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.64 (d, J = 5.1 Hz, 1H), 7.75 (d, J = 6.5 Hz, 2H), 7.28 (dd,
J = 11.8, 5.0 Hz, 1H), 4.94 (s, 2H), 4.55 (s, 2H), 4.31 (s, 5H).
109S. H. H. Zaidi, K. Muthukumaran, S.-i. Tamaru, J. S. Lindsey, J. Org. Chem. 2004, 69, 8356–8365.
110M. Ociepa, O. Baka, J. Narodowiec, D. Gryko, Adv. Synth. Catal. 2017, 359, 3560–3565.
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13C-NMR (100 MHz, CDCl3, ppm): δ = 190.9, 152.4, 150.4, 150.3, 137.0, 130.4, 123.3, 123.3,
123.3, 78.8, 72.4, 72.4, 71.0, 70.8, 69.4, 69.3.
FT-IR (ATR, cm-1): ν̃ = 2923, 1652, 1570, 1446, 1422, 1369, 1239, 1121, 1106, 1045, 1024,
1002, 986, 942, 837, 810, 762, 721, 693.
MS (EI, 70 eV): m/z (%) = 2923, 1652, 1570, 1446, 1422, 1369, 1239, 1121, 1106, 1045, 1024,
1002, 986, 942, 837, 810, 762, 721, 693.
S-(Pyridin-2-yl) quinoline-2-carbothioate (5o)
N
SPy
O
S-(Pyridin-2-yl) quinoline-2-carbothioate (5o) was prepared according to TP4 from
quinoline-2-carboxylic acid (4j, 856 mg, 5.00 mmol) and was obtained as yellow crystals
(998 mg, 3.75 mmol, 75%).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
m.p.: 142.8 – 144.2 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 – 8.70 (m, 1H), 8.38 – 8.25 (m, 2H), 8.03 (d, J = 8.4
Hz, 1H), 7.90 (dd, J = 8.2, 1.4 Hz, 1H), 7.87 – 7.73 (m, 3H), 7.69 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H),
7.35 (ddd, J = 7.3, 4.8, 1.4 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 192.1, 152.5, 151.1, 150.6, 147.9, 137.8, 137.4, 131.0,
130.7, 130.6, 130.5, 129.2, 127.9, 123.7, 117.3.
FT-IR (ATR, cm-1): ν̃ = 2926, 1682, 1668, 1572, 1561, 1502, 1461, 1448, 1419, 1378, 1305,
1279, 1263, 1227, 1206, 1142, 1108, 1082, 1046, 988, 964, 912, 834, 792, 763, 738, 722,702.
MS (EI, 70 eV): m/z (%) = 266 (3), 238 (19), 237 (40), 206 (40), 205 (23).
HR-MS (EI, 70 eV): [C15H10N2OS], calcd.: 266.0514; found: 266.0509.
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tert-Butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k)
O
N
Boc
SPy
tert-Butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k) was prepared according
to TP5 from (tert-butoxycarbonyl)-L-proline (4k, 2.15 g, 10.0 mmol) and was obtained as a yellow
solid (2.24 g, 7.3 mmol, 73% yield). The analytical data is in full consistency with the data reported
in the literature.77c
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.61 (dd, J = 5.0, 2.0 Hz, 0.6 H), 8.60 – 8.56 (m, 0.4 H),
7.72 (qd, J = 7.1, 6.5, 1.9 Hz, 1H), 7.65 (d, J = 7.9 Hz, 0.4 H), 7.55 (d, J = 7.9 Hz, 0.6 H), 7.26 (td,
J = 9.7, 8.7, 5.0 Hz, 1.1 H), 4.57 (dd, J = 8.3, 3.4 Hz, 0.4 H), 4.44 (dd, J = 8.8, 3.8 Hz, 0.6 H), 3.54
(dtdd, J = 37.3, 18.1, 9.0, 6.1 Hz, 2H), 2.36 – 1.99 (m, 3H), 1.91 (pd, J = 7.6, 3.8 Hz, 1H), 1.48 (d,
J = 7.1 Hz, 9H).
Optical rotation: [α]ϕλ = -118 (c = 1.17, CHCl3).
Chiral HPLC: >99% ee, AD-H column, i-PrOH:heptane = 5:95, 1.5 mL/min, 30 ◦C.
S-(Pyridin-2-yl) (S)-2-(4-isobutylphenyl)propanethioate (5l)
O
Me
i-Pr
SPy
(S)-2-(4-Isobutylphenyl)propanethioate (5l) was prepared according to TP5 from
(S)-2-(4-isobutylphenyl)- propanoic acid (4l, 412 mg, 2.00 mmol) and was obtained as a
yellow oil (574 mg, 1.96 mmol, 96% yield).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (t, J = 1.8 Hz, 1H), 7.69 (dt, J = 7.6, 1.4 Hz, 1H), 7.34
(ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.32 – 7.23 (m, 1H), 7.20 – 7.14 (m, 2H), 7.09 – 7.02 (m, 2H), 4.01
(q, J = 7.1 Hz, 1H), 2.47 (d, J = 7.1 Hz, 2H), 1.86 (dp, J = 13.6, 6.8 Hz, 1H), 1.60 (d, J = 7.1 Hz,
3H), 0.91 (d, J = 6.7 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.5, 151.8, 150.2, 141.3, 137.1, 136.2, 130.1, 129.6,
127.9, 123.4, 54.2, 45.1, 30.2, 22.4, 18.4.
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FT-IR (ATR, cm-1): ν̃ = 2954, 2928, 2868, 1706, 1573, 1563, 1511, 1448, 1420, 1368, 1240,
1217, 1183, 1168, 1140, 121, 1097, 1084, 1066, 1045, 998, 988, 930, 847, 802, 763, 738, 724,
663.
MS (ESI, 70 eV): [C18H22NOS], calcd.: 300.1417; found: 300.1416 [M
++H].
Optical rotation: [α]ϕλ = 104 (c = 1.24 CHCl3).
Chiral HPLC: 98% ee, OD-H column, i-PrOH:heptane = 10:90, 1.0 mL/min, 30 ◦C.
S-(Pyridin-2-yl) (S)-2-methylbutanethioate (5m)
Me SPy
O
Me
S-(Pyridin-2-yl) (S)-2-methylbutanethioate (5m) was prepared according to TP5 from
(S)-2-methylbutanoic acid (4m, 510 mg, 5 mmol) and was obtained as a yellow oil (950 mg, 4.87
mmol, 97% yield).
Purification: i-hexane:ethyl acetate = 9:1 to 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.61 (ddd, J = 5.1, 1.8, 0.9 Hz, 1H), 7.72 (td, J = 7.7,
1.9 Hz, 1H), 7.60 (dt, J = 7.9, 1.0 Hz, 1H), 7.26 (ddd, J = 7.6, 4.7, 1.1 Hz, 1H), 2.70 (h, J = 6.9 Hz,
1H), 1.82 (dt, J = 13.7, 7.2 Hz, 1H), 1.54 (tt, J = 14.4, 7.1 Hz, 1H), 1.25 (d, J = 6.9 Hz, 3H), 0.97 (t,
J = 7.4 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.8, 151.8, 150.4, 137.1, 130.3, 123.5, 50.6, 27.2, 17.1,
11.7.
FT-IR (ATR, cm-1): ν̃ = 2968, 2934, 2877, 1702, 1573, 15622, 1448, 1418, 1380, 1260, 1201,
1139, 1118, 1084, 1045, 987, 967, 939, 829, 807, 762, 732, 719, 669, 670.
MS (EI, 70 eV): m/z (%) = 196 (2), 166 (15), 139 (18), 134 (65), 112 (91), 111 (100), 67 (26).
HR-MS (EI, 70 eV): [C10H14NOS], calcd.: 196.0791; found: 196.0789 [M
++H].
Optical rotation: [α]ϕλ = 19 (c = 1.20 CHCl3).
Chiral HPLC: 98% ee, OD-H column, i-PrOH:heptane = 2:98, 1.0 mL/min, 30 ◦C.
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3.2 Cobalt-Catalyzed Acylation-Reactions of (Hetero)arylzinc Pivalates with
Organic Thiopyridylester Derivatives
Preparation of arylzinc pivalates by magnesium insertion (TP6):
(Het)ArBr
1) Mg (1.2 equiv)
    LiCl (1.2 equiv)
2) Zn(OPiv)2 (1.0 equiv)
THF, 0 °C
(Het)Ar-ZnOPiv
6
Magnesium turnings (1.2 equiv), dry LiCl (1.2 equiv) and dry THF (1.0 M) solution relating to the
aryl bromide) were added to a dry and argon flushed Schlenk-tube equipped with a magnetic
stirring bar and a septum. The tube was charged with the aromatic bromide (1.0 equiv). For
controlling the following initial heat evolution of the insertion reaction, the Schlenk-tube was
placed in an ice bath for cooling. To monitor the progress of the insertion reaction, reaction
aliquots quenched with iodine and were analyzed as water-quenched samples by GC-analysis.
When the insertion was completed, solid Zn(OPiv)2 (1.0 equiv) was added in one portion at
0 ◦C and stirred at ambient temperature for 15 min.
Preparation of arylzinc pivalates by halogen/magnesium exchange (TP7):
1) i-PrMgCl·LiCl (1.1 equiv)
THF, -40–0 °C, 2–4 h
2) Zn(OPiv)2 (1.0 equiv)
THF, 0 °C
X
X = Br, I
R1
ZnOPiv
R1
6
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum was
charged with the corresponding aryl halide (1.0 mmol) in THF (0.5 M) Then, after stirring for
5 min at ambient temperature, the resulting solution was cooled to the appropiate tepmperature,
i-PrMgCl (1.1 mmol, 1.1 equiv) was added dropwise. GC-analysis was used to monitor the
progress of the halogen-magnesium exchange, by analysis of reaction aliquots quenched with I2.
After the reaction was completed Zn(OPiv)2 (1.0 equiv) was added in one portion and the mixture
was slowly warmed to rt.
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Cobalt-catalyzed acylation of arylzinc pivalates with thiopyridyl esters TP8:
R SPy
O
CoCl2 (10 mol%)
dtbbpy (10 mol%)
THF, 0°C or rt, 4 h
(Het)Ar-ZnOPiv
6 (1.9 equiv)
R (Het)Ar
O
5 7
A dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum was
charged with CoCl2 (6.5 mg, 0.05 mmol, 0.10 equiv, dried in vacuo at 400
◦C prior to use). Then,
the ligand 4,4’-di-tert-butyl-2,2’- dipyridyl (13.0 mg, 0.05 mmol, 0.10 equiv) and the corresponding
thiopyridyl ester (5, 0.5 mmol, 1.0 equiv) were added to the Schlenk -tube. The resulting mixture
was dissolved in dry THF (1 mL). Then, the organozinc pivalate, synthesized via TP6 or TP7 (6,
0.95 mmol, 1.9 equiv) was added and stirring was continued for 4 h, at 25 ◦C. For products 7t-7y
the reaction was carried out at 0 ◦C. The reaction conversion was monitored by GC-analysis of
water-quenched reaction aliquots (C14H30 was used as an internal standard). Upon consumption
of the starting material, sat. aq. NH4Cl solution (10 mL) was added, the phases were separated
and the aq. phase was extracted with EtOAc (3 x 25 mL). The combined organic layers were
dried over MgSO4. The solvents were evaporated and the residue was subjected to column
chromatographical purification (pentane/ethyl acetate) on silica yielding the corresponding title
compound 7.
Cyclohexyl(4-methoxyphenyl)methanone (7a)
O
OMe
Following TP8 S-(pyridin-2-yl) cyclohexanecarbothioate (5a, 111 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-(methoxy)phenylzinc pivalate (6a, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 96 mg, 0.44 mmol, 88%, colorless crystals.
Purification: pentane:ethyl acetate = 99:1.
m.p.: 64.2 – 66.8 ◦C.
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.94 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.9 Hz, 2H), 3.86 (s,
3H), 3.22 (tt, J = 11.5, 3.2 Hz, 1H), 1.85 (tdd, J = 11.7, 6.2, 3.0 Hz, 4H), 1.73 (dddt, J = 12.8, 5.0,
3.3, 1.7 Hz, 1H), 1.57 – 1.38 (m, 3H), 1.36 – 1.19 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 202.6, 163.3, 130.6, 129.4, 113.8, 55.6, 45.4, 29.7, 26.1,
26.1.
FT-IR (ATR, cm-1): ν̃ = 3065, 3019, 2973, 2944, 2916, 2846, 1639, 1628, 1594, 1573, 1504,
1499, 1466, 1454, 1442, 1416, 1405, 1302, 1296, 1284, 1256, 1224, 1182, 1175, 1148, 1116,
1094, 1064, 1028, 1013, 967, 959, 949, 928, 856, 842, 828, 815, 789, 763, 682.
MS (EI, 70 eV): m/z (%) = 2923, 2851, 1658, 1598, 1571, 1505, 1458, 1420, 1370, 1334, 1313,
1299, 1251, 1208, 1163, 1133, 1103, 1025, 972, 896, 844, 825, 791, 770, 742, 687.
HR-MS (EI, 70 eV): [C14H18O2], calcd.: 218.1307; found: 218.1302.
1-(Benzo[d][1,3]dioxol-5-yl)hexadecan-1-one (7b)
H31C15
O
O
O
Following TP8 S-(pyridin-2-yl) hexadecanethioate (5b, 175 mg, 0.50 mmol, 1.0 equiv) was coupled
with (benzo[d ][1,3]dioxol-5-yl)zinc pivalate (6b, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 162 mg, 0.45 mmol, 90%, white solid.
Purification: pentane:ethyl acetate = 100:2.
m.p.: 73.5 – 75.3 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (dd, J = 8.2, 1.7 Hz, 1H), 7.44 (d, J = 1.7 Hz, 1H),
6.84 (d, J = 8.1 Hz, 1H), 6.04 (s, 2H), 2.87 (t, J = 7.5 Hz, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.25 (s,
26H), 0.88 (t, J = 6.7 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.9, 151.7, 148.3, 132.1, 124.4, 108.1, 108.0, 101.9,
38.6, 32.1, 29.9, 29.8, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 24.8, 22.9, 14.3.
FT-IR (ATR, cm-1): ν̃ = 2961, 2952, 2914, 2868, 2847, 2774, 1675, 1604, 1497, 1488, 1472,
1462, 1444, 1418, 1373, 1359, 1285, 1279, 1263, 1258, 1250, 1200, 1110, 1092, 1051, 1004,
990, 940, 900, 889, 824, 811, 805, 780, 757, 742, 730, 719, 655.
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MS (EI, 70 eV): m/z (%) = 281 (21), 225 (8), 209 (8), 208 (10), 207 (84), 191 (16), 165 (10), 164
(100), 149 (57), 121 (12), 44 (7).
HR-MS (EI, 70 eV): [C23H36O3], calcd.: 360.2664; found: 360.2662.
1-(1-Methyl-1H-indol-5-yl)hexadecan-1-one (7c)
C15H31
O
N
Me
Following TP8 S-(pyridin-2-yl) hexadecanethioate (5b, 175 mg, 0.50 mmol, 1.0 equiv) was coupled
with ((1-methyl-1H-indol-5-yl)zinc pivalate (6c, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 137 mg, 0.37 mmol, 74%, pale yellow crystals.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 71.6 – 73.5 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.31 (d, J = 1.6 Hz, 1H), 7.91 (dd,J = 8.7, 1.7 Hz, 1H),
7.34 (d, J = 8.7 Hz, 1H), 7.11 (d, J = 3.2 Hz, 1H), 6.61 (d, J = 3.1 Hz, 1H), 3.82 (s, 3H), 3.03 (t,
J = 7.5 Hz, 2H), 1.77 (p, J = 7.5 Hz, 2H), 1.26 (s, 18H), 0.88 (t, J = 6.7 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.9, 139.2, 130.4, 129.4, 128.0, 122.9, 121.9, 109.2,
103.1, 38.7, 33.2, 32.1, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 25.1, 22.9, 14.3.
FT-IR (ATR, cm-1): ν̃ = 2948, 2920, 2848, 1657, 1606, 1556, 1513, 1464, 1450, 1212, 1412,
1368, 1343, 1309, 1297, 1264, 1249, 1229, 1163, 1145, 1090, 968, 821, 803, 780, 766, 733, 724.
MS (EI, 70 eV): m/z (%) = 130 (14), 158 (72), 173 (100), 174 (14), 369 (11).
HR-MS (EI, 70 eV): [C25H39N], calcd.: 369.3032; found: 369.3037.
Cyclobutyl(4-(trifluoromethyl)phenyl)methanone (7d)
O
CF3
Following TP8 S-(pyridin-2-yl) cyclobutanecarbothioate (5c, 97 mg, 0.50 mmol, 1.0 equiv)
was coupled with (4-(trifluoromethyl)phenyl)zinc pivalate (6d, 0.95 mmol, 1.9 equiv) prepared
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according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 96 mg, 0.42 mmol, 84% yield, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (dt, J = 8.1, 1.0 Hz, 2H), 7.74 – 7.68 (m, 2H), 4.13 –
3.93 (m, 1H), 2.50 – 2.26 (m, 4H), 2.18 – 2.05 (m, 1H), 1.99 – 1.86 (m, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 199.9, 138.3, 134.2 (q, J = 32.6 Hz), 128.6 , 125.7 (q,
J = 3.8 Hz), 123.6 (q, J = 272.7 Hz), 42.4, 24.97, 18.1.
FT-IR (ATR, cm-1): ν̃ = 2951, 1674, 1510, 1410, 1322, 1252, 1227, 1212, 1166, 1125, 1108,
1065, 1015, 967, 949, 922, 893, 856, 842, 783, 774, 762, 731, 684, 671
MS (EI, 70 eV): m/z (%) = 227 (1), 174 (8), 173 (11), 173 (100), 145 (25).
HR-MS (EI, 70 eV): [C12H11F3O], calcd.: 228.0762; found: 228.0758.
Cyclobutyl(4-(dimethylamino)phenyl)methanone (7e)
O
NMe2
Following TP8 S-(pyridin-2-yl) cyclobutanecarbothioate (5c, 97 mg, 0.50 mmol, 1.0 equiv)
was coupled with (4-(dimethylamino)phenyl)zinc pivalate (6e, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 97 mg, 0.48 mmol, 95% yield, white solid.
Purification: pentane:ethyl acetate = 95:5.
m.p.: 75.2 – 77.0 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.71 (m, 2H), 6.67 – 6.57 (m, 2H), 3.88 (pd, J = 8.6,
1.1 Hz, 1H), 2.98 (s, 6H), 2.42 – 2.27 (m, 2H), 2.18 (dddd, J = 12.4, 10.6, 8.8, 3.9 Hz, 2H), 2.08 –
1.91 (m, 1H), 1.81 (ddddd, J = 14.6, 9.2, 7.9, 4.0, 1.1 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 199.4, 153.0, 130.4, 111.0, 110.9, 41.7, 40.3, 25.3, 18.2.
FT-IR (ATR, cm-1): ν̃ = 2959, 1667, 1622, 1478, 1387, 1261, 1195, 1167, 1025, 909, 856, 819.
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MS (EI, 70 eV): m/z (%) = 203 (16), 148 (100), 44 (12), 42 (39).
HR-MS (EI, 70 eV): [13 xH17NO], calcd.: 203.1310; found: 203.1305.
Cyclohexyl(4-fluorophenyl)methanone (7f)
O
F
Following TP8 S-(pyridin-2-yl) cyclohexanecarbothioate (5a, 111 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-fluorophenyl)zinc pivalate (6f, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 62 mg, 0.30 mmol, 60%, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.07 – 7.85 (m, 2H), 7.21 – 7.03 (m, 2H), 3.21 (tt, J = 11.4,
3.2 Hz, 1H), 1.95 – 1.79 (m, 4H), 1.74 (dtt, J = 13.0, 3.5, 1.8 Hz, 1H), 1.58 – 1.16 (m, 5H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 202.4, 165.7 (d, J = 254.0 Hz), 132.8 (d, J = 3.0 Hz),
131.0 (d, J = 9.2 Hz), 115.8 (d, J = 21.7 Hz), 45.7, 29.6, 26.1, 26.0.
FT-IR (ATR, cm-1): ν̃ = 3068, 2929, 2853, 1678, 1596, 1505, 1463, 1450, 1409, 1371, 1332,
1312, 1295, 1289, 1249, 1233, 1205, 1176, 1154, 1134, 1102, 1027, 1012, 974, 893, 860, 841,
824, 806, 800, 776, 738, 675.
MS (EI, 70 eV): m/z (%) = 206 (9), 151 (21), 138 (9), 124 (8), 123 (100), 95 (8).
HR-MS (EI, 70 eV): [C13H15FO], calcd.: 206.1107; found: 206.1101.
4-(Cyclohexanecarbonyl)-2-fluorobenzonitrile (7g)
O
CN
F
Following TP8 S-(pyridin-2-yl) cyclohexanecarbothioate (5a, 111 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-cyano-3-fluorophenyl)zinc pivalate (6g, 0.95 mmol, 1.9 equiv) prepared according
to TP7 from the corresponding bromide at -20 ◦C in 2 h. The solution was stirred for 4 h and was
worked-up as usual.
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Isolated yield: 91 mg, 0.39 mmol, 79%, colorless crystals.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 54.4 – 56.2 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.85 – 7.68 (m, 3H), 3.16 (tt, J = 11.3, 3.1 Hz, 1H), 1.86
(dp, J = 9.5, 3.4 Hz, 4H), 1.75 (dddd, J = 11.5, 5.2, 3.3, 1.7 Hz, 1H), 1.58 – 1.16 (m, 5H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 201.2 (d, J = 1.6 Hz), 163.4 (d, J = 261.1 Hz), 142.2 (d,
J = 6.1 Hz), 134.1, 124.3 (d, J = 3.7 Hz), 116.1 (d, J = 20.5 Hz), 113.4, 105.2 (d, J = 15.9 Hz),
46.2, 29.2, 25.9, 25.7.
FT-IR (ATR, cm-1): ν̃ = 3076, 2930, 2855, 2239, 1686, 1618, 1567, 1495, 1463, 1450, 1421,
1415, 1373, 1331, 1313, 1299, 1290, 1274, 1253, 1230, 1192, 1157, 1133, 1120, 1103, 996, 988,
921, 908, 901, 873, 836, 797, 772, 734, 706.
MS (EI, 70 eV): m/z (%) = 231 (43), 225 (8), 216 (9), 213 (18), 190 (31), 189 (12), 188 (12), 177
(10), 176 (100), 165 (7), 164 (26), 163 (26), 158 (7), 148 (86), 121 (59), 129 (10), 105 (24), 100
(21), 83 (16), 77 (9), 68 (8), 67 (11), 55 (27).
HR-MS (EI, 70 eV): [C14H14FNO], calcd.: 231.1059; found: 231.1054.
(Adamantan-1-yl)(3-(trifluoromethyl)phenyl)methanone (7h)
O
CF3
Following TP8 S-(pyridin-2-yl)-adamantane-1-carbothioate (5d, 137 mg, 0.50 mmol, 1.0 equiv)
was coupled with (3-(trifluoromethyl)phenyl) zinc pivalate (6h, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 94 mg, 0.31 mmol, 61%, white solid.
Purification: pentane:ethyl acetate = 98:2.
m.p.: 63.6 – 65.3 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.76 (d, J = 2.0 Hz, 1H), 7.70 (t, J = 8.4 Hz, 2H), 7.52 (t,
J = 7.8 Hz, 1H), 2.09 (q, J = 3.1 Hz, 3H), 1.99 (d, J = 2.9 Hz, 6H), 1.82 – 1.68 (m, 6H).
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13C-NMR (100 MHz, CDCl3, ppm): δ = 209.0, 140.3, 131.7 – 129.7 (m), 130.4 (d, J = 1.4 Hz),
128.7, 126.9 (q, J = 3.7 Hz), 124.1 (q, J = 3.9 Hz), 123.9 (q, J = 272.5 Hz), 47.1, 39.1, 36.5, 28.1.
FT-IR (ATR, cm-1): ν̃ = 2943, 2914, 2854, 1661, 1605, 1453, 1329, 1309, 1261, 1225, 1184,
1162, 1119, 1102, 1071, 998, 922, 808, 778, 762, 734, 695, 659.
MS (EI, 70 eV): m/z (%) = 308 (1), 136 (12), 135 (100), 93 (12), 79 (12).
HR-MS (EI, 70 eV): [C18H19F3O], calcd.: 308.1388; found: 308.1382.
4-(Adamantane-1-carbonyl)-2-fluorobenzonitrile (7i)
O
CN
F
Following TP8 S-(pyridin-2-yl)-adamantane-1-carbothioate (5d, 137 mg, 0.50 mmol, 1.0 equiv)
was coupled with (4-cyano-3-fluorophenyl)zinc pivalate (6g, 0.95 mmol, 1.9 equiv) prepared
according to TP7 from the corresponding bromide at -20 ◦C in 2 h. The solution was stirred for 4
h and was worked-up as usual.
Isolated yield: 114 mg, 0.41 mmol, 81%, colorless crystals.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 103.9 -105.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.66 (dd, J = 7.9, 6.2 Hz, 1H), 7.31 (ddd, J = 21.5, 8.5,
1.4 Hz, 2H), 2.07 (q, J = 3.1 Hz, 3H), 1.93 (d, J = 3.0 Hz, 6H), 1.81 – 1.65 (m, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 207.6 (d, J = 1.4 Hz), 162.6 (d, J = 261.2 Hz), 146.3 (d,
J = 6.2 Hz), 133.5, 123.2 (d, J = 3.9 Hz), 115.1 (d, J = 20.9 Hz), 113.4, 102.8 (d, J = 15.6 Hz),
47.2, 38.8, 36.3, 27.9.
FT-IR (ATR, cm-1): ν̃ = 3053, 2930, 2901, 2858, 2849, 2673, 2652, 2241, 1682, 1620, 1561,
1497, 1451, 1413, 1344, 1323, 1297, 1276, 1269, 1252, 1225, 1209, 1191, 1179, 1171, 1106,
1099, 1003, 968, 938, 902, 884, 879, 851, 819, 793, 764, 751, 732, 718, 677, 661.
MS (EI, 70 eV): m/z (%) = 136 (11), 135 (100), 107 (14), 93 (16), 79 (13).
HR-MS (EI, 70 eV): [C18H18FNO], calcd.: 283.1372; found: 283.1266.
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3-(5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoyl)benzonitrile (7j)
O
OMe
Me
CN
Me Me
3
Following TP8 S-(pyridin-2-yl) 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanethioate (5e, 172 mg,
0.50 mmol, 1.0 equiv) was coupled with (3-cyanophenyl)zinc pivalate (6i, 0.95 mmol, 1.9 equiv)
prepared according to TP7 from the corresponding iodide at -20 ◦C in 2 h. The solution was
stirred for 4 h and was worked-up as usual.
Isolated yield: 110 mg, 0.33 mmol, 66%, yellow oil.
Purification: pentane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 (d, J = 1.8 Hz, 1H), 7.92 (dt, J = 8.0, 1.5 Hz, 1H), 7.74
(dt, J = 7.7, 1.4 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 6.66 (dd, J = 7.5, 1.5 Hz,
1H), 6.60 – 6.54 (m, 1H), 3.90 (t, J = 6.0 Hz, 2H), 2.29 (s, 3H), 2.13 (s, 3H), 2.02 – 1.91 (m, 2H),
1.80 – 1.67 (m, 2H), 1.37 (s, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 206.7, 156.8, 139.8, 136.6, 134.2, 131.8, 131.4, 130.4,
129.3, 123.4, 120.9, 118.2, 112.8, 111.8, 67.5, 47.9, 37.4, 26.0, 25.1, 21.5, 16.0.
FT-IR (ATR, cm-1): ν̃ = 2922, 2230, 1677, 1677, 1583, 1508, 1470, 1414, 1388, 1309, 1284,
1262, 1223, 1156, 1128, 1043, 1017, 999, 844, 803, 752, 683.
MS (EI, 70 eV): m/z (%) = 335 (4), 214 (100), 144 (13), 130 (26), 122 (17), 102 (10), 83 (12), 55
(15).
HR-MS (EI, 70 eV): [C22H25NO2], calcd.: 335.1885; found: 335.1888.
1-(3-((tert-Butyldimethylsilyl)oxy)phenyl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentan-1-
one (7k)
O
OMe
Me
OTBS
Me Me
3
Following TP8 S-(pyridin-2-yl) 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanethioate (5e, 172 mg,
0.50 mmol, 1.0 equiv) was coupled with (3-((tert-butyldimethylsilyl)oxy)phenyl)zinc pivalate (6j,
0.95 mmol, 1.9 equiv) prepared according to TP6 from the corresponding bromide. The solution
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was stirred for 4 h and was worked-up as usual.
Isolated yield: 158 mg, 0.36 mmol, 78%, pale yellow oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.13 – 6.99 (m, 2H), 6.93 (t, J = 2.0 Hz, 1H), 6.79 (d,
J = 7.5 Hz, 1H), 6.73 (ddd, J = 7.8, 2.5, 1.3 Hz, 1H), 6.44 (dd, J = 7.6, 1.5 Hz, 1H), 6.37 (d, J = 1.5
Hz, 1H), 3.68 (t, J = 6.1 Hz, 2H), 2.09 (s, 3H), 1.94 (s, 3H), 1.79 – 1.68 (m, 2H), 1.59 – 1.48 (m,
2H), 1.14 (s, 6H), 0.78 (s, 9H), 0.00 (s, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 208.6, 156.9, 155.4, 140.3, 136.4, 130.3, 129.2, 123.5,
122.7, 120.7, 120.5, 119.3, 111.8, 67.8, 47.7, 37.5, 26.2, 25.7, 25.1, 21.4, 18.2, 15.8, -4.4.
FT-IR (ATR, cm-1): ν̃ = 2953, 2927, 1672, 1594, 1576, 1508, 1470, 1421, 1388, 1362, 1251,
1183, 1156, 1129, 1044, 1000, 913, 834, 800, 779, 759, 685.
MS (EI, 70 eV): m/z (%) = 320 (23), 319 (100), 235 (32), 83 (8), 73 (14).
HR-MS (EI, 70 eV): [C27H40O3Si], calcd.: 440.2747; found: 440.2751.
Ethyl 4-benzoylbenzoate (7l)
O
CO2Et
Following TP8 S-(pyridin-2-yl) benzothioate (5f, 108 mg, 0.50 mmol, 1.0 equiv) was coupled with
(4-(ethoxycarbonyl)phenyl)zinc pivalate (6k, 0.95 mmol, 1.9 equiv) prepared according to TP7
from the corresponding iodide at -40 ◦C in 2 h. The solution was stirred for 4 h and was worked-up
as usual.
Isolated yield: 90mg, 0.35mmol, 71% yield, colorless crystals.
Purification: pentane:ethyl acetate = 95:5.
m.p.: 93.6 – 95.4 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = .20 – 8.11 (m, 2H), 7.82 (ddd, J = 14.6, 7.6, 1.8 Hz, 4H),
7.66 – 7.57 (m, 1H), 7.50 (dd, J = 8.4, 7.1 Hz, 2H), 4.42 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz,
3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.2, 166.0, 141.3, 137.1, 133.7, 133.1, 130.3, 129.9,
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129.6, 128.6, 61.6, 14.5.
FT-IR (ATR, cm-1): ν̃ = 2979, 1704, 1660, 1604, 1480, 1446, 1399, 1367, 1266, 1179, 1102,
1019, 1004, 937, 925, 845, 752, 712, 695, 656.
MS (EI, 70 eV): m/z (%) = 177 (28), 105 (100), 149 (59), 152 (39), 181 (59), 209 (59), 226 (30),
254 (35).
HR-MS (EI, 70 eV): [C16H14O3], calcd.: 254.0943; found: 254.0939.
Benzo[b]thiophen-2-yl(phenyl)methanone (7m)
S
O
Following TP8, using TMEDA (10 mol%, 0.05 mmol, 6 mg) as ligand, S-(pyridin-2-yl) benzothioate
(5f, 108 mg, 0.50 mmol, 1.0 equiv) was coupled with (benzo[b]thiophen-2-yl)zinc pivalate (6l,
0.95 mmol, 1.9 equiv) prepared by directed metalation from benzo[b]thiophen and TMPMgCl
(1.0 equiv) at 0 ◦C for 3 h, followed by transmetalation with Zn(OPiv)2 (1.0 equiv) The solution was
stirred for 4 h and was worked-up as usual.
Isolated yield: 81 mg, 0.34 mmol, 68%, orange oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.96 – 7.85 (m, 5H), 7.68 – 7.60 (m, 1H), 7.54 (dd, J = 8.3,
6.9 Hz, 2H), 7.49 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.42 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 189.8, 143.2, 142.8, 139.2, 138.0, 132.6, 132.4, 129.4,
128.7, 127.6, 126.2, 125.2, 123.1.
FT-IR (ATR, cm-1): ν̃ = 1631, 1593, 1576, 1509, 1455, 1444, 1425, 1314, 1285, 1245, 1187,
1175, 1157, 1114, 1066, 1025, 880, 869, 833, 790, 746, 731, 708, 701, 664.
MS (EI, 70 eV): m/z (%) = 238 (100), 23 (11), 210 (10), 161 (97), 133 (16), 105 (40), 89 (23), 77
(31).
HR-MS (EI, 70 eV): [C15H10OS], calcd.: 238.0452; found: 238.0454.
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(4-Chlorophenyl)(2-fluoro-4-methoxyphenyl)methanone (7n)
O
OMeCl
F
Following TP8 S-(pyridin-2-yl) 4-chlorobenzothioate (5g, 125 mg, 0.50 mmol, 1.0 equiv) was
coupled with (2-fluoro-4-methoxyphenyl)zinc pivalate (6m, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 121 mg, 0.46, 92%, colorless oil.
Purification: pentane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.74 (dd, J = 8.5, 1.6 Hz, 2H), 7.57 (t, J = 8.4 Hz, 1H), 7.46
– 7.40 (m, 2H), 6.80 (dd, J = 8.6, 2.4 Hz, 1H), 6.66 (dd, J = 12.0, 2.4 Hz, 1H), 3.88 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 191.5 (d, J = 1.0 Hz), 164.2 (d, J = 11.3 Hz), 163.1, 161.9
(d, J = 254.1 Hz), 139.2, 136.7, 132.7 (d, J = 4.4 Hz), 130.9 (d, J = 1.7 Hz), 128.6, 118.9 (d,
J = 13.6 Hz), 101.9 (d, J = 25.7 Hz), 55.9.
FT-IR (ATR, cm-1): ν̃ = 1671, 1588, 1570, 1560, 1544, 1446, 1426, 1340, 1282, 1235, 1218,
1154, 1116, 1069, 1054, 986, 916, 885, 791, 58, 733, 690.
MS (EI, 70 eV): m/z (%) = 139 (16), 153 (100), 154 (9), 187 (9), 220 (11), 264 (25), 266 (8).
HR-MS (EI, 70 eV): [C14H10ClFO2], calcd.: 264.0353; found: 264.0351.
(4-Methoxyphenyl)(3-(methylthio)phenyl)methanone (7o)
O
SMe
MeO
Following TP8 S-(pyridin-2-yl) 4-methoxybenzothioate (5p, 123 mg, 0.50 mmol, 1.0 equiv) was
coupled with (3-(methylthio)phenylzinc pivalate (6n, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 123 mg, 0.48 mmol, 96%, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.89 – 7.77 (m, 2H), 7.62 (t, J = 1.7 Hz, 1H), 7.55 – 7.30
(m, 3H), 7.05 – 6.88 (m, 2H), 3.89 (s, 3H), 2.52 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 195.3, 163.5, 139.3, 139.0, 132.7, 130.1, 129.8, 128.6,
127.1, 126.5, 113.7, 55.7, 15.8.
FT-IR (ATR, cm-1): ν̃ = 2916, 2847, 1650, 1597, 1567, 1507, 1419, 1315, 1282, 1256, 1175,
1154, 1026, 842, 756, 710.
MS (EI, 70 eV): m/z (%) = 258 (36), 211 (19), 136 (9) 135 (100), 77 (11).
HR-MS (EI, 70 eV): [C15H14O2S], calcd.: 258.0715; found: 258.0709.
(2-Methoxyphenyl)(3-(methylthio)phenyl)methanone (7o’)
O
SMe
OMe
Following TP8 S-(pyridin-2-yl) 2-methoxybenzothioate (5p’, 123 mg, 0.50 mmol, 1.0 equiv) was
coupled with (3-(methylthio)phenylzinc pivalate (6n, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 91 mg, 0.35 mmol, 71%, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.74 (t, J = 1.8 Hz, 1H), 7.54 – 7.40 (m, 3H), 7.39 – 7.29
(m, 2H), 7.04 (td, J = 7.4, 0.9 Hz, 1H), 6.99 (dd, J = 8.5, 0.9 Hz, 1H), 3.73 (s, 3H), 2.50 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.2, 157.5, 139.3, 138.5, 132.2, 130.9, 129.8, 128.7,
128.7, 127.0, 127.0, 120.7, 111.6, 55.7, 15.8.
FT-IR (ATR, cm-1): ν̃ = 2920, 2836, 1659, 1597, 1581, 1567, 1486, 1462, 1434, 1413, 1294,
1241, 1180, 1154, 1111, 1077, 1047, 1020, 994, 973, 959, 949, 936, 889, 809, 750, 716, 672.
MS (EI, 70 eV): m/z (%) = 258 (32), 211 (43), 138 (23), 135 (100), 121 (58), 79 (26), 77 (38)
HR-MS (EI, 70 eV): [C15H14O2S], calcd.: 258.0715; found: 258.0707.
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(4-Fluorophenyl)(4-methoxyphenyl)methanone (7p)
O
FMeO
Following TP8 S-(pyridin-2-yl) 4-methoxybenzothioate (5p, 123 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-fluorophenyl)zinc pivalate (6f, 0.95 mmol, 1.9 equiv) prepared according to
TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as usual.
Isolated yield: 99 mg, 0.43 mmol, 86% yield, white solid.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 97.1 – 98.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (dt, J = 8.7, 2.7 Hz, 4H), 7.15 (t, J = 8.6 Hz, 2H), 7.03
– 6.92 (m, 2H), 3.89 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 194.3, 165.2 (d, J = 253.2 Hz), 163.4, 134.6 (d, J = 3.1 Hz),
132.6, 132.4 (d, J = 9.1 Hz), 130.1, 115.5 (d, J = 21.8 Hz), 113.8, 55.7.
FT-IR (ATR, cm-1): ν̃ =3065, 3019, 2973, 2944, 2916, 2846, 1639, 1628, 1594, 1573, 1504,
1499, 1466, 1454, 1442, 1416, 1405, 1302, 1296, 1284, 1256, 1224, 1182, 1175, 1148, 1116,
1094, 1064, 1028, 1013, 967, 959, 949, 928, 856, 842, 828, 815, 789, 763, 682.
MS (EI, 70 eV): m/z (%) = 231 (7), 230 (43), 199 (13), 136 (9), 135 (100), 123 (16), 77 (9).
HR-MS (EI, 70 eV): [C14H11FO2], calcd.: 230.0743; found: 230.0737.
Ferrocenyl-(4-(trifluoromethoxy)phenyl)methanone (7q)
Fe O
OCF3
Following TP8 S-(pyridin-2-yl) ferrocenecarbothioate (5i, 162 mg, 0.50 mmol, 1.0 equiv) was
coupled with 4-(trifluoromethoxy)phenyl)zinc pivalate (6o, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
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Isolated yield: 151 mg, 0.40 mmol, 81%, red solid.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 38.2 – 40.1 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 – 7.91 (m, 2H), 7.30 (d, J = 8.3 Hz, 2H), 4.89 (t,
J = 1.9 Hz, 2H), 4.62 (t,J = 2.0 Hz, 2H), 4.21 (s, 5H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 197.7, 153.8 – 150.2 (m), 138.2, 130.1, 120.5 (q,
J = 258.3 Hz), 120.4, 77.9, 73.0, 71.6, 70.4.
FT-IR (ATR, cm-1): ν̃ = 2924, 1627, 1598, 1447, 1251, 1213, 1152, 1104, 1054, 1027, 1014,
1002, 968, 951, 923, 852, 822, 767, 713.
MS (EI, 70 eV): m/z (%) = 375 (20), 374 (100), 372 (6), 212 (7), 185 (9), 139 (24).
HR-MS (EI, 70 eV): [C18H13F3FeO2], calcd.: 374.0217; found: 374.0214.
Ferrocenyl-(4-(trifluoromethoxy)phenyl)methanone (7r)
Fe O
N
Me
Following TP8 S-(pyridin-2-yl) ferrocenecarbothioate (5i, 162 mg, 0.50 mmol, 1.0 equiv) was
coupled with ((1- methyl-1 H-indol-5-yl)zinc pivalate (6c, 0.95 mmol, 1.9 equiv) prepared according
to TP6 from the corresponding bromide. The solution was stirred for 4 h and was worked-up as
usual.
Isolated yield:144 mg, 0.42, 84%, red oil.
Purification: pentane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.32 (d, J = 1.8 Hz, 1H), 7.87 (dd, J = 8.6, 1.7 Hz, 1H),
7.38 (d, J = 8.6 Hz, 1H), 7.14 (d, J = 3.1 Hz, 1H), 6.62 (d, J = 3.1 Hz, 1H), 4.98 (t, J = 2.0 Hz, 2H),
4.56 (t, J = 2.0 Hz, 2H), 4.21 (s, 5H), 3.85 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 199.1, 138.6, 131.6, 130.3, 127.7, 122.7, 122.5, 109.0,
102.7, 79.5, 72.0, 71.9, 70.3, 33.2.
FT-IR (ATR, cm-1): ν̃ = 3093, 2920, 1624, 1597, 1564, 1511, 1489, 1441, 1416, 1373, 1337,
1305, 1286, 1267, 1242, 1210, 1149, 1135, 1098, 1081, 1044, 1025, 1000, 900, 841, 818, 776,
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753, 736, 722.
MS (EI, 70 eV): m/z (%) = 344 (23), 343 (100), 341 (7), 194 (9), 130 (9).
HR-MS (EI, 70 eV): [C20H17FeNO], 343.0660, found: 343.0659.
Quinolin-2-yl(4-(trifluoromethoxy)phenyl)methanone (7s)
O
N
OCF3
Following TP8 S-(pyridin-2-yl) quinoline-2-carbothioate (5j, 133 mg, 0.50 mmol, 1.0 equiv) was
coupled with 4- (trifluoromethoxy)phenyl)zinc pivalate (6o, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 108 mg, 0.34 mmol, 68%, colorless oil.
Purification: pentane:ethyl acetate = 99:1
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.41 – 8.33 (m, 3H), 8.20 (dq, J = 8.6, 0.9 Hz, 1H), 8.16
(d, J = 8.5 Hz, 1H), 7.93 (dd, J = 8.2, 1.4 Hz, 1H), 7.81 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.69 (ddd,
J = 8.1, 6.9, 1.2 Hz, 1H), 7.35 (dq, J = 9.1, 1.1 Hz, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 192.1, 154.2, 152.8, 152.7, 146.8, 137.5, 134.5, 133.7,
130.7, 130.4, 129.2, 128.9, 127.8, 121.9 – 119.1 (m, 2C)
FT-IR (ATR, cm-1): ν̃ = 1662, 1605, 1587, 1508, 1309, 1295, 1202, 1140, 1112, 967, 957, 920,
850, 835, 794, 769, 743, 669.
MS (EI, 70 eV): m/z (%) = 95, (12), 189 (100), 189 (29), 191 (15), 204 (42), 232 (17), 288 (69),
289 (53), 316 (28), 317 (30).
HR-MS (EI, 70 eV): [C17H10F3NO2], calcd.: 317.0664, found: 317.0660.
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tert-Butyl (S)-2-(4-methoxybenzoyl)pyrrolidine-1-carboxylate (7t)
O
N
Boc
OMe
Following TP8 tert-butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k, 154 mg,
0.50 mmol, 1.0 equiv) was coupled with ((4-methoxyphenyl)zinc pivalate (6a, 0.95 mmol, 1.9 equiv)
prepared according to TP6 from the corresponding bromide. The solution was stirred for 4 h and
was worked-up as usual.
Isolated yield: 110 mg, 0.36 mmol, 72%, pale yellow crystals.
Purification: pentane:ethyl acetate = 8:2 to 6:4.
m.p.: 124.8–126.9 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): (mixture of rotamers) δ = 8.06 – 7.85 (m, 2H), 7.04 – 6.82 (m,
2H), 5.29 (dd, J = 9.3, 2.9 Hz, 0H), 5.15 (dd, J = 8.8, 3.8 Hz, 1H), 3.87 (s, 2H), 3.85 (s, 1H), 3.71
– 3.58 (m, 1H), 3.54 (dt, J = 10.6, 6.6 Hz, 1H), 3.46 (dt, J = 10.3, 7.3 Hz, 0H), 2.41 – 2.18 (m, 1H),
1.91 (ttd, J = 15.0, 7.2, 3.5 Hz, 3H), 1.46 (s, 3H), 1.25 (s, 5H).
13C-NMR (100 MHz, CDCl3, ppm): (mixture of rotamers) δ = 197.5, 197.0, 163.7, 163.6, 154.6,
154.0, 130.9, 130.6, 128.3, 128.1, 114.0, 113.9, 79.8, 79.7, 61.1, 60.9, 55.6, 55.6, 46.9, 46.7,
31.1, 30.1, 28.6, 28.3, 24.3, 23.7.
FT-IR (ATR, cm-1): ν̃ = 2972, 1680, 1597, 1574, 1510, 1477, 1455, 1391, 1363, 1307, 1254,
1228, 1158, 1115, 1080, 1025, 1010, 988, 918, 880, 838, 809, 771, 688.
MS (EI, 70 eV): m/z (%) = 170 (34), 125 (81), 114 (89), 77 (13), 70 (100), 57 (67), 41 (14).
HR-MS (EI, 70 eV): [C17H23NO4], 305.1627, found: 305.1624.305.1627, found: 305.1624.
Optical rotation: [α]ϕλ = -23 (c = 1.02 CHCl3).
Chiral HPLC: 99% ee, OJ-H column, i-PrOH:heptane = 5:95, 1.0 mL/min, 30 ◦C.
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tert-Butyl (S)-2-(benzo[d][1,3]dioxole-5-carbonyl)pyrrolidine-1-carboxylate (7u)
O
N
Boc
O
O
Following TP8 tert-butyl 2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k, 154 mg,
0.50 mmol, 1.0 equiv) was coupled with (benzo[d ][1,3]dioxol-5-yl)zinc pivalate (6b, 0.95 mmol,
1.9 equiv) prepared according to TP6 from the corresponding bromide. The solution was stirred
for 4 h and was worked-up as usual.
Isolated yield: 130 mg, 0.41 mmol, 82%, brown oil.
Purification: pentane:ethyl acetate = 8:2.
1H-NMR (400 MHz, DMSO-d6, ppm): (mixture of rotamers) δ = 7.66 (ddd, J = 8.2, 2.8, 1.7 Hz,
1H), 7.49 (t, J = 1.9 Hz, 1H), 7.06 (dd, J = 8.1, 0.9 Hz, 1H), 6.15 (s, 2H), 5.25 (ddd, J = 10.8, 9.0,
3.8 Hz, 1H), 3.39 (dddd, J = 14.2, 11.8, 7.3, 4.6 Hz, 2H), 2.37 – 2.23 (m, 1H), 1.91 – 1.63 (m, 4H),
1.38 (s, 4H), 1.17 (s, 6H).
13C-NMR (100 MHz, DMSO-d6, ppm): (mixture of rotamers)δ = 197.3, 196.5, 153.8, 153.4,
152.1, 148.4, 129.7, 129.5, 125.2, 125.0, 108.7, 108.7, 108.2, 108.0, 102.6, 102.6, 79.0, 78.8,
61.0, 61.0, 47.0, 46.9, 31.0, 30.1, 28.6, 28.3, 27.5, 24.3, 23.6.
FT-IR (ATR, cm-1): ν̃ = 2974, 1682, 1614, 1605, 1505, 1488, 1442, 1392, 1364, 1245, 1160,
1120, 1108, 1097, 1034, 1000, 973, 927, 910, 884, 856, 807, 772, 740, 718.
MS (EI, 70 eV): m/z (%) = 319 (4), 246 (11), 170 (48), 149 (100), 121 (18), 70 (75), 58 (23), 57
(48), 43 (53).
HR-MS (EI, 70 eV): [C17H21NO5], 319.1420, found: 319.1411.
Optical rotation: [α]ϕλ = -29 (c = 0,4 CHCl3).
Chiral HPLC: 98% ee, OJ-H column, i-PrOH:heptane = 1:99, 1.0 mL/min, 30 ◦C.
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(S)-2-(4-Isobutylphenyl)-1-(6-methoxynaphthalen-2-yl)propan-1-one (7v)
O
Me
i-Pr
OMe
Following TP8 S-(pyridin-2-yl) (S)-2-(4-isobutylphenyl)propanethioate (5l, 150 mg, 0.50 mmol,
1.0 equiv) was coupled with (6-methoxynaphthalen-2-yl)zinc pivalate (6p, 0.95 mmol, 1.9 equiv)
prepared according to TP6 from the corresponding bromide. The solution was stirred for 4 h and
was worked-up as usual.
Isolated yield: 144 mg, 0.42 mmol, 89%, white solid.
Purification: pentane:ethyl acetate = 95:5 to 9:1.
m.p.: 70.1 – 72.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.34 (d, J = 1.7 Hz, 1H), 7.92 (dd, J = 8.7, 1.8 Hz, 1H),
7.70 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 8.7 Hz, 1H), 7.20 – 7.13 (m, 2H), 7.07 (dd, J = 8.9, 2.5 Hz,
1H), 7.01 (d, J = 2.6 Hz, 1H), 7.00 – 6.96 (m, 2H), 4.72 (q, J = 6.8 Hz, 1H), 3.83 (s, 3H), 2.31 (d,
J = 7.2 Hz, 2H), 1.71 (dp, J = 13.5, 6.7 Hz, 1H), 1.49 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.6 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.4, 159.8, 140.4, 139.1, 137.2, 132.0, 131.3, 130.4,
129.8, 127.9, 127.6, 127.1, 125.5, 119.7, 105.7, 77.1, 55.5, 47.4, 5.1, 30.3, 22.5, 22.5, 19.8.
FT-IR (ATR, cm-1): ν̃ = 2954, 2923, 1670, 1622, 1508, 1480, 1458, 1438, 1389, 1369, 1337,
1271, 1264, 1231, 1200, 1167, 1150, 1061, 1024, 945, 911, 901, 893, 864, 856, 849, 830, 817,
801, 776, 770, 762, 738, 698.
MS (EI, 70 eV): m/z (%) = 142 (7), 157 (13), 185 (100), 186 (13), 346 (1).
HR-MS (EI, 70 eV): [C24H26O2], 346.1933, found: 346.1927.
Optical rotation: [α]ϕλ = -89 (c = 1.02 CHCl3).
Chiral HPLC: 98% ee, OD-H column, i-PrOH:heptane = 2:98, 1.0 mL/min, 30 ◦C.
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(S)-2-(4-iso-Butylphenyl)-1-(3-(methylthio)phenyl)propan-1-one (7w)
O
Me
i-Pr
SMe
Following TP8 S-(pyridin-2-yl) 2-(4-isobutylphenyl)propanethioate (5l, 150 mg, 0.50 mmol,
1.0 equiv) was coupled with (3-(methylthio)phenylzinc pivalate (6n, 0.95 mmol, 1.9 equiv) prepared
according to TP6 from the corresponding bromide. The solution was stirred for 4 h and was
worked-up as usual.
Isolated yield: 110 mg, 0.35 mmol, 71%, colorless oil
Purification: pentane:ethyl acetate = 98:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 (t, J = 1.8 Hz, 1H), 7.69 (dt, J = 7.6, 1.4 Hz, 1H), 7.34
(ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.32 – 7.23 (m, 1H), 7.20 – 7.14 (m, 2H), 7.09 – 7.02 (m, 2H), 4.61
(q, J = 6.9 Hz, 1H), 2.45 (s, 3H), 2.40 (d, J = 7.2 Hz, 2H), 1.80 (dp, J = 13.6, 6.8 Hz, 1H), 1.51 (d,
J = 6.9 Hz, 3H), 0.86 (dd, J = 6.6, 0.8 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 200.1, 140.4, 139.4, 138.5, 137.1, 130.6, 129.8, 128.7,
127.4, 126.1, 125.4, 47.7, 45.0, 30.2, 22.4, 22.4, 19.5, 15.6.
FT-IR (ATR, cm-1): ν̃ = 2957, 2926, 1682, 1584, 1569, 1509, 1465, 1453, 1415, 1384, 1373,
1333, 1215, 1080, 1061, 1014, 960, 882, 848, 795, 747, 686, 667.
MS (EI, 70 eV): m/z (%) = 312 (4), 161 (35), 152 (9), 151 (100), 123 (10).
HR-MS (EI, 70 eV): [C20H24OS], 312. 1548, found: 312.2539.
Optical rotation: [α]ϕλ = 107 (c = 0.53 CHCl3).
Chiral HPLC: 98% ee, OD-H column, i-PrOH:heptane = 2:98, 1.0 mL/min, 30 ◦C.
(/kuS)-N,N-Dimethyl-4-(2-methylbutanoyl)benzamide (7x)
Me
O
Me O
NMe2
Following TP8 S-(pyridin-2-yl) (S)-2-methylbutanethioate (5m, 98 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-(dimethylcarbamoyl)phenyl)zinc pivalate (6q, 0.95 mmol, 1.9 equiv) prepared
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according to TP7 from the corresponding iodide at 0 ◦C in 2 h. The solution was stirred for 4 h and
was worked-up as usual.
Isolated yield: 80 mg, 0.34 mmol, 69%, yellow oil.
Purification: pentane:ethyl acetate = 6:4, 5% NEt3
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 – 7.94 (m, 2H), 7.54 – 7.47 (m, 2H), 3.38 (h,
J = 6.7 Hz, 1H), 3.13 (s, 3H), 2.96 (s, 3H), 1.82 (dqd, J = 13.8, 7.4, 6.3 Hz, 1H), 1.49 (ddd, J
= 14.0, 7.6, 6.8 Hz, 1H), 1.19 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 203.9, 170.6, 140.4, 137.4, 128.4, 127.3, 42.3, 26.6, 16.6,
11.7.
FT-IR (ATR, cm-1): ν̃ = 2963, 2933, 2363, 1684, 1636, 1508, 1458, 1396, 1266, 1219, 1081,
1015, 971, 861, 839, 709, 699.
MS (EI, 70 eV): m/z (%) = 233 (7), 189 (5), 177 (11), 176 (100), 120 (6), 104 (11).
HR-MS (EI, 70 eV): [C14H19NO2], 233.1416, found: 233.1407.
Optical rotation: [α]ϕλ = 13 (c = 0.1 CHCl3).
Chiral HPLC: 98% ee, AD-H column, i-PrOH:heptane = 1:99, 2.0 mL/min, 30 ◦C.
(S)-1-(3-(Dimethylamino)phenyl)-2-methylbutan-1-one (7y)
Me
O
Me
NMe2
Following TP8 S-(pyridin-2-yl) 2-(4-isobutylphenyl)propanethioate (5m, 150 mg, 0.50 mmol,
1.0 equiv) was coupled with (3-(dimethylamino)phenyl)zinc pivalate (6r, 0.95 mmol, 1.9 equiv)
prepared according to TP6 from the corresponding bromide. The solution was stirred for 4 h and
was worked-up as usual.
Isolated yield: 110 mg, 0.35 mmol, 71%, colorless oil.
Purification:pentane:ethyl acetate = 98:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.35 – 7.15 (m, 3H), 6.86 (ddd, J = 8.0, 2.6, 1.3 Hz, 1H),
3.34 (h, J = 6.7 Hz, 1H), 2.94 (s, 6H), 1.78 (ddd, J = 13.9, 7.5, 6.5 Hz, 1H), 1.52 – 1.37 (m, 1H),
1.13 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H).
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13C-NMR (100 MHz, CDCl3, ppm): δ = 205.3, 150.7, 137.6, 129.1, 116.8, 116.5, 111.5, 42.2,
40.6, 39.4, 35.3, 26.8, 17.0, 11.9.
FT-IR (ATR, cm-1): ν̃ = 2965, 2932, 2874, 1677, 1597, 1574, 1496, 1460, 1434, 1353, 1261,
1213, 1146, 1062, 986, 943, 865, 773, 7421, 682.
MS (EI, 70 eV): m/z (%) = 205 (77), 149 (12), 148 (74), 137 (22), 136 (14), 121 (38), 120 (100),
77 (15).
HR-MS (EI, 70 eV): [C13H19NO], 205.1467, found: 205.1460..
Optical rotation: [α]ϕλ = 41 (c = 1.05 CHCl3).
Chiral HPLC: 98% ee, OD-H column, i-PrOH:heptane = 1:99, 1.0 mL/min, 30 ◦C.
Fenofibrate (7z)
O
O Cl
Me Me
i-Pr-O
O
KOH (560 mg, 1.0 equiv, 10 mmol) was added to a solution of 4-iodophenol (9, 2.2 g, 10
mmol, 1.0 equiv) in EtOH (20 mL) at 0 ◦C. After 30 min, isopropyl 2-bromo-2-methylpropanoate
(10, 2.09 g, 10 mmol, 1.0 equiv) was added and the mixture was refluxed for 16 h. After
solvent evaporation the product was subjected to column chromatographical purification with
i-hexane/EtOAc (98:2) as eluent. Isopropyl 2-(4-iodophenoxy)-2- methylpropanoate (11) was
obtained as a yellow oil (2.44 g, 7 mmol, 70% yield).
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.57 – 7.44 (m, 2H), 6.71 – 6.51 (m, 2H), 5.17 – 4.95 (m,
1H), 1.57 (s, 7H), 1.21 (d, J = 6.3 Hz, 6H).
Magnesium turnings (1.2 equiv), dry LiCl (1.2 equiv), Zn(OPiv)2 (1.0 equiv) and dry THF (0.5 M)
were added to a dry and argon flushed Schlenk-tube equipped with a magnetic stirring bar
and a septum. The tube was charged with isopropyl 2-(4-iodophenoxy)-2-methylpropanoate
(11, 1.0 equiv) at rt. To monitor the progress of the insertion reaction, reaction aliquots
were quenched with iodine and analyzed by GC-analysis. The insertion was completed
within 4 h and the concentration was determined by titration with iodine, yielding
(4-((1-isopropoxy- 2-methyl-1-oxopropan-2-yl)oxy)phenylzinc pivalate 6s in 70%. A dry
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and argon flushed Schlenk-tube equipped with a magnetic stirring bar and a septum
was charged with CoCl2 (3.2 mg, 0.025 mmol, 0.10 equiv, dried in vacuo at 400
◦C prior
to use). Then, the ligand 4,4’-di-tert-butyl-2,2’- dipyridyl (6.5 mg, 0.25 mmol, 0.10 equiv)
and S-(pyridin-2-yl) 4-chlorobenzothioate (5g, 63 mg, 0.25 mmol, 1.0 equiv) added to
the Schlenk-tube. The resulting mixture was dissolved in dry THF (0.5 mL). Then, (4-((1-
isopropoxy-2-methyl-1-oxopropan-2-yl)oxy)phenylzinc pivalate (6s , 0.48 mmol, 1.9 equiv) was
added and stirring was continued for 4 h, at 25 ◦C. Upon consumption of the starting material,
satured aq. NH4Cl solution (10 mL) was added, the phases were separated and the aq. phase
was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over MgSO4.
The solvents were evaporated and the residue was subjected to column chromatographical
purification.
Isolated yield: 59 mg, 0.16 mmol, 64% yield, colorless solid.
Purification: pentane:ethyl acetate = 90:10.
m.p.: 65.6 – 67.4 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.75 – 7.71 (m, 2H), 7.71 – 7.66 (m, 2H), 7.50 – 7.41 (m,
2H), 6.91 – 6.82 (m, 2H), 5.08 (h, J = 6.3 Hz, 1H), 1.66 (s, 6H), 1.20 (d, J = 6.2 Hz, 6H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 194.3, 173.1, 159.7, 138.4, 136.4, 132.0, 131.2, 130.2,
128.5, 117.2, 79.4, 69.4, 25.4, 21.5.
FT-IR (ATR, cm-1): ν̃ = 2983, 2932, 1728, 1653, 1898, 1496, 1466, 1384, 1285, 1242, 1173,
1143, 4401, 1090, 1014, 972, 926, 898, 843, 825, 762, 740, 682, 655.
MS (EI, 70 eV): m/z (%) = 121 (100), 138 (78), 140 26), 197 (70), 232 (66), 234 (21), 273 (65),
275 (26), 360 (5).
HR-MS (EI, 70 eV): [C20H21ClO4], 360.1128, found: 360.1125.
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4 Cobalt-Catalyzed Cross-Coupling of functionalized Alkylzinc
Reagents with (Hetero)aryl Halides
4.1 Preparation of Starting Materials
2-(2-Bromoethyl)-6,6-dimethylbicyclo[3.1.1]hept-2-ene111
Br
Me Me
The title compound was prepared according to literature procedure from (1R)-(-)-nopol (6.7 mL,
40 mmol) affording (1R,5S)-2-(2-bromoethyl)-6,6-dimethylbicyclo[3.1.1]hept-2-ene as pale yellow
oil (8.25 g, 36.0 mmol, 90 %). The analytical data is in full consistency with the data reported in
the literature.111
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.32 (tq, J = 2.9, 1.5 Hz, 1H), 3.36 (td, J = 7.7, 3.8 Hz, 2H),
2.56 – 2.48 (m, 2H), 2.37 (dt, J = 8.6, 5.6 Hz, 1H), 2.31 – 2.15 (m, 2H), 2.09 (ttd, J = 5.8, 2.8,
1.3 Hz, 1H), 2.01 (td, J = 5.6, 1.5 Hz, 1H), 1.27 (s, 3H), 1.17 (d, J = 8.6 Hz, 1H), 0.83 (s, 3H).
(4-Bromobut-1-yn-1-yl)trimethylsilane112
Ph
N
N
TMS
Br
The title compound was prepared according to literature procedure from
(4-(trimethylsilyl)-3-butyn-1-ol (3.00 g, 21 mmol), affording (4-bromobut-1-yn-1-yl)trimethylsilane
as a colorless liquid (3.10 g, 16.0 mmol, 76%). The analytical data is in full consistency with the
data reported in the literature.112
1H-NMR (400 MHz, CDCl3, ppm): δ = 3.43 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 0.16 (s, 9H).
1-(3-Bromopropyl)-2,5-dimethyl-1H-pyrrole113
Ph
N
N
Br N
Me
Me
111B. Akgun, D. G. Hall, Angewandte Chemie International Edition 2016, 55, 3909–3913.
112H. M. Wisniewska, E. C. Swift, E. R. Jarvo, Journal of the American Chemical Society 2013, 135, 9083–9090.
113S. P. Bruekelman, S. E. Leach, G. D. Meakins, M. D. Tirel, J. Chem. Soc., Perkin Trans. 1 1984, 2801–2807.
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The title compound was prepared according to literature procedure from 3-bromopropylammonium
bromide (5.00 g, 22.8 mmol) affording 1-(3-bromopropyl)-2,5-dimethyl-1H-pyrrole as a yellow oil
(2.50 g, 11.6 mmol, 54%). The analytical data is in full consistency with the data reported in the
literature.113
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.77 (s, 2 H), 3.95 – 3.88 (m, 2 H,), 3.42 (m, 2 H), 2.24 (s,
6 H), 2.20 – 2.15 (m, 2 H).
3-(2-Bromoethyl)thiophene114
Ph
N
N
Br
S
The title compound was prepared according to literature procedure from
2-(thiophen-3-yl)ethan-1-ol (2.56 g, 20 mmol), affording 3-(2-bromoethyl)thiophene as a
colorless liquid (2.75 g,14.4 mmol, 72%). The analytical data is infull consistency with data
reported in the literature.114
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.29 (dd, J = 4.9, 2.9 Hz, 1H), 7.07 (d, J = 2.9 Hz, 1H),
6.98 (d, J = 4.9 Hz, 1H), 3.57 (t, J = 7.5 Hz, 2H), 3.21 (t, J = 7.5 Hz, 2H).
1-Iodo-3-methylcyclohexane
Ph
N
N
Me I
1-Iodo-3-methylcyclohexane was prepared according to TP1 from 3-methylcyclohexanol (4.56 g,
40 mmol) and was obtained as a pale pink oil (6.05 g, 27 mmol, 68% yield). The analytical data is
in full consistency with the data reported in the literature.115
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.91 – 4.79 (m, 1H), 4.15 (tt, J = 12.3, 4.0 Hz, 0.5H), 2.40
(ttq, J = 10.9, 3.6, 1.9 Hz, 1H), 2.14 – 1.80 (m, 4H), 1.80 – 1.33 (m, 5H), 1.32 – 1.18 (m, 3H), 1.07
– 0.81 (m, 5H).
114P. Taranekar, A. Baba, T. M. Fulghum, R. Advincula, Macromolecules 2005, 38, 3679–3687.
115X. Mu, Y. Shibata, Y. Makida, G. C. Fu, Angew. Chem. Int. Ed. 2017, 56, 5821–5824.
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1-(4-Iodocyclohexyl)-1H-pyrrole (21)
1-(4-Iodocyclohexyl)-1H-pyrrole was prepared according to TP1 from
4-(1H-pyrrol-1-yl)cyclohexan-1-ol (6.6 g, 40.0 mmol), which was prepared according to
literature procedure116 from 4-aminocyclohexan-1-ol. 1-(4- iodocyclohexyl)-1H-pyrrole and was
obtained as colorless crystals (6.08 g, 22.1 mmol, 55% yield).
Purification: i-hexane:ethyl acetate = 95:5.
m.p.: 51.0 – 52.7 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.81 (t, J = 2.1 Hz, 2H), 6.20 (t, J = 2.1 Hz, 2H), 4.90 –
4.80 (m, 1H), 3.92 (tt, J = 11.7, 3.9 Hz, 1H), 2.38 – 2.13 (m, 4H), 2.11 – 1.95 (m, 2H), 1.82 – 1.65
(m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 118.6, 107.8, 57.6, 35.8, 33.2, 30.6.
FT-IR (ATR, cm-1): ν̃ = 2945, 2934, 2832, 1490, 1438, 1428, 1410, 1346, 1392, 1276, 1258,
1238, 1214, 1188, 1160, 1088, 1068, 1054, 1021, 1005, 961, 904, 875, 864, 820, 772, 723, 712,
697.
MS (EI, 70 eV): m/z (%) = 275 (31), 149 (11), 148 (100), 120 (11), 118 (16), 106 (10), 81 (31), 80
(17), 79 (27), 68 (16).
HR-MS (EI, 70 eV): [C10H14NI], calcd.: 275.0171; found: 275.0167.
1-Iodo-4-(trifluoromethyl)cyclohexane (22)
Ph
N
N
I
F3C
1-Iodo-4-(trifluoromethyl)cyclohexane was prepared according to TP1 from ethyl 4-(trifluoromethyl)
cyclohexan-1-ol (1.00 g, 6.00 mmol) and was obtained as a colorless oil (750 mg, 2.74 mmol,
46% yield). The analytical data is in full consistency with the data reported in the literature.115
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.74 (p, J = 3.4 Hz, 1H), 2.17 – 2.06 (m, 2H), 2.05 – 1.89
(m, 1H), 1.90 – 1.69 (m, 4H), 1.60 – 1.41 (m, 2H).
116N. B. Kumar, O. A. Mukhina, A. G. Kutateladze, J. Am. Chem. Soc. 2013, 135, 9608–9611.
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(Bromoethynyl)benzene (23)
Ph
N
N
Ph Br
The title compound was prepared according to literature procedure from ethynylbenzene (306 mg,
3.00 mmol), affording (bromoethynyl)benzene as a pale yellow liquid (467 mg, 2.58 mmol,
86%).117
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.49 – 7.42 (m, 2H), 7.37 – 7.27 (m, 3H).
(Bromoethynyl)triisopropylsilane (24)
Ph
N
N
TIPS Br
The title compound was prepared according to literature procedure from ethynyltriisopropylsilane
(546 mg, 3.00 mmol), affording (bromoethynyl)triisopropylsilane as a colorless oil (734 mg,
2.80 mmol, 93%). 117
1H-NMR (400 MHz, CDCl3, ppm): δ = 1.07 (s, 21H).
4.2 Cobalt-Catalyzed Cross-Coupling of functionalized Alkylzinc Reagents with
(Hetero)aryl Halides
Preparation of alkylzinc chlorides by magnesium insertion (TP9)
Alk-Br
1) Mg (1.2 equiv)
    LiCl (1.2 equiv)
2) ZnCl2 (1.0 equiv)
THF, 0 °C
Alk-ZnCl
13
Dry LiCl (1.2 equiv) was placed in a dry and argon flushed 50 mL Schlenk -tube equipped with a
magnetic stirring bar, a septum and was dried over 5 min at 300 ◦C under high vacuum (0.1 mbar).
Magnesium turnings (1.2 equiv) were added followed by dry THF (1.0 M solution relating to the
aryl halide) and the respective alkyl bromide (1.0 equiv). After the exothermic reaction started, the
mixture was cooled with an ice bath. To monitor the progress of the insertion reaction, reaction
aliquots quenched with iodine were analyzed as water-quenched samples by GC-analysis. When
the insertion was completed, the concentration of the magnesium reagents was determined via
titration of a small aliquot with I2 (50 mg in 2 mL THF). A ZnCl2 solution (1.00 M in THF, 1.0 equiv)
was added at 0 ◦C and stirred at ambient temperature for 15 min affording the corresponding
alkylzinc chloride 13.118
117Y. Ping, K. Wang, Q. Pan, Z. Ding, Z. Zhou, Y. Guo, W. Kong, ACS Catalysis 2019, 9, 7335–7342.
118F. Piller, P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 6802–6806.
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Preparation of alkylzinc halides by zinc insertion (TP10)55c
Alk-X
Zn (3.0 equiv) 
LiCl (1.5 equiv)
TMSCl (0.05 equiv)
DBE (0.05 equiv)
THF, rt or 50 °C
Alk-ZnX
13
Dry LiCl (1.5 equiv) was placed in a dry and argon flushed 25 mL Schlenk-tube equipped with
a magnetic stirring bar and a septum, was dried over 5 min at 300 ◦C under high vacuum
(0.1 mbar). Zn powder (3.0 equiv) was added under argon and the heterogeneous mixture of Zn
and LiCl was dried one more time at 300 ◦C for 5 min under high vacuum. The reaction flask was
evacuated and refilled with argon three times. THF (0.5 M solution relating to the alkyl iodide)
and 1,2-dibromoethane (0.05 equiv) were added. The mixture was then gently heated in order to
activate the Zn surface. TMSCl (0.05 equiv) was added and the reaction mixture was again gently
heated. The respective primary alkyl bromide or cyclohexyl iodide (1.0 equiv) was added neat at
rt in one portion. The resulting reaction mixture was stirred until full consumption of the alkyl
halide, in case of the primary alkyl bromides the insertion reaction was stirred at 50 ◦C. To monitor
the progress of the insertion reaction, reaction aliquots quenched with iodine and quenched with
sat. aq. NH4Cl were analyzed by GC-analysis. When the insertion was completed the solution
was then filtered from the remaining Zn powder via syringe filter (30 mm with 0.45µm glass
fiber membrane) and transferred to a dry argon flushed Schlenk -tube. The concentrations of all
cyclohexylzinc reagents were determined via titration of a small aliquot with I2 (50 mg in 2 mL THF).
Cobalt-catalyzed acylation of arylzinc pivalates with thiopyridyl esters (TP11)
12
CoCl2 (10 mol%)
bipy or dtbbpy (20 mol%)
THF or MeCN, 0 °C or rt, 16 h
Alk-ZnX
13 (1.5 equiv)
14
(Het)Ar-Hal (Het)Ar-Alk
A dry and argon flushed Schlenk-tube, equipped with a magnetic stir bar and a septum was
charged with dry CoCl2 (6.5 mg, 0.05 mmol, 10 mol%), which was dried at 300
◦C under high
vacuum prior to use.
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A) For primary alkylzinc species:
Bipyridine (17 mg, 0.1 mmol, 20 mol%) the respective (hetero)aryl halide (12, 0.5 mmol, 1.0 equiv)
and dry THF (1.0 mL) were added. The reaction mixture was cooled to 0 ◦C with an ice bath and
a solution of the appropriate alkylzinc halide (13, 0.75 mmol, 1.5 equiv) was added via syringe.
B) For secondary alkylzinc species:
4,4’-Di-tert-butyl-2,2’-bipyridine (27 mg, 0.10 mol, 20 mol%), the respective (hetero)aryl halide (
12, 0.5 mmol, 1.0 equiv) and dry MeCN (1.0 mL) were added (for the synthesis of 14y and 14z
the reaction was performed in THF). The appropriate alkylzinc halide (13, 0.75 mmol, 1.5 equiv)
was added via syringe at rt.
In both cases the reaction was stirred for 16 h at rt. The solvent was removed and the crude
product was subjected to column chromatography purification on silica yielding the corresponding
coupling product.
6-(2-(1,3-Dioxan-2-yl)ethyl)nicotinonitrile (14a)
Ph
N
N
N
O
O
NC
Following TP11-A 6-chloronicotinonitrile (12v, 138 mg, 1.00 mmol, 1.0 equiv) was coupled with
(2-(1,3-dioxan-2- yl)ethyl)zinc chloride (13a, 1.50 mmol, 1.5 equiv) prepared according to TP9
from the corresponding bromide.
Isolated yield: 163 mg, 0.75 mmol, 75%, white solid.
Purification: pentane:ethyl acetate = 7:3.
m.p.: 100.1 – 102.7 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.73 (dd, J = 2.2, 0.9 Hz, 1H), 7.78 (dd, J = 8.1, 2.2 Hz,
1H), 7.38 – 6.90 (m, 1H), 4.50 (t, J = 5.0 Hz, 1H), 4.03 (ddt, J = 10.5, 4.9, 1.4 Hz, 2H), 3.80 – 3.52
(m, 2H), 3.00 – 2.76 (m, 2H), 2.18 – 1.89 (m, 3H), 1.28 (dtt, J = 13.5, 2.6, 1.4 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.4, 152.2, 139.4, 123.1, 117.13, 107.3, 101.1, 67.0,
34.2, 32.8, 25.9.
FT-IR (ATR, cm-1): ν̃ = 2966, 2934, 2865, 227, 1979, 1596, 156, 1492, 1474, 1453, 1424, 1381,
1318, 1290, 1266, 1241, 1191, 1138, 1121, 1070, 1040, 1029, 998, 952, 943, 926, 888, 865, 856,
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834, 758, 668.
MS (EI, 70 eV): m/z (%) = 217 (12), 159 (49), 143 (13), 132 (25), 131 (96), 118 (31), 101 (20), 87
(100).
HR-MS (EI, 70 eV): [C12H13N2O2], calcd.: 217.0972; found:217.0970 [M
+-H].
6-(3-Phenylpropyl)nicotinonitrile (14b)
Ph
N
N
N
NC
Ph
Following TP11-A 6-chloronicotinonitrile (12a, 69 mg, 0.50 mmol, 1.0 equiv) was coupled with
(3-phenylpropyl)zinc chloride (13b, 0.75 mmol, 1.5 equiv) prepared according to TP9 from the
corresponding bromide.
Isolated yield: 81 mg, 0.36 mmol, 73%, white solid.
Purification: i-hexane:ethyl acetate = 8:2.
m.p.: 62.3 – 64.1 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.87 – 8.74 (m, 1H), 7.84 (dd, J = 8.1, 2.2 Hz, 1H), 7.33
– 7.19 (m, 3H), 7.20 – 7.16 (m, 3H), 2.96 – 2.83 (m, 2H), 2.69 (t, J = 7.6 Hz, 2H), 2.09 (p, J =
7.7 Hz, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 152.3, 141.6, 139.4, 128.6, 128.6, 126.1, 123.0,
117.1, 107.3, 38.2, 35.5, 30.9.
FT-IR (ATR, cm-1): ν̃ = 3045, 3021, 2946, 2922, 2858, 2229, 1594, 1553, 1495, 1484, 1452,
1387, 1316, 1289, 1204, 1187, 1156, 1129, 1076, 1043, 1027, 1017, 934, 914, 868, 849, 827,
750, 700, 677.
MS (EI, 70 eV): m/z (%) = 223 (1), 131 (3), 119 (8), 118 (100), 117 (1), 91 (5).
HR-MS (EI, 70 eV): [C15H15N2], calcd.: 223.1230; found: 223.1229 [M
++H].
6-(2-((1R,4R)-5,5-Dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)nicotinonitrile (14c)
N
Me MeNC
Following TP11-A 6-bromonicotinonitrile (12b, 92 mg, 0.50 mmol, 1.0 equiv) was coupled
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with (2-((1R,4R)-5,5- dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (13c, 0.75 mmol,
1.5 equiv) prepared according to TP9 from the corresponding bromide.
Isolated yield: 98 mg, 0.39 mmol, 78%, red crystals.
Purification:i-hexane:ethyl acetate = 9:1.
m.p.: 34.2 – 35.8 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.79 (dd, J = 2.2, 0.9 Hz, 1H), 7.85 (dd, J = 8.1, 2.2 Hz,
1H), 7.30 – 7.26 (m, 1H), 5.23 (tp, J = 3.0, 1.4 Hz, 1H), 2.98 – 2.86 (m, 2H), 2.44 – 2.31 (m, 3H),
2.30 – 2.12 (m, 3H), 2.11 – 2.02 (m, 2H), 1.27 (s, 3H), 1.10 (d, J = 8.5 Hz, 1H), 0.80 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.8, 152.1, 146.8, 139.5, 123.0, 117.2, 117.1, 107.3,
45.9, 40.8, 4.1, 36.6, 36.4, 31.7, 31.7, 26.4, 21.3.
FT-IR (ATR, cm-1): ν̃ = 2975 , 2925, 2834, 2231, 1595, 1554, 1482, 1447, 1382, 1364, 1338,
1304, 1264, 1202, 1119, 1098, 1025, 1003, 936, 886, 862, 838, 806, 725.
MS (EI, 70 eV): m/z (%) = 252 (5), 251 (6), 237 (7), 223 (7), 211 (5), 209 (52), 207 (7), 184 (13),
183 (100), 181 (7).
HR-MS (EI, 70 eV): [C17H19N2], 251.1548; found: 251.1539.
Optical rotation: [α]ϕλ = -34(c = 0.83 CHCl3).
6-(4-(Trimethylsilyl)but-3-yn-1-yl)nicotinonitrile (14d)
Ph
N
N
N
TMS
NC
Following TP11-A 6-bromonicotinonitrile (12b, 92 mg 0.50 mmol, 1.0 equiv) was coupled with
(4-(trimethylsilyl)but-3-yn- 1-yl)zinc chloride (13d, 0.75 mmol, 1.5 equiv) prepared according to
TP9 from the corresponding bromide.
Isolated yield: 71 mg, 0.31 mmol, 62%, yellow solid.
Purification: i-hexane:ethyl acetate = 8:2.
m.p.: 70.0 – 71.2 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.81 (dd, J = 2.3, 0.9 Hz, 1H), 7.87 (dd, J = 8.1, 2.2 Hz,
1H), 7.35 (dd, J = 8.1, 1.0 Hz, 1H), 3.05 (t, J = 7.2 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 0.09 (s, 9H).
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13C-NMR (100 MHz, CDCl3, ppm): δ = 164.6, 152.3, 139.2, 123.5, 117.0, 107.8, 105.3, 86.4,
37.4, 19.7, 0.1.
FT-IR (ATR, cm-1): ν̃ = 2925, 2231, 2172, 1591, 1551, 1482, 1434, 1384, 1242, 1048, 1025, 999,
843, 757, 699.
MS (EI, 70 eV): m/z (%) = 229 (3), 228 (11), 227 (93), 213 (59), 157 (12), 156 (11), 155 (100).
HR-MS (EI, 70 eV): [C13H16N2Si], calcd.: 228.1083; found: 228.1036.
4-(5-(Trifluoromethyl)pyridin-2-yl)butanenitrile (14e)
Ph
N
N
N
CN
F3C
Following TP11-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol,
40 mol%), 2-bromo-5- (trifluoromethyl)pyridine (12c, 113 mg, 0.50 mmol, 1.0 equiv) was coupled
with (3-cyanopropyl)zinc bromide (13e, 0.95 mmol, 1.9 equiv) prepared according to TP10 from
the corresponding bromide.
Isolated yield: 93 mg, 0.43 mmol, 87%, colorless oil.
Purification: i-hexane:ethyl acetate = 7:3 to 6:4.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.92 – 8.73 (m, 1H), 7.86 (dd, J = 8.2, 2.4 Hz, 1H), 7.32
(d, J = 8.1 Hz, 1H), 3.03 (t, J = 7.4 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 2.17 (p, J = 7.2 Hz, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 8.9 – 8.7 (m, 1H), 7.9 (dd, J = 8.2, 2.4 Hz, 1H), 7.3 (d, J =
8.1 Hz, 1H), 3.0 (t, J = 7.4 Hz, 2H), 2.4 (t, J = 7.1 Hz, 2H), 2.2 (p, J = 7.2 Hz, 2H).
FT-IR (ATR, cm-1): ν̃ = 2940, 2247, 1608, 1574, 1496, 1430, 1396, 1325, 1166, 1121, 1079,
1017, 940, 854, 750.
MS (EI, 70 eV): m/z (%) = 175 (4), 174 (41), 161 (100), 147 (5), 146 (5), 141 (3), 126 (3).
HR-MS (EI, 70 eV): [C10H10F3N2], calcd.: 215.0791; found: 215.0783 [M
++H].
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2-(3-(2,5-Dimethyl-1H-pyrrol-1-yl)propyl)-5-(trifluoromethyl)pyridine (14f)
Ph
N
N
N
N
Me
Me
F3C
Following TP11-A 2-bromo-5-(trifluoromethyl)pyridine (12c, 113 mg, 0.50 mmol, 1.0 equiv) was
coupled with (3-(2,5- dimethyl-1H-pyrrol-1-yl)propyl)zinc chloride (13f, 0.75 mmol, 1.5 equiv)
prepared according to TP9 from the corresponding bromide.
Isolated yield: 107 mg, 0.38 mmol, 76%, brown oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 (dt, J = 2.0, 1.0 Hz, 1H), 7.89 – 7.80 (m, 1H), 7.28 (d,
J = 8.2 Hz, 1H), 5.76 (s, 2H), 3.88 – 3.77 (m, 2H), 2.92 (t, J = 7.7 Hz, 2H), 2.20 (s, 6H), 2.18 –
2.04 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.8, 146.1 (q, J = 4.1 Hz), 133.7 (q, J = 3.5 Hz), 127.4,
124.5 (q, J = 33.0 Hz), 123.6 (q, J = 272.0 Hz), 122.6, 105.3, 43.0, 35.2, 30.1, 12.5.
FT-IR (ATR, cm-1): ν̃ = 2933, 2575, 1608, 1573, 1395, 1332, 1161, 1128, 1081, 1017, 853, 750.
MS (EI, 70 eV): m/z (%) = 282 (42), 189 (11), 188 (100), 187 (43), 186 (25), 178 (9), 174 (73),
161 (27), 160 (10), 121 (7), 120 (9), 109 (7), 108 (32), 94 (15).
HR-MS (EI, 70 eV): [C15H17F3N2], calcd.: 282.1344; found: 282.1335.
Ethyl 6-(4-acetoxybutyl)nicotinate (14g)
Ph
N
N
N OAc
EtO2C
Following TP11-A using CoCl2 (13 mg, 0.1 mmol, 20 mo%) and bipyridine (31 mg, 0.2 mmol,
40 mol%), ethyl 6- chloronicotinate (12d, 93 mg, 0.50 mmol, 1.0 equiv) was coupled with
(4-acetoxybutyl)zinc bromide (13g, 0.95 mmol, 1.9 equiv) prepared according to TP10 from the
corresponding bromide.
Isolated yield: 87 mg, 0.33 mmol, 66%, colorless oil.
Purification: i-hexane:ethyl acetate = 1:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.13 (dd, J = 2.3, 0.9 Hz, 1H), 8.20 (dd, J = 8.1, 2.2 Hz,
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1H), 7.25 – 7.20 (m, 1H), 4.40 (q, J = 7.1 Hz, 2H), 4.08 (t, J = 6.5 Hz, 2H), 2.96 – 2.83 (m, 2H),
2.03 (s, 3H), 1.89 – 1.77 (m, 2H), 1.76 – 1.63 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.3, 166.3, 165.6, 150.7, 137.6, 124.1, 122.5, 64.3,
6.4, 38.1, 28.4, 26.1, 21.2, 14.4.
FT-IR (ATR, cm-1): ν̃ = 2955, 1718, 1598, 1568, 1464, 1385, 1366, 1278, 1234, 1173, 1112,
1026, 855, 763.
MS (EI, 70 eV): m/z (%) = 206 (33), 192 (23), 178 (100), 165 (72), 164 (45), 150 (40), 137 (87).
HR-MS (EI, 70 eV): [C14H20NO4], calcd.: 266.1387; found: 266.1383 [M
++H].
Ethyl 6-(2-((1R,4R)-5,5-dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)nicotinate (14h)
N
EtO2C Me Me
Following TP11-A ethyl 6-chloronicotinate (12d, 93 mg, 0.50 mmol, 1.0 equiv) was coupled
with (2-((1R,4R)-5,5- dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (13c, 0.75 mmol,
1.5 equiv) prepared according to TP9 from the corresponding bromide.
Isolated yield: 108 mg, 0.36 mmol, 72%, yellow oil.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.12 (dd, J = 2.3, 0.8 Hz, 1H), 8.22 (dd, J = 8.1, 2.2 Hz,
1H), 7.29 – 7.22 (m, 1H), 5.23 (tt, J = 3.0, 1.5 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.99 – 2.89 (m,
2H), 2.45 – 2.30 (m, 3H), 2.28 – 2.10 (m, 2H), 2.10 – 2.01 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.26
(s, 3H), 1.11 (d, J = 8.5 Hz, 1H), 0.80 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.4, 165.4, 150.0, 147.1, 138.0, 124.2, 122.8, 117.0,
61.5, 45.8, 40.9, 38.1, 36.7, 36.2, 31.7, 31.4, 26.4, 21.3, 14.4.
FT-IR (ATR, cm-1): ν̃ = 2982, 2913, 2831, 1678, 1619, 1600, 1563, 1504, 1468, 1427, 1381,
1364, 1312, 1319, 1264, 1220, 1140, 1115, 1082, 1016, 954, 886, 869, 824, 782, 753.
MS (EI, 70 eV): m/z (%) = 299 (10), 298 (10), 284 (15), 270 (20), 258 (13), 256 (31), 231 (13),
230 (100), 228 (36), 216 (15), 204 (12), 203 (11), 202 (84), 188 (13), 174 (11), 165 (60), 150 (10),
137 (62), 91 (12).
HR-MS (EI, 70 eV): [C19H25NO2], 299.1885; found: 299.1885.
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Optical rotation: [α]ϕλ = - 23 (c = 1.35 CHCl3).
Ethyl (S)-6-(3,7-dimethyloct-6-en-1-yl)nicotinate (14i)
N
EtO2C
Me
MeMe
Following TP11-A ethyl 6-chloronicotinate (12d, 93 mg, 0.50 mmol, 1.0 equiv) was coupled with
(S)-(3,7-dimethyloct-6- en-1-yl)zinc chloride (12w, 0.75 mmol, 1.5 equiv) prepared according to
TP9 from the corresponding bromide.
Isolated yield: 120 mg, 0.42 mmol, 83%, colorless oil.
Purification: i-hexane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.18 – 9.04 (m, 1H), 8.18 (dd, J = 8.1, 2.1 Hz, 1H), 7.22
(d, J = 8.1 Hz, 1H), 5.15 – 5.01 (m, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.85 (qdd, J = 13.8, 10.1, 5.6 Hz,
2H), 2.10 – 1.84 (m, 2H), 1.74 (ddq, J = 15.2, 9.6, 5.0, 4.5 Hz, 1H), 1.67 (s, 3H), 1.58 (s, 3H),
1.56 – 1.44 (m, 1H), 1.39 (t, J = 7.1 Hz, 4H), 1.44 – 1.33 (m, 1H), 1.19 (m, 1H), 0.95 (d, J = 6.3
Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 167.5, 165.6, 150.6, 137.5, 131.4, 124.9, 123.9, 122.4,
61.4, 37.1, 37.0, 36.3, 32.5, 25.9, 25.6, 19.6, 17.8, 14.4.
FT-IR (ATR, cm-1): ν̃ = 2961, 1719, 1598, 1568, 1462, 1380, 1368, 1276, 1173, 1112, 1027, 972,
856, 773, 736.
MS (EI, 70 eV): m/z (%) = 260 (4), 246 (31), 206 (7), 178 (37), 165 (100), 150 (17), 137 (40).
HR-MS (EI, 70 eV): [C16H22NO2], 260.1651; found: 260.1647 [M
+-Et].
Optical rotation: [α]ϕλ = 5 (c = 0.75 CHCl3).
Ethyl 2-(2-(thiophen-3-yl)ethyl)nicotinate (14j)
Ph
N
N
N
S
CO2Et
Following TP11-A ethyl 2-chloronicotinate (12e, 93 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-(thiophen-3- yl)ethyl)zinc chloride (12x, 0.75 mmol, 1.5 equiv) prepared according to TP9 from
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the corresponding bromide.
Isolated yield: 111 mg, 0.42 mmol, 85%, pale yellow oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (dd, J = 4.9, 1.8 Hz, 1H), 8.27 – 8.18 (m, 1H), 7.32 –
7.27 (m, 1H), 7.24 (dd, J = 4.9, 2.9 Hz, 1H), 7.04 – 6.95 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.57 –
3.46 (m, 2H), 3.14 – 3.04 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 165.9, 161.7, 150.6, 141.6, 139.8, 128.4, 126.4, 125.3,
121.5, 120.7, 61.7, 30.4, 27.1, 14.3.
FT-IR (ATR, cm-1): ν̃ = 2982, 2118, 1714.2, 1587, 1568, 1439, 1389, 1366, 1277, 1249, 1198,
1171, 1125, 1080, 1062, 1018, 934, 858, 840, 828, 779, 741, 686, 664.
MS (EI, 70 eV): m/z (%) = 262 (12), 261 (62), 233 (18), 232 (100), 215 (14), 213 (23), 187 (18),
186 (2), 97 (92), 79 (15), 57 (13), 53 (23), 45 (16), 43 (17).
HR-MS (EI, 70 eV): [C12H10NO2S], 232.0423; found: 232.0414 [M
+-Et].
Methyl 2-(4-(trimethylsilyl)but-3-yn-1-yl)nicotinate (14k)
Ph
N
N
N
CO2Me
TMS
Following TP11-A methyl 2-chloronicotinate (12y, 93 mg, 0.50 mmol, 1.0 equiv) was coupled with
with (4- (trimethylsilyl)but-3-yn-1-yl)zinc chloride (13d, 0.75 mmol, 1.5 equiv) prepared according
to TP9 from the corresponding bromide.
Isolated yield: 108 mg, 0.41 mmol, 83%, yellow oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.69 – 8.62 (m, 1H), 8.23 – 8.13 (m, 1H), 7.25 – 7.22 (m,
1H), 3.93 (s, 3H), 3.44 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 0.10 (d, J = 1.0 Hz, 9H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 167.0, 161.2, 152.0, 138.6, 125.7, 121.3, 106.6, 85.0,
52.5, 35.6, 19.8, 0.2.
FT-IR (ATR, cm-1): ν̃ = 2955, 2175, 1726, 1584, 1569, 1431, 1279, 1248, 1190, 1132, 1082,
1066, 1042, 1000, 964, 886, 838, 758, 698, 664.
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MS (EI, 70 eV): m/z (%) = 261 (13), 260 (100), 246 (63), 216 (19), 214 (15), 188 (74), 186 (11),
156 (11), 142 (18).
HR-MS (EI, 70 eV): [C14H19NO2Si], 261.1185; found: 261.1138.
2-(2-(1,3-Dioxan-2-yl)ethyl)quinoline (14l)
Ph
N
N
N
O
O
Following TP11-A 2-bromoquinoline (12h, 104 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-(1,3-dioxan-2-yl)ethyl)zinc chloride (13a, 0.75 mmol, 1.5 equiv) prepared according to TP9
from the corresponding bromide.
Isolated yield: 115 mg, 0.47 mmol, 95%, colorless crystals.
Purification: i-hexane:ethyl acetate = 7:3.
m.p.: 54.8 – 56.7 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.03 (dd, J = 8.5, 1.8 Hz, 2H), 7.79 – 7.73 (m, 1H), 7.70 –
7.61 (m, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 4.59 (t, J = 5.2 Hz, 1H), 4.10 (dd,
J = 11.4, 4.9 Hz, 2H), 3.73 (td, J = 12.4, 2.5 Hz, 2H), 3.14 – 3.00 (m, 2H), 2.23 – 1.98 (m, 3H),
1.31 (ddt, J = 13.6, 3.1, 1.5 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.0, 148.0, 136.3, 129.4, 129.0, 127.5, 126.8, 125.8,
121.6, 101.6, 67.0, 34.8, 33.5, 25.9.
FT-IR (ATR, cm-1): ν̃ = 2971, 2922, 2856, 1732, 1618, 1601, 1563, 1505, 1469, 1444, 1426,
1407, 1380, 1292, 1247, 1213, 1198, 1144, 1082, 1055, 1044, 998, 964, 942, 922, 905, 886, 850,
822, 788, 766, 741.
MS (EI, 70 eV): m/z (%) = 242 (2), 158 (12), 156 (51), 144 (11), 143 (100), 128 (12).
HR-MS (EI, 70 eV): [C15H16NO2], 242.1187; found: 242.1175 [M
+-H].
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2-(3-(2,5-Dimethyl-1H-pyrrol-1-yl)propyl)quinoline (14n)
Ph
N
N
N
N
Me
Me
Following TP11-A 2-bromoquinoline (12h, 104 mg, 0.50 mmol, 1.0 equiv) or 2-chloroquinoline
(12i, 82 mg, 0.50 mmol, 1.0 equiv) were coupled with (3-(2,5-dimethyl-1H-pyrrol-1-yl)propyl)zinc
chloride (13f, 0.75 mmol, 1.5 equiv) prepared according to TP9 from the corresponding bromide.
Isolated yield: using 2-bromoquinoline 112 mg, 0.42 mmol, 85%, yellow oil, using
2-chloroquinoline 108 mg, 0.41 mmol, 82%, yellow oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.10 (t, J = 10.2 Hz, 2H), 7.81 (d, J = 8.1 Hz, 1H), 7.72 (t,
J = 7.7 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 5.76 (s, 2H), 3.93 – 3.81 (m,
2H), 3.06 (t, J = 7.6 Hz, 2H), 2.22 (s, 8H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.1, 136.8, 129.8, 128.5, 127.6, 127.4, 126.8, 126.1,
121.2, 121.2, 105.1, 43.2, 35.9, 30.3, 12.5.
FT-IR (ATR, cm-1): ν̃ = 2932, 1619, 1600, 152, 1518, 1503, 1426, 1407, 1370, 1298, 1140, 1115,
1017, 974, 873, 826, 781, 743.
MS (EI, 70 eV): m/z (%) = 264 (5), 170 (24), 169 (19), 168 (13), 157 (12), 156 (100), 143 (54),
128 (12).
HR-MS (EI, 70 eV): [C18H20N2], calcd.: 264.1626; found: 264.1620.
2-(2-((1R,4R)-5,5-Dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)quinoline (14m)
N
Me Me
Following TP11-A 2-bromoquinoline (12h, 104 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-((1R,4R)-5,5- dimethylbicyclo[2.1.1]hex-2-en-2-yl)ethyl)zinc chloride (13c, 0.75 mmol,
1.5 equiv) prepared according to TP9 from the corresponding bromide.
Isolated yield: 103 mg, 0.37 mmol, 75%, yellow oil.
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Purification: i-hexane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.09 (d, J = 8.4 Hz, 2H), 7.78 (dd, J = 8.2, 1.4 Hz, 1H),
7.69 (ddd, J = 8.3, 6.9, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H),
5.29 (tt, J = 3.0, 1.5 Hz, 1H), 3.13 – 3.00 (m, 2H), 2.47 (ddq, J = 10.0, 6.4, 1.8 Hz, 2H), 2.38 (dt,
J = 8.5, 5.6 Hz, 1H), 2.29 – 2.18 (m, 2H), 2.15 (td, J = 5.6, 1.5 Hz, 1H), 2.08 (ttd, J = 5.8, 2.8, 1.2
Hz, 1H), 1.28 (s, 3H), 1.16 (d, J = 8.5 Hz, 1H), 0.84 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 162.7, 147.5, 136.9, 129.8, 128.5, 127.6, 126.9, 126.1,
126.1, 121.5, 116.8, 45.9, 40.9, 38.2, 37.0, 37.0, 31.8, 31.4, 26.4, 21.4.
FT-IR (ATR, cm-1): ν̃ = 2914.5, 1601.4, 1503.9, 1427.4, 1364.6, 1219.8, 904.6, 830.1, 731.6.
MS (EI, 70 eV): m/z (%) = 277 (5), 276 (9), 262 (5), 236 (8), 234 (18), 209 (15), 208 (97), 206 (8)
194 (13), 193 (8), 180 (15), 167 (8), 156 (12), 144 (11), 143 (100), 142 (6), 128 (8).
HR-MS (EI, 70 eV): [C20H22N], 276.1752; found: 276.1748.
Optical rotation: [α]ϕλ = - 37 (c = 1.36 CHCl3).
4-(4-Methylquinolin-2-yl)butanenitrile (14o)
Ph
N
N
N
CN
Me
Following TP11-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (12j , 31 mg,
0.2 mmol, 40 mol%), 2-chloro-4-methylquinoline (89 mg, 0.50 mmol, 1.0 equiv) was coupled with
(3-cyanopro-pyl)zinc bromide (13e, 0.9 mmol, 1.9 equiv) prepared according to TP10 from the
corresponding bromide.
Isolated yield: 73 mg, 0.35 mmol, 70%, brown oil.
Purification: i-hexane:ethyl acetate = 7:3.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.07 – 8.00 (m, 1H), 7.97 (dd, J = 8.4, 1.4 Hz, 1H), 7.70
(ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.53 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.15 (d, J = 1.2 Hz, 1H), 3.08
(t, J = 7.4 Hz, 2H), 2.69 (d, J = 0.9 Hz, 3H), 2.48 (t, J = 7.2 Hz, 2H), 2.32 – 2.15 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.7, 147.8, 145.1, 129.5, 129.5, 127.1, 126.0, 123.8,
122.3, 119.81, 37.1, 25.0, 18.9, 16.9.
FT-IR (ATR, cm-1): ν̃ = 2931, 2246, 1602, 1562, 1508, 1448, 1412, 1380, 1346, 1159, 1123,
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1026, 953, 878, 865, 757.
MS (EI, 70 eV): m/z (%) = 210 (3), 170 (24), 158 (12), 157 (100), 156 (10), 142 (7), 115 (18).
HR-MS (EI, 70 eV): [C14H14N2], calcd.: 210.1157; found: 210.1151.
4-(6-Chloroquinolin-2-yl)butyl acetate (14p)
Ph
N
N
N
Cl
OAc
Following TP11-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol,
40 mol%), 2,6- dichloroquinoline (12k, 99 mg, 0.50 mmol, 1.0 equiv) was coupled with
(4-acetoxy-butyl)zinc bromide (13g, 0.95 mmol, 1.9 equiv) prepared according to TP10 from the
corresponding bromide.
Isolated yield: 81 mg, 0.29 mmol, 58%, yellow oil.
Purification: i-hexane:ethyl acetate = 7:3 to 6:4.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 (t, J = 8.5 Hz, 2H), 7.75 (d, J = 2.4 Hz, 1H), 7.61 (dd,
J = 9.0, 2.4 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 4.10 (t, J = 6.5 Hz, 2H), 3.08 – 2.91 (m, 2H), 2.03 (s,
3H), 1.96 – 1.82 (m, 2H), 1.80 – 1.66 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.3, 162.7, 146.3, 135.6, 131.6, 130.5, 130.4, 127.4,
126.3, 122.3, 64.4, 38.7, 28.5, 26.3, 2.1.
FT-IR (ATR, cm-1): ν̃ = 2933, 1733, 1599, 1558, 1490, 1462, 1388, 1365, 1303, 1237, 1188,
1118, 1073, 1039, 959, 921, 876, 831, 745, 717, 683.
MS (EI, 70 eV): m/z (%) = 234 (9), 220 (11), 218 (33), 204 (19), 192 (13), 190 (40), 179 (33), 178
(11), 177 (100), 176 (13), 142 (13), 150 (12).
HR-MS (EI, 70 eV): [C13H13ClN], 218.0737; found: 218.0730 [M
+-OAc].
1-(2-(thiophen-3-yl)ethyl)isoquinoline (14q)
Ph
N
N
N S
Following TP11-A 1-bromoisoquinoline (12l, 104 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-(thiophen-3-yl)ethyl)zinc chloride (13i, 0.75 mmol, 1.5 equiv) prepared according to TP9 from
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the corresponding bromide.
Isolated yield: 73 mg, 0.31 mmol, 61%, brown oil.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.46 (d, J = 5.9 Hz, 1H), 8.20 – 8.11 (m, 1H), 7.92 – 7.84
(m, 1H), 7.78 – 7.70 (m, 1H), 7.64 (dddd, J = 9.9, 8.4, 5.0, 2.7 Hz, 2H), 7.29 – 7.23 (m, 1H), 7.07
– 7.01 (m, 2H), 3.76 – 3.65 (m, 2H), 3.30 – 3.20 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.9, 136.8, 131.2, 128.4, 128.0, 128.0, 127.7, 127.0,
125.8, 125.8, 125.6, 120.9, 120.4, 35.6, 30.2.
FT-IR (ATR, cm-1): ν̃ = 3050, 2922, 2854, 1622, 1586, 1562, 1536, 1502, 1444, 1410, 1386,
1357, 1239, 1199, 1140, 1080, 1020, 979, 867, 822, 798, 774, 737, 684
MS (EI, 70 eV): m/z (%) = 241 (5), 240 (18), 239 (100), 238 (70), 224 (20), 223 (8), 206 (14), 204
(9), 156 (17), 129 (30), 114 (18), 97 (25).
HR-MS (EI, 70 eV): [C15H13NS], calcd.: 239.0769; found: 239.0770.
4-(But-3-en-1-yl)-6,7-dimethoxyquinazoline (14r)
Ph
N
N
N
N
MeO
MeO
Following TP11-A 4-chloro-6,7-dimethoxyquinazoline (12m, 112 mg, 0.50 mmol, 1.0 equiv) was
coupled with but-3-en-1-ylzinc chloride (13j, 0.75 mmol, 1.5 equiv) prepared according to TP9
from the corresponding bromide.
Isolated yield: 73 mg, 0.30 mmol, 60%, green solid.
Purification: i-hexane:ethyl acetate = 6:4.
m.p.: 66.9 – 69.1 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.02 (s, 1H), 7.45 (s, 1H), 7.21 (s, 1H), 5.88 (ddt, J = 16.9,
10.2, 6.7 Hz, 1H), 5.10 – 4.90 (m, 1H), 4.02 (d, J = 13.4 Hz, 6H), 3.38 – 3.25 (m, 2H), 2.64 (tdt,
J = 7.9, 6.6, 1.4 Hz, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 167.3, 156.2, 152.6, 150.6, 147.6, 137.3, 119.7, 115.9,
107.0, 101.9, 56.7, 56.4, 33.8, 32.5.
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FT-IR (ATR, cm-1): ν̃ = 3079, 2923, 1639, 1613, 1579, 1554, 1501, 1464, 1452, 1427, 1363,
1307, 1280, 1264, 1230, 1207, 1190, 1173, 1126, 1014, 995, 972, 890, 852, 828, 788, 760.
MS (EI, 70 eV): m/z (%) = 244 (61), 243 (89), 230 (13), 229 (100), 228 (10), 227 (10), 213 (12),
201 (13), 199 (11), 198 (11), 197 (16), 185 (16).
HR-MS (EI, 70 eV): [C14H16N2O2], calcd.: 244.1212; found: 244.1209.
2-(2-(Thiophen-3-yl)ethyl)pyrimidine (14s)
Ph
N
N
N
N
S
Following TP11-A 2-bromopyrimidine (12n, 80 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-(thiophen-3-yl)ethyl)zinc chloride (13i 0.75 mmol, 1.5 equiv) prepared according to TP9 from
the corresponding bromide.
Isolated yield: 65 mg, 0.34 mmol, 70%, yellow oil.
Purification:i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.69 (d, J = 4.9 Hz, 2H), 7.24 (dd, J = 4.6, 3.3 Hz, 1H),
7.16 (t, J = 4.9 Hz, 1H), 7.01 – 6.95 (m, 2H), 3.37 – 3.26 (m, 2H), 3.20 (ddd, J = 8.3, 6.2, 1.1 Hz,
2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.1, 157.1, 141.4, 128.3, 125.6, 120.8, 118.9, 39.9,
29.0.
FT-IR (ATR, cm-1): ν̃ = 1566, 1426, 1232, 907, 797, 731.
MS (EI, 70 eV): m/z (%) = 191 (11), 190 (100), 189 (36), 175 (12), 157 (16), 145 (7), 107 (9), 98
(5), 97 (94), 84 (12), 80 (10), 53 (6), 45 (11).
HR-MS (EI, 70 eV): [C10H10N2S], calcd.: 190.0565; found: 190.559.
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4-(2-(1,3-Dioxan-2-yl)ethyl)-2-fluorobenzonitrile (14t)
Ph
N
N
F
O
O
NC
Following TP11-A 4-bromo-2-fluorobenzonitrile (12o, 100 mg, 0.50 mmol, 1.0 quiv) was coupled
with (2-(1,3-dioxan-2- yl)ethyl)zinc chloride (13a, 0.75 mmol, 1.5 equiv) prepared according to
TP9 from the corresponding bromide.
Isolated yield: 77 mg, 0.33 mmol, 66%, colorless oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.51 (dd, J = 7.9, 6.7 Hz, 1H), 7.11 – 7.00 (m, 2H), 4.50 (t,
J = 5.0 Hz, 1H), 4.10 (ddt, J = 10.6, 5.1, 1.4 Hz, 2H), 3.79 – 3.67 (m, 2H), 2.83 – 2.72 (m, 2H),
2.07 (dtt, J = 13.6, 12.5, 5.0 Hz, 1H), 1.96 – 1.82 (m, 2H), 1.35 (dtt, J = 13.6, 2.7, 1.4 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 163.3 (d, J = 258.6 Hz), 151.0 (d, J = 7.7 Hz), 133.4,
125.1 (d, J = 3.2 Hz), 116.5 (d, J = 19.0 Hz), 114.4, 100.8 , 98.9 (d, J = 15.5 Hz), 67.0 , 35.8 ,
30.2, 30.2, 25.8.
FT-IR (ATR, cm-1): ν̃ = 2965, 2936, 2863, 2232, 1980, 162, 1569, 1502, 1458, 1430, 1404, 1377,
1283, 1270, 1260, 1248, 1236, 1220, 1190, 1145, 1129, 1113, 1081, 1046, 995, 962, 942, 925,
890, 850, 826, 7750, 744, 729.
MS (EI, 70 eV): m/z (%) = 235 (2), 234 (18), 176 (20), 148 (51), 135 (35), 134 (37), 114 813),
107 (11), 87 (100).
HR-MS (EI, 70 eV): [C13H14FNO2], calcd.: 235.1009; found: 235.1003.
(2-(2-(1,3-Dioxan-2-yl)ethyl)phenyl)(phenyl)methanone (14x)
Ph
N
N
O
O
O
Following TP11-A (2-chlorophenyl)(phenyl)methanone (12q, 108 mg, 0.50 mmol, 1.0 equiv)
was coupled with (2-(1,3- dioxan-2-yl)ethyl)zinc chloride (13a, 0.75 mmol, 1.5 equiv) prepared
according to TP9 from the corresponding bromide.
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Isolated yield: 104 mg, 0.35 mmol, 70%, colorless oil.
Purification: i-hexane:ethyl acetate = 8:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.75 (m, 2H), 7.61 – 7.54 (m, 1H), 7.48 – 7.39 (m,
3H), 7.35 (d, J = 7.7 Hz, 1H), 7.31 – 7.20 (m, 2H), 4.42 (t, J = 5.3 Hz, 1H), 4.11 – 3.97 (m, 2H),
3.67 (td, J = 12.4, 2.5 Hz, 2H), 2.83 – 2.69 (m, 2H), 2.03 (qt, J = 12.8, 5.0 Hz, 1H), 1.93 – 1.79 (m,
2H), 1.40 – 1.21 (m, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 198.4, 140.9, 138.5, 137.8, 133.1, 130.4, 130.2, 128.7,
128.4, 125.3, 101.39, 66.8, 36.7, 27.6, 25.8.
FT-IR (ATR, cm-1): ν̃ = 2961, 2850, 1661, 1597, 1580, 1484, 1448, 1403, 1378, 1314, 1265,
1239, 1196, 1178, 1145, 1132, 1104, 1078, 1048, 1028, 999, 970, 927, 886, 851, 801, 762, 700.
MS (EI, 70 eV): m/z (%) = 296 (2), 278 (1), 237 (2), 221 (1), 220 (4).
HR-MS (EI, 70 eV): [C19H20O3], 296.1412; found: 296.1409.
(4-(2-(1,3-Dioxan-2-yl)ethyl)phenyl)(phenyl)methanone (14v)
Ph
N
N
O
O
O
Following TP11-A (4-bromophenyl)(phenyl)methanone (12r,131 mg, 0.50 mmol, 1.0 equiv)
was coupled with (2-(1,3- dioxan-2-yl)ethyl)zinc chloride (13a, 0.75 mmol, 1.5 equiv) prepared
according to TP9 from the corresponding bromide.
Isolated yield: 126 mg, 0.43 mmol, 85%, colorless crystals.
Purification: i-hexane:ethyl acetate = 8:2.
m.p.: 68.6 – 70.5 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.81 – 7.77 (m, 2H), 7.74 (d, J = 7.9 Hz, 2H), 7.58 (td,
J = 7.4, 1.6 Hz, 1H), 7.52 – 7.41 (m, 2H), 7.30 (d, J = 8.0 Hz, 2H), 4.53 (t, J = 5.1 Hz, 1H), 4.19 –
4.06 (m, 2H), 3.85 – 3.68 (m, 2H), 2.81 (dd, J = 9.3, 6.8 Hz, 2H), 2.20 – 2.01 (m, 1H), 2.01 – 1.86
(m, 2H), 1.35 (dq, J = 13.7, 1.9 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.6, 147.1, 138.0, 135.4, 132.3, 130.5, 130.1, 128.5,
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128.3, 101.3, 67.0, 36.4, 30.3, 25.9.
FT-IR (ATR, cm-1): ν̃ = 2914, 2846, 2048, 1981, 1646, 1603, 1576, 1443, 1415, 1404, 1382,
1317, 1306, 1278, 1238, 1186, 1143, 1131, 1077, 1040, 1000, 970, 940, 920, 886, 856, 786, 745,
699, 666.
MS (EI, 70 eV): m/z (%) = 296 (14), 237 (27), 220 (16), 167 (16), 161 (14), 114 (100), 105 (44),
87 (95), 77 (15).
HR-MS (EI, 70 eV): [C19H20O3], calcd.: 296.1412; found: 296.1407.
Ethyl 4-(2-(4-fluorobenzoyl)phenyl)butanoate (14w)
Ph
N
N
O
CO2Et
F
Following TP11-A using CoCl2 (13 mg, 0.1 mmol, 20 mol%) and bipyridine (31 mg, 0.2 mmol,
40 mol%), (2- chlorophenyl)(4-fluorophenyl)methanone (12s, 117 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-ethoxy-4- oxobutyl)zinc bromide (13u,0.95 mmol, 1.9 equiv) prepared according
to TP10 from the corresponding bromide.
Isolated yield: 115 mg, 0.37 mmol, 73%, pale yellow oil.
Purification: i-hexane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.83 – 7.68 (m, 2H), 7.35 (dt, J = 7.7, 4.2 Hz, 1H), 7.26 (d,
J = 7.5 Hz, 1H), 7.23 – 7.15 (m, 2H), 7.10 – 6.98 (m, 2H), 3.99 (q, J = 7.1 Hz, 2H), 2.69 – 2.47 (m,
2H), 2.18 (t, J = 7.4 Hz, 2H), 1.89 – 1.69 (m, 2H), 1.13 (t, J = 7.1 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.99, 173.42, 165.98 (d, J = 255.4 Hz), 140.66, 138.32,
134.25 (d, J = 2.9 Hz), 132.97 (d, J = 9.3 Hz), 130.51 (d, J = 7.9 Hz), 128.59, 125.66, 115.87,
115.65, 60.41, 33.92, 32.55, 26.86, 14.34.
FT-IR (ATR, cm-1): ν̃ = 2981, 1729, 1663, 1596, 1504, 1485, 1446, 1410, 1374, 1262, 1227,
1195, 1147, 1096, 1035, 930, 852, 810, 750, 688.
MS (EI, 70 eV): m/z (%) = 227 (25), 225 (249, 213 (32), 212 (100), 209 (10), 183 (15), 123 (23).
HR-MS (EI, 70 eV): [C19H19NO3], calcd.: 314.1318; found: 314.1314.
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(4-Cyclopropylphenyl)(phenyl)methanone (14y)
Ph
N
N
Ph
O
Following TP11-B (4-bromophenyl)(phenyl)methanone (12r, 131 mg, 0.50 mmol, 1.0 equiv) was
coupled with cyclopropylzinc chloride (13l, 0.75 mmol, 1.5 equiv) in THF prepared according to
TP9 from the corresponding bromide.
Isolated yield: 74 mg, 0.33 mmol, 67%, pale yellow oil.
Purification: i-hexane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.82 – 7.74 (m, 2H), 7.74 – 7.67 (m, 2H), 7.60 – 7.51 (m,
1H), 7.51 – 7.42 (m, 2H), 7.18 – 7.10 (m, 2H), 1.97 (tt, J = 8.3, 5.0 Hz, 1H), 1.12 – 1.02 (m, 2H),
0.84 – 0.74 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.4, 149.9, 138.1, 134.8, 132.2, 130.5, 130.0, 128.3,
125.3, 15.8, 10.5.
FT-IR (ATR, cm-1): ν̃ = 3002, 2194, 1928, 1646, 1603, 1578, 1447, 1417, 1317, 1278, 1227,
1188, 1176, 1150, 1109, 1072, 1049, 1024, 1000, 971, 958, 971, 937, 922, 893, 840, 817, 791,
758, 741, 700, 675.
MS (EI, 70 eV): m/z (%) = 223 (18), 222 (69), 146 (10), 145 (100), 117 (9), 116 (8), 115 (28), 105
(49), 91 (12), 76 (33), 57 (6), 43 (10).
HR-MS (EI, 70 eV): [C16H14O], calcd.: 222.1045; found: 222.1035.
(4-Chlorophenyl)(2-cyclopropylphenyl)methanone (14z)
O
Following TP11-B (2-chlorophenyl)(4-chlorophenyl)methanone (12q, 126 mg, 0.50 mmol,
1.0 equiv) was coupled with cyclopropylzinc chloride (13l, 0.75 mmol, 1.5 equiv) in THF prepared
according to TP9 from the corresponding bromide.
Isolated yield: 85 mg, 0.34 mmol, 68%, pale yellow oil.
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Purification: i-hexane:ethyl acetate = 98:2.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.78 – 7.67 (m, 2H), 7.42 – 7.26 (m, 3H), 7.23 – 7.08 (m,
2H), 6.97 (dd, J = 7.9, 1.0 Hz, 1H), 1.81 (tt, J = 8.5, 5.2 Hz, 1H), 0.79 – 0.67 (m, 2H), 0.62 – 0.49
(m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 197.8, 142.1, 139.8, 139.4, 136.3, 131.6, 130.6, 128.9,
127.9, 125.4, 125.4, 13.8, 9.2.
FT-IR (ATR, cm-1): ν̃ = 3067, 3004, 1924, 1664, 1584, 1571, 1484, 1457, 1445, 1399, 1300,
1257, 1221, 1174, 1151, 1030, 1013, 951, 929, 897845, 822, 778, 752, 682, 656.
MS (EI, 70 eV): m/z (%) = 241 (10), 230 (32), 229 (15), 228 (100), 193 (41), 178 (8), 165 (23),
115 (12).
HR-MS (EI, 70 eV): [C16H12OCl], calcd.: 255.0571; found: 255.0570 [M
+-H].
6-(3-Methylcyclohexyl)nicotinonitrile (14aa)
Ph
N
N
N
CN
Me
Following TP11-B 6-bromonicotinonitrile (12b, 91 mg, 0.50 mmol, 1.0 equiv) was coupled with
(3-methylcyclohexyl)zinc iodide (13m, 0.75 mmol, 1.5 equiv) prepared according to TP10 from the
corresponding iodide.
Isolated yield: 80 mg, 0.40 mmol, 80%, dr = 91:1, colorless oil.
Purification: pentane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.79 (dd,J = 2.3, 0.9 Hz, 1H), 7.86 (dd, J = 8.2, 2.2 Hz,
1H), 7.29 – 7.24 (m, 1H), 2.80 (tt, J = 12.0, 3.4 Hz, 1H), 1.98 – 1.79 (m, 3H), 1.75 (ddt, J = 12.9,
3.4, 1.8 Hz, 1H), 1.67 – 1.48 (m, 1H), 1.43 (tdd, J = 9.6, 4.8, 2.9 Hz, 2H), 1.28 – 1.11 (m, 1H),
0.94 (d, J = 6.5 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 170.9, 152.1, 139.6, 121.4, 117.2, 107.2, 46.9, 41.0, 34.6,
32.8, 32.2, 26.2, 22.8.
FT-IR (ATR, cm-1): ν̃ = 2921, 2231, 2009, 1592, 1554, 1456, 1377, 1125, 1023, 839.
MS (EI, 70 eV): m/z (%) = 200 (39), 185 (54), 157 (100), 145 (32), 143 (30), 131 (84), 118 (44).
HR-MS (EI, 70 eV): [C13H16N2], calcd.: 200.1313; found: 200.1305.
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6-(3-Isopropylcyclohexyl)nicotinonitrile (14ab)
Ph
N
N
N
CN
i-Pr
Following TP11-B 6-bromonicotinonitrile (12b, 91 mg, 0.50 mmol, 1.0 equiv) was coupled with
(3-isopropylcyclohexyl)zinc iodide (13n, 0.75 mmol, 1.5 equiv) prepared according to TP10 from
the corresponding iodide.
Isolated yield: 72 mg, 0.32 mmol, 63%, dr = 96:4, colorless crystals.
Purification: pentane:ethyl acetate = 95:5.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.80 (dd, J = 2.2, 0.9 Hz, 1H), 7.86 (dd, J = 8.2, 2.2 Hz,
1H), 7.28 (dd, J = 8.2, 0.9 Hz, 1H), 2.77 (tt, J = 11.6, 3.4 Hz, 1H), 2.01 – 1.86 (m, 3H), 1.77 (ddq,
J = 11.5, 4.9, 1.5 Hz, 1H), 1.56 – 1.36 (m, 3H), 1.31 – 1.19 (m, 2H), 1.02 (dddd, J = 15.0, 12.4,
8.9, 3.7 Hz, 1H), 0.88 (d, J = 3.3 Hz, 3H), 0.87 (d, J = 3.3 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 171.0, 152.0, 139.5, 121.4, 117.1, 107.1, 47.1, 43.9, 35.9,
33.0, 32.4, 29.1, 26.3, 19.8, 19.7.
FT-IR (ATR, cm-1): ν̃ = 2927, 2854, 2231, 1592, 1478, 1462, 1447, 1384, 1368, 1023, 839.
MS (EI, 70 eV): m/z (%) = 228 (4), 185 (100), 157 (23), 145 (36), 143 (18), 131 (42), 118 (23).
HR-MS (EI, 70 eV): [C15H20N2], calcd.: 228.1626; found: 228.1621.
2-(3-Isopropylcyclohexyl)pyrimidine (14ac)
Ph
N
N
N
N
i-Pr
Following TP11-B 2-bromopyrimidine (12n, 80 mg, 0.50 mmol, 1.0 equiv) was coupled with
(3-isopropylcyclohexyl)zinc iodide (13n, 0.75 mmol, 1.5 equiv) prepared according to TP10 from
the corresponding iodide.
Isolated yield: 53 mg, 0.26 mmol, 52%, dr = 94:6 colorless oil.
Purification: pentane:ethyl acetate = 95:5.
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1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 (d, J = 4.9 Hz, 2H), 7.09 (t, J = 4.9 Hz, 1H), 2.88 (tt,
J = 11.9, 3.5 Hz, 1H), 1.98 (dddq, J = 10.8, 5.0, 3.4, 2.0 Hz, 2H), 1.90 (dp, J = 13.2, 3.2 Hz, 1H),
1.73 (dddd, J = 12.8, 4.8, 3.3, 1.6 Hz, 1H), 1.56 (ddd, J = 13.3, 12.2, 3.5 Hz, 1H), 1.51 – 1.44 (m,
1H), 1.44 – 1.37 (m, 1H), 1.37 – 1.30 (m, 1H), 1.30 – 1.21 (m, 1H), 1.03 (tdd, J = 12.6, 11.2,
3.7 Hz, 1H), 0.87 (d, J = 2.2 Hz, 3H), 0.86 (d, J = 2.2 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.9, 157.1, 118.6, 48.0, 44.0, 35.4, 33.1, 32.0, 29.3,
26.4, 19.9, 19.9.
FT-IR (ATR, cm-1): ν̃ = 2928, 2853, 1571, 1558, 1462, 1446, 1422, 1385, 1368, 799, 665.
MS (EI, 70 eV): m/z (%) = 204 (32), 162 (100), 133 (24), 121 (26), 119 (27), 107 (29).
HR-MS (EI, 70 eV): [C13H20N2], calcd.: 204.1626; found: 204.1621.
Ethyl-4-(5-(trifluoromethyl)pyridin-2-yl)cyclohexane-1-carboxylate (14ad)
Ph
N
N
EtO2C
N
CF3
Following TP11-B 2-bromo-5-(trifluoromethyl)pyridine (12c, 113 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4- (ethoxycarbonyl)cyclohexyl)zinc iodide (13o, 0.75 mmol, 1.5 equiv) prepared
according to TP10 from the corresponding iodide.
Isolated yield: 77 mg, 0.26 mmol, 51%, dr = 80:20, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.72 (dq, J = 4.1, 2.5, 1.8 Hz, 1H), 7.77 (dd, J = 8.3,
2.6 Hz, 1H), 7.26 – 7.18 (m, 1H), 4.17 – 4.01 (m, 2H), 2.71 (m, J 1H), 2.37 – 2.23 (m, 1H), 2.23 –
1.88 (m, 4H), 1.87 – 1.61 (m, 1H), 1.60 – 1.48 (m, 3H), 1.21 (td, J = 7.1, 1.8 Hz, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.9, 169.5 (d, J = 1.8 Hz), 146.3 (q, J = 4.1 Hz), 133.7
(q, J = 3.5 Hz)124.5 (q, J = 32.9 Hz), 123.8 (q, J = 272.0 Hz), 121.1, 60.4, 45.7, 42.9, 31.7, 28.9,
14.4.
FT-IR (ATR, cm-1): ν̃ = 2936, 2862, 1728, 1606, 1452, 1393, 1377, 1326, 1161, 1128, 1081,
1041, 1015, 904, 842, 728.
MS (EI, 70 eV): m/z (%) = 301 (14) 228 (100), 200 (48), 198 (30), 186 (30), 174 (53), 161 (259).
HR-MS (EI, 70 eV): [C15H18F3NO2], calcd.: 301.1290; found: 301.1283.
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2-(4-(1H-Pyrrol-1-yl)cyclohexyl)-5-(trifluoromethyl)pyridine (14ae)
Ph
N
N
N
N
CF3
Following TP11-B 2-bromo-5-(trifluoromethyl)pyridine (12c, 113 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4-(1H- pyrrol-1-yl)cyclohexyl)zinc iodide (13p, 0.75 mmol, 1.5 equiv) prepared
according to TP10 from the corresponding iodide.
Isolated yield: 79 mg, 0.27 mmol, 54%, dr = 98:2, colorless crystals.
Purification: pentane:ethyl acetate = 9:1.
m.p.: 130.8 – 132.4 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.88 – 8.76 (m, 1H), 7.87 (dd, J = 8.2, 2.4 Hz, 1H), 7.32
(d, J = 8.2 Hz, 1H), 6.78 (t, J = 2.1 Hz, 2H), 6.18 (t, J = 2.1 Hz, 2H), 4.05 – 3.90 (m, 1H), 2.88 (tt,
J = 11.4, 3.6 Hz, 1H), 2.38 – 2.25 (m, 2H), 2.14 (dt, J = 13.3, 2.7 Hz, 2H), 1.96 – 1.70 (m, 4H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 169.0 (d, J = 1.5 Hz), 146.4 (q, J = 4.1 Hz), 133.8 (q,
J = 3.6 Hz), 123.8 (q, J = 272.0 Hz), 124.6 (q, J = 32.9 Hz), 121.2, 118.6, 107.8, 58.1, 45.5, 34.3,
31.7.
FT-IR (ATR, cm-1): ν̃ = 2940, 2860, 1706, 1605, 1571, 1489, 1452, 1399, 1366, 1325, 1272,
1259, 1243, 1197, 1161, 1128, 1097, 1079, 1013, 957, 907, 813, 766, 722, 674.
MS (EI, 70 eV): m/z (%) = 295 (18), 294 (100), 165 (179, 118 8249, 212 (16), 200 (16), 198 (46),
186 (19), 174 (46), 161 (19).
HR-MS (EI, 70 eV): [C16H17F3N2], calcd.: 294.1344; found: 294.1339.
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2-(4-(Trifluoromethyl)cyclohexyl)pyrimidine (14af)
Ph
N
N
N
N
F3C
Following TP11-B 2-bromopyrimidine (12n, 80 mg, 0.50 mmol, 1.0 equiv) was coupled with (3-
(trifluoromethyl)cyclohexyl)zinc iodide (13q, 0.75 mmol, 1.5 equiv) prepared according to TP10
from the corresponding iodide.
Isolated yield: 84 mg, 0.37 mmol, 73%, dr = 98:2, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.36 – 7.22 (m, 4H), 7.22 – 7.15
(m, 1H), 7.12 (t, J = 4.9 Hz, 1H), 2.97 (tt, J = 12.1, 3.6 Hz, 1H), 2.63 (tt, J = 12.1, 3.5 Hz, 1H),
2.18 (dtd, J = 15.1, 4.6, 4.2, 2.2 Hz, 2H), 2.06 (dtd, J = 15.1, 4.9, 4.2, 2.4 Hz, 2H), 1.95 – 1.73 (m,
2H), 1.73 – 1.53 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.5, 157.1, 147.4, 128.5, 127.0, 126.1, 118.7, 47.2,
43.9, 34.0, 32.2.
FT-IR (ATR, cm-1): ν̃ = 2925, 2867, 1987, 1572, 1561, 1464, 1427, 1382, 1375, 1168, 1024, 960,
832, 798.
MS (EI, 70 eV): m/z (%) = 238 (100), 133 (38), 121 (52), 119 (78), 115 (32), 107 898), 91 (38).
HR-MS (EI, 70 eV): [C16H18N2], calcd.: 238.1470; found: 238.1462.
2-(4-Phenylcyclohexyl)pyrimidine (14ag)
Ph
N
N
Following TP11-B 2-bromopyrimidine (12n, 80 mg, 0.50 mmol, 1.0 equiv) was coupled with
(4-phenylcyclohexyl)zinc iodide (13r, 0.75 mmol, 1.5 equiv) prepared according to TP10 from the
corresponding iodide.
Isolated yield: 80 mg, 0.34 mmol, 67%, dr = 96:4, colorless crystals.
Purification: pentane:ethyl acetate = 9:1.
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m.p.: 117.8 – 119.1 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.36 – 7.22 (m, 4H), 7.22 – 7.15
(m, 1H), 7.12 (t, J = 4.9 Hz, 1H), 2.97 (tt, J = 12.1, 3.6 Hz, 1H), 2.63 (tt, J = 12.1, 3.5 Hz, 1H),
2.18 (dtd, J = 15.1, 4.6, 4.2, 2.2 Hz, 2H), 2.06 (dtd, J = 15.1, 4.9, 4.2, 2.4 Hz, 2H), 1.95 – 1.73 (m,
2H), 1.73 – 1.53 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.5, 157.1, 147.4, 128.5, 127.0, 126.1, 118.7, 47.2,
43.9, 34.0, 32.2.
FT-IR (ATR, cm-1): ν̃ = 2925, 2867, 1987, 1572, 1561, 1464, 1427, 1382, 1375, 1168, 1024, 960,
832, 798.
MS (EI, 70 eV): m/z (%) = 238 (100), 133 (38), 121 (52), 119 (78), 115 (32), 107 898), 91 (38).
HR-MS (EI, 70 eV): [C16H18N2], calcd.: 238.1470; found: 238.1462.
2-(4-(1H-Pyrrol-1-yl)cyclohexyl)-4-(4-chlorophenyl)pyrimidine(14ah)
N
N
N
Cl
Following TP11-B 2-bromo-4-(4-chlorophenyl)pyrimidine (12z, 135 mg, 0.50 mmol, 1.0 equiv)
was coupled with (4-(1H-pyrrol-1-yl)cyclohexyl)zinc iodide (13p, 0.75 mmol, 1.5 equiv) prepared
according to TP10 from the corresponding iodide.
Isolated yield: 108 mg, 0.32 mmol, 64%, dr = 91:9, colorless crystals.
Purification: pentane:ethyl acetate = 8:2.
m.p.: 104.0 – 105.7 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.43 (d, J = 5.2 Hz, 1H), 7.92 – 7.85 (m, 2H), 7.34 – 7.28
(m, 2H), 6.77 (d, J = 5.3 Hz, 1H), 6.73 (t, J = 2.1 Hz, 2H), 6.53 (t, J = 2.1 Hz, 2H), 3.61 (tt, J = 11.9,
3.9 Hz, 1H), 3.05 (tt, J = 12.1, 3.6 Hz, 1H), 2.33 – 2.18 (m, 2H), 2.13 – 1.98 (m, 2H), 1.98 – 1.82
(m, 2H), 1.74 – 1.52 (m, 2H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.2, 162.2, 158.0, 137.2, 135.8, 129.3, 128.7, 118.5,
113.8, 108.3, 58.1, 46.6, 34.4, 31.2.
FT-IR (ATR, cm-1): ν̃ = 2929, 2856, 1706, 1597, 1568, 1545, 1491, 1462, 1436, 1409, 1384,
1315, 1294, 1274, 1259, 1089, 1065, 1013, 962, 907, 822, 801,774, 721.
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MS (EI, 70 eV): m/z (%) = 339 (39), 338 (27), 227 (100), 243 (229), 217 (59), 137 (26), 95 (24),
93 (27), 67 8339, 43 (31), 40 (22).
HR-MS (EI, 70 eV): [C20H20ClN3], calcd.: 337.1346; found: 337.1334.
2-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)
pyrimidine ((14ai)
i-Pr
Me
Me
Me
H
H
H
N
N
i-Pr
Me
Me
H
N
N
Following TP11-B 2-bromopyrimidine (12n, 80 mg, 0.50 mmol, 1.0 equiv) was coupled with
((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)- 2,3,4,7,8,9,10,11,12,
13,14,15,16,17- tetradecahydro-1H-cyclopenta[/kua]phenanthren-3-yl)zinc chloride (13s,
0.75 mmol, 1.5 equiv) prepared according to TP10 from the corresponding chloride.
Isolated yield: 174 mg, 0.39 mmol, 78%, dr = 98:2, colorless crystals.
Purification: pentane:ethyl acetate = 95:5.
m.p.: 125.2 – 127.0 ◦C.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.12 (t, J = 4.9 Hz, 1H), 5.39 (dt,
J = 5.3, 1.9 Hz, 1H), 2.89 (ddt, J = 15.9, 8.8, 4.0 Hz, 1H), 2.66 (tq, J = 13.2, 2.6 Hz, 1H), 2.37 –
2.25 (m, 1H), 2.10 – 1.78 (m, 7H), 1.65 – 1.44 (m, 8H), 1.44 – 1.19 (m, 6H), 1.21 – 0.95 (m, 8H),
0.92 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 1.9 Hz, 3H), 0.86 (d, J = 1.9 Hz, 3H), 0.69 (s, 3H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.1, 157.0, 142.3, 120.5, 118.6, 56.8, 56.2, 50.3, 48.8,
42.3, 39.8, 39.5, 39.4, 37.8, 37.0, 36.2, 35.8, 32.0, 31.9, 28.3, 28.0, 24.3, 23.9, 22.9, 22.6, 21.0,
19.7, 18.7, 11.9.
FT-IR (ATR, cm-1): ν̃ = 2937, 2867, 1572, 1561, 1463, 1427, 1382, 1375, 1333, 1167, 1062,
1024, 960, 833, 797, 670.
MS (EI, 70 eV): m/z (%) = 448 (566), 107 (39), 94 (22), 89 (41), 55 (48), 42 (100), 41 (49).
HR-MS (EI, 70 eV): [C31H48N2], calcd.: 448.3817; found: 448.3820.
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Optical rotation: [α]ϕλ = 104 (c = 0.98 CHCl3).
2-((2S,4R,4aS,6R)-6-Isopropyl-4,4a-dimethyldecahydronaphthalen-2-yl)pyrimidine (14aj)
i-Pr
Me
Me
H
N
N
Following TP11-B 2-bromopyrimidine (12n, 80 mg, 0.5 mmol, 1.0 equiv) was coupled with
((4R,4aS, 6R)-6-isopropyl- 4,4a-dimethyldecahydronaphthalen-2-yl)zinc iodide (13t, 0.75 mmol,
1.5 equiv) prepared according to TP10 from the corresponding iodide.
Isolated yield: 149 mg, 0.26 mmol, 52%, dr = 98:2 colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 (d, J = 4.9 Hz, 2H), 7.09 (t, J = 4.9 Hz, 1H), 3.02 (tt,
J = 11.9, 4.7 Hz, 1H), 1.80 – 1.52 (m, 6H), 1.46 – 1.13 (m, 6H), 0.96 (qd, J = 12.2, 5.1 Hz, 1H),
0.87 – 0.80 (m, 9H), 0.77 (s, 3H), 0.66 (t, J = 12.4 Hz, 1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 174.5, 157.1, 118.5, 47.8, 46.3, 43.3, 42.3, 39.0, 36.5,
36.1, 34.0, 33.3, 30.0, 29.8, 29.0, 20.2, 19.7, 15.2, 11.8.
FT-IR (ATR, cm-1): ν̃ = 2917, 2857, 1571, 1558, 1464, 1422, 1384, 1366, 1119, 963, 890, 780,
668.
MS (EI, 70 eV): m/z (%) = 287 (20), 286 (96), 243 (32), 159 (29), 147 (75), 145 (44), 135 (39),
133 (64), 131 (34), 119 (67), 107 (100), 94 (64).
HR-MS (EI, 70 eV): [C19H30N2], calcd.: 286.2409; found: 286.2404.
Optical rotation: [α]ϕλ = 22 (c = 0.87 CHCl3).
2-(4-Phenylbut-3-yn-1-yl)-1,3-dioxane (14ak)
O
O
Ph
Following TP11-B (bromoethynyl)benzene (24, 91 mg, 0.50 mmol, 1.0 equiv) was coupled with
(2-(1,3-dioxan-2- yl)ethyl)zinc chloride (0.75 mmol, 1.5 equiv) prepared according to TP10 from
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the corresponding bromide.
Isolated yield: 59 mg, 0.28 mmol, 55%, colorless oil.
Purification: pentane:ethyl acetate = 9:1.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.45 – 7.33 (m, 2H), 7.34 – 7.21 (m, 3H), 4.71 (t, J =
5.2 Hz, 1H), 4.12 (ddt, J = 10.5, 5.0, 1.4 Hz, 2H), 3.90 – 3.69 (m, 2H), 2.51 (t, J = 7.3 Hz, 2H),
2.09 (dtt, J = 13.4, 12.4, 5.0 Hz, 1H), 1.89 (td, J = 7.3, 5.2 Hz, 2H), 1.36 (dtt, J = 13.5, 2.7, 1.4 Hz,
1H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 131.7, 128.3, 127.7, 124.0, 101.0, 89.5, 80.8, 67.1, 34.3,
26.0, 14.4.
FT-IR (ATR, cm-1): ν̃ = 2965, 2851, 1598, 1490, 1469, 1442, 1430, 1406, 1379, 1286, 1243,
1218, 1202, 1132, 1085, 1061, 1047, 1007, 971, 960, 936, 922, 882, 789, 755, 691.
MS (EI, 70 eV): m/z (%) = 216 (9), 215 (22), 158 (14), 157 (35), 130 (22), 129 (100), 128 (58),
115 (53).
HR-MS (EI, 70 eV): [C14H16O2], calcd.: 216.1150; found: 216.1148.
Triisopropyl((4-phenylcyclohexyl)ethynyl)silane (14al)
Ph
TIPS
Following TP11-B (bromoethynyl)triisopropylsilane (23, 131 mg, 0.50 mmol, 1.0 equiv) was
coupled with (4- phenylcyclohexyl)zinc iodide (0.75 mmol, 1.5 equiv) prepared according to TP10
from the corresponding iodide.
Isolated yield: 92 mg, 0.27 mmol, 54 %, dr = 99:1 colorless oil.
Purification: pentane.
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.25 – 7.17 (m, 2H), 7.16 – 7.08 (m, 3H), 2.44 (tt, J = 11.6,
3.5 Hz, 1H), 2.26 (tt,J = 11.7, 3.7 Hz, 1H), 2.13 – 1.99 (m, 2H), 1.83 (dt, J = 12.2, 2.5 Hz, 2H),
1.58 – 1.30 (m, 4H), 1.00 (d, J = 5.1 Hz, 21H).
13C-NMR (100 MHz, CDCl3, ppm): δ = 147.3, 128.5, 126.9, 126.2, 113.7, 79.3, 43.7, 33.8, 33.7,
30.5, 18.8, 11.4.
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FT-IR (ATR, cm-1): ν̃ = 2938, 2892, 2863, 2173, 1498, 1463, 1449, 1382, 1298, 1073, 1018, 882,
754, 697, 686, 671, 657.
MS (EI, 70 eV): m/z (%) = 298 (25), 297 (100), 269 (10), 241 (9), 227 (7), 120 (8), 91 (9), 59 (14).
HR-MS (EI, 70 eV): [C23H36Si], calcd.: 340.2586; found: 340.2583.
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2 Single Crystal X-Ray Diffraction Studies
(1-(((trans)-4-(tert-Butyl)cyclohexyl)ethynyl)-4-methoxybenzene (3o)
3o
Empirical formula C19H26O
Formula mass 270.40
T[K] 138(2)
Crystal size [mm] 0.47 x 0.20 x 0.18
Crystal description colorless rod
Crystal system monoclinic
Space group P21/c
a [Ǻ] 9.8412(4)
b [Ǻ] 24.2551(7)
c [Ǻ] 7.2296(3)
α [◦] 90
β [◦] 111.080(4)
γ [◦] 90
V [Ǻ3] 1610.21(11)
Z 4
ρcalcd. [g cm-3] 1.115
µ [mm-1] 0.066
F(000) 592
θ range [◦] 4.14 – 25.68
Index ranges -13 ≤ h ≤ 14
-34 ≤ k ≤ 34
-10 ≤ l ≤ 10
Reflns. collected 17161
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Reflns. obsd. 3640
Reflns. unique 4889
(Rint = 0.0418)
R1, wR2 (2σ data) 0.0459, 0.1071
R1, wR2 (all data) 0.0673, 0.1197
GOOF on F2 1.039
Peak/hole [e Ǻ-3] 0.275 / -0.173
(3β)-3-(trimethylsilyl(ethynyl))cholest-5-ene (3x)
3x
Empirical formula C32H54Si
Formula mass 466.84
T[K] 143(2)
Crystal size [mm] 0.49 x 0.20 x 0.09
Crystal description colorless rod
Crystal system monoclinic
Space group P21
a [Ǻ] 14.7063(6)
b [Ǻ] 6.1180(2)
c [Ǻ] 17.3324(6)
α [◦] 90
β [◦] 103.688(4)
γ [◦] 90
V [Ǻ3] 1515.16(10)
Z 2
ρcalcd. [g cm-3] 1.023
µ [mm-1] 0.094
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F(000) 520
θ range [◦] 4.16 – 25.24
Index ranges -21 ≤ h ≤ 21
-8 ≤ k ≤ 8
-24 ≤ l ≤ 24
Reflns. collected 16324
Reflns. obsd. 6106
Reflns. unique 8150
(Rint = 0.0418)
R1, wR2 (2σ data) 0.0531, 0.1084
R1, wR2 (all data) 0.0806, 0.1236
GOOF on F2 1.018
Peak/hole [e Ǻ-3] 0.350 / -0.179
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2-(4-(1H-Pyrrol-1-yl)cyclohexyl)-5-(trifluoromethyl)pyridine (14ae)
14ae
Empirical formula C16H17F3N2
Formula mass 294.32
T[K] 132(2)
Crystal size [mm] 0.25 x 0.20 x 0.03
Crystal description colorless block
Crystal system triclinic
Space group P-1
a [Ǻ] 9.3100(9)
b [Ǻ] 9.3232(11)
c [Ǻ] 9.3565(9)
α [◦] 66.006(10)
β [◦] 72.336(9)
γ [◦] 76.892(9)
V [Ǻ3] 701.97(14)
Z 2
ρcalcd. [g cm-3] 1.392
µ [mm-1] 0.111
F(000) 308
θ range [◦] 2.31 – 25.24
Index ranges -11 ≤ h ≤ 11
-11 ≤ k ≤ 11
-11 ≤ l ≤ 10
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Reflns. collected 4530
Reflns. obsd. 1669
Reflns. unique 2670
(Rint = 0.0288)
R1, wR2 (2σ data) 0.0548, 0.0923
R1, wR2 (all data) 0.1003, 0.1093
GOOF on F2 1.028
Peak/hole [e Ǻ-3] 0.193 / -0.211
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3 Additional NMR Data
Compound 3w
1H-NMR Spectrum
NMR Spectrum
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Compound 14ac
1H-NMR Spectrum
13C-NMR Spectrum
174
COSY-NMR Spectrum
NOESY-NMR Spectrum
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HSQC-NMR Spectrum
HMBC-NMR Spectrum
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4 Chiral HPLC Analysis
tert-Butyl (R/S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k)
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tert-Butyl (S)-2-((pyridin-2-ylthio)carbonyl)pyrrolidine-1-carboxylate (5k)
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S-(Pyridin-2-yl) (R/S)-2-(4-isobutylphenyl)propanethioate (5l)
 3/13/2019 1:04:10 PM  Page 1 / 1 
 C:\LabSolutions\Data\Lucie\Methods\LG-S,R-Ibuprofen-Rac1.lcd 
min
mAU
0 5 10
0
100
200
 5
.6
4 
 6
.7
3 
PDA Ch2 268nm
Peak#
 1 
 2 
Total
Ret. Time
 5.64 
 6.73 
Area
 3345973 
 3571156 
Height
 279898 
 238609 
Area%
 48.4 
 51.6 
 100.0 
UV Spectrum
Peak#: 2
Reten on Time: 6.727 min
nm
mAU
   0
  50
 100
 150
 200
 250
 300
 350
 400
 450
 500
 550
200 300
208
269
Method File : OD-H_90_10_run.lcm
Date Processed : 13/03/2019 12:54:18
S-(pyridin-2-yl) (R/S)-2-(4-isobutylphenyl)propanethioate (1l)
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S-(Pyridin-2-yl) (S)-2-(4-isobutylphenyl)propanethioate (5l)
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S-(Pyridin-2-yl) (R/S)-2-methylbutanethioate5m
 3/13/2019 12:58:39 PM  Page 1 / 1 
 C:\LabSolutions\Data\Lucie\Methods\LG-2-methylbutSM-Rac-98ODH3.lcd 
min
mAU
0 5 10
0
100
200
300
400  9
.6
6 
 1
0.
36
 
PDA Ch2 268nm
Peak#
 1 
 2 
Total
Ret. Time
 9.66 
 10.36 
Area
 7082537 
 7374118 
Height
 432518 
 410870 
Area%
 49.0 
 51.0 
 100.0 
UV Spectrum
Peak#: 2
Reten on Time: 10.362 min
nm
mAU
    0
  500
 1000
 1500
200 300
268246
Method File : OD-H_98_2_run.lcm
Date Processed : 30/01/2019 14:37:29
S-(pyridin-2-yl) (R/S)-2-methylbutanethioate (1m)
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S-(Pyridin-2-yl) (S)-2-methylbutanethioate (5m)
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S-(pyridin-2-yl) (S)-2-methylbutanethioate (1m)
UV Spectrum
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tert-Butyl (R/S)-2-(4-methoxybenzoyl)pyrrolidine-1-carboxylate (7t)
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tert-Butyl (S)-2-(4-methoxybenzoyl)pyrrolidine-1-carboxylate (7t)
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tert-Butyl (R/S)-2-(benzo[d][1,3]dioxole-5-carbonyl)pyrrolidine-1-carboxylate (7u)
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tert-Butyl (S)-2-(benzo[d][1,3]dioxole-5-carbonyl)pyrrolidine-1-carboxylate (7u)
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(R/S)-2-(4-iso-Butylphenyl)-1-(6-methoxynaphthalen-2-yl)propan-1-one (7v)
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(S)-2-(4-iso-Butylphenyl)-1-(6-methoxynaphthalen-2-yl)propan-1-one (7v)
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(R/S)-2-(4-iso-Butylphenyl)-1-(3-(methylthio)phenyl)propan-1-one (7w)
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(S)-2-(4-iso-Butylphenyl)-1-(3-(methylthio)phenyl)propan-1-one (7w)
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(R/S)-N,N-Dimethyl-4-(2-methylbutanoyl)benzamide (7x)
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(S)-N,N-Dimethyl-4-(2-methylbutanoyl)benzamide (7x)
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(R/S)-1-(3-(Dimethylamino)phenyl)-2-methylbutan-1-one (7y)
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(S)-1-(3-(Dimethylamino)phenyl)-2-methylbutan-1-one (7y)
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